BioScience Trends is one of a series of peer-reviewed journals of the International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA) Group and is published bimonthly by the International Advancement Center for Medicine & Health Research Co., Ltd. (IACMHR Co., Ltd.) and supported by the IRCA-BSSA and Shandong University China-Japan Cooperation Center for Drug Discovery & Screening (SDU-DDSC).

BioScience Trends devotes to publishing the latest and most exciting advances in scientific research. Articles cover fields of life science such as biochemistry, molecular biology, clinical research, public health, medical care system, and social science in order to encourage cooperation and exchange among scientists and clinical researchers.

BioScience Trends publishes Original Articles, Brief Reports, Reviews, Policy Forum articles, Case Reports, News, and Letters on all aspects of the field of life science. All contributions should seek to promote international collaboration.

Editorial Board

Editor-in-Chief:
Norihiro KOKUDO
The University of Tokyo, Tokyo, Japan

Co-Editors-in-Chief:
Xue-Tao CAO
Chinese Academy of Medical Sciences, Beijing, China
Rajendra PRASAD
University of Delhi, Delhi, India
Arthur D. RIGGS
Beckman Research Institute of the City of Hope, Duarte, CA, USA

Chief Director & Executive Editor:
Wei TANG
The University of Tokyo, Tokyo, Japan

Senior Editors:
Xunjia CHENG
Fudan University, Shanghai, China
Yoko FUJITA-YAMAGUCHI
Beckman Research Institute of the City of Hope, Duarte, CA, USA
Na HE
Fudan University, Shanghai, China
Kiyoshi KITAMURA
The University of Tokyo, Tokyo, Japan
Misao MATSUSHITA
Tokai University, Hiratsuka, Japan
Munehiro NAKATA
Tokai University, Hiratsuka, Japan
Takashi SEKINE

Managing Editor:
Jianjun GAO
Qingdao University, Qingdao, China

Web Editor:
Yu CHEN
The University of Tokyo, Tokyo, Japan

Proofreaders:
Curtis BENTLEY
Roswell, GA, USA
Christopher HOLMES
The University of Tokyo, Tokyo, Japan
Thomas R. LEBON
Los Angeles Trade Technical College, Los Angeles, CA, USA

Editorial Office
Pearl City Koishikawa 603, 2-4-5 Kasuga, Bunkyo-ku, Tokyo 112-0003, Japan
Tel: +81-3-5840-8764
Fax: +81-3-5840-8765
E-mail: office@bioscience trends.com

www.bioscience trends.com
Editorial Board Members

Girdhar G. AGARWAL  
(Lucknow, India)

Hirotsugu AIGA  
(Geneva, Switzerland)

Hidechika AKASHI  
(Tokyo, Japan)

Moazzam ALI  
(Geneva, Switzerland)

Ping AO  
(Shanghai, China)

Hisao ASAMURA  
(Tokyo, Japan)

Michael E. BARISH  
(Duarte, CA, USA)

Boon-Huat BAY  
(Singapore, Singapore)

Yasunari BESSHO  
(Nara, Japan)

Generoso BEVILACQUA  
(Pisa, Italy)

Shiuan CHEN  
(Duarte, CA, USA)

Yuan CHEN  
(Duarte, CA, USA)

Naoshi DOHMAE  
(Wako, Japan)

Zheng FAN  
(Houston, TX, USA)

Ding-Zhi FANG  
(Chengdu, China)

Xiaobin FENG  
(Chongqing, China)

Yoshitaru FUKUDA  
(Shinjuku, Japan)

Zheng FAN  
(Shanghai, China)

Rajiv GARG  
(Lucknow, India)

Ravindra K. GARG  
(Lucknow, India)

Makoto GOTO  
(Tokyo, Japan)

Demin HAN  
(Shanghai, China)

David M. HELFMAN  
(Milano, Italy)

Yutaka MATSUYAMA  
(Tokyo, Japan)

Qingyue MENG  
(Shanghai, China)

Satoko NAGATA  
(Tokyo, Japan)

Mihyo OBA  
(Tokyo, Japan)

Carlos SAINZ-FERNANDEZ  
(Santander, Spain)

Yoshihiro SAKAMOTO  
(Tokyo, Japan)

Xianjun QU  
(Shanghai, China)

Takehito SATO  
(Tokyo, Japan)

Akihito SHIMAZU  
(Tokyo, Japan)

Zhifeng SHAO  
(Shanghai, China)

Peipei SONG  
(Tokyo, Japan)

Ji'an JIN  
(China)

Ashitai YAMACHI  
(Chiba, Japan)

Masahiro UMEZAKI  
(Tokyo, Japan)

Sumihito TAMURA  
(Tokyo, Japan)

Puay Hoon TAN  
(Singapore, Singapore)

Koji TANAKA  
(Tokyo, Japan)

John TERMINI  
(Duarte, CA, USA)

Usa C. THISYAKORN  
(Bangkok, Thailand)

Toshifumi TSUKAHARA  
(Tokyo, Japan)

Hisashi TANAKA  
(Tokyo, Japan)

Shin'ichi TAKEDA  
(Tokyo, Japan)

(as of October 25, 2015)
Human resources for health development: toward realizing Universal Health Coverage in Japan.
Hidechika Akashi, Yasuyo Osanai, Rumiko Akashi

Associating liver partition and portal vein ligation (ALPPS): Taking a view of trails.
Takeshi Takamoto, Yasuhiko Sugawara, Takuya Hashimoto, Masatoshi Makuuchi

A systematic review and meta-analysis of feasibility, safety and efficacy of associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) versus two-stage hepatectomy (TSH).
Zhipeng Sun, Wei Tang, Yoshihiro Sakamoto, Kiyoshi Hasegawa, Norihiro Kokudo

Transarterial Y90 radioembolization versus chemoembolization for patients with hepatocellular carcinoma: A meta-analysis.
Yafei Zhang, Yiming Li, Hong Ji, Xin Zhao, Hongwei Lu

Adenovirus-mediated P311 inhibits TGF-β1-induced epithelialmesenchymal transition in NRK-52E cells via TGF-β1-Smad-ILK pathway.
Fanghua Qi, Pingping Cai, Xiang Liu, Min Peng, Guomin Si

DHEA promotes osteoblast differentiation by regulating the expression of osteoblast-related genes and Foxp3 regulatory T cells.
Xuemian Qiu, Yiyin Gui, Yingping Xu, Dajin Li, Ling Wang

Protective effect of oleanolic acid on oxidized-low density lipoprotein induced endothelial cell apoptosis.
Jianhua Cao, Guanghui Li, Meizhi Wang, Hui Li, Zhiwu Han

Decrease of ZEB1 expression inhibits the B16F10 cancer stem-like properties.
Fengshu Zhao, Xiangfeng He, Yaqin Wang, Fangfang Shi, Di Wu, Meng Fan, Miao Li, Songyan Wu, Xiaoying Wang, Jun Dou
CONTENTS

335 - 341  The risk factors for suboptimal CD4 recovery in HIV infected population: an observational and retrospective study in Shanghai, China.
Fengdi Zhang, Meiyan Sun, Jianjun Sun, Liqian Guan, Jiangrong Wang, Hongzhou Lu

342 - 349  Serum concentrations of Flt-3 ligand in rheumatic diseases.
Kayo Nakamura, Noriko Nakatsuka, Masatoshi Jinnin, Takamitsu Makino, Ikko Kajihara, Katsunari Makino, Noritoshi Honda, Kuniko Inoue, Satoshi Fukushima, Hironobu Ihn

Guide for Authors

Copyright
Human resources for health development: toward realizing Universal Health Coverage in Japan

Hidechika Akashi¹,*, Yasuyo Osanai², Rumiko Akashi³

¹Bureau of International Health Cooperation, National Center for Global Health and Medicine, Tokyo, Japan; ²Center Hospital, National Center for Global Health and Medicine, Tokyo, Japan; ³Department of Social Work, Meijigakuin University, Tokyo, Japan.

1. Introduction

Universal health coverage (UHC) has been announced as one of the important topics in the post-Millennium Development Goal (MDG) agenda (1). Japan has gained international recognition for its outstanding achievement of UHC during the second half of the 20th century (2). Japan established UHC in 1961 with the completion of its universal health insurance (“kokumin kaihoken”) system (2-4). However, a universal health insurance system, which enables the whole population to have financial access to health care services, is not sufficient for establishing UHC. Indeed, establishment of UHC would require a formal health service provision system including an adequate health workforce as suggested by the World Health Organization (WHO) in its six building-block model of an effective health system (5). Blockages in health systems, including a critical shortage of skilled, motivated, and geographically distributed health workers, can lead to inefficient and ineffective health coverage (6).

There are some cross-sectional studies of human resources development toward UHC in several countries (7,8). Similarly, there are other articles on the...
chronological history on human resource development in the health care system of Japan (9), but these present neither its fundamental meaning in relation to UHC development nor a model for UHC establishment. Ikegami and Buchan (10) discussed health policies in introducing licensed practical nurses (i.e., auxiliary nurses), which were important for promoting UHC; however, there are few articles like theirs. In this paper, we examine how Japan attained UHC from a human resource perspective through reviewing existing publications and data on the Japanese history of human resources for health development. More specifically, we discuss human resource development with a focus on physicians and nurses because these health personnel are the main providers of medical services, and attempt to extract from this discussion important lessons and a schematic explanation of human resource development to provide a method of enabling such development towards UHC in other countries.

2. Chronological changes on the production of health service providers

2.1. Nurses

The following phases, listed chronologically, of nursing staff production in Japan were identified.

Phase 1 "Health workforce shortage": This phase, starting at around World War II (WWII), was characterized by a decrease in the number of nurses (11).

Phase 2 "Rapid production of auxiliary nurses": The Government of Japan (GOJ) implemented shorter nursing education programs (i.e., auxiliary nurse education programs "jun-kangoshi"), a form of two-year specialty education, while increasing the number of schools offering these programs from around 300 in the early 1950s to over 400 in the mid-1950s and over 500 in the late 1950s (12). The number of auxiliary nursing schools continuously increased after 1961, reaching over 700 in the mid-1960s. The number of prefectoral schools with such schools increased from 41 in 1958 to 47 later on; eventually, every prefecture had them (12-14). These shorter programs were organized by local physicians' associations or hospitals, and were located throughout each prefecture, including in rural areas. Auxiliary nurse licenses were issued by prefectural governors. Using this strategy, the number of auxiliary nurses increased dramatically from less than 10,000 in the 1940s and early 1950s to around 70,755 in 1961 and 133,811 in 1969; the number of registered nurses (i.e., completed a three-year program) plateaued at around 110,000 in the 1950s and 60s (11).

Phase 3 "Quality improvement through upgrade education": During Phase 2 (in 1959), the GOJ began offering upgrade courses for auxiliary nurses (two-year program), thereby enabling auxiliary nurses to become registered nurses. Additionally, the production of formally educated nurses also increased.

Phase 4 "Predominance of formal nurses": This phase was characterized by a marked reduction in nurses with two-year educations, causing nurses with formal educations (more than three-year education) to become the predominant human resource for health; such nurses included bachelors of nursing course (four-year) graduates.

2.2. Physicians

The GOJ employed similar steps for physicians as for nurses. Before WWII, Japanese medical education included a six-year course for medical doctors and four-year vocational education courses.

Phase 1 "Health workforce shortage": Before WWII, there was a clear physician shortage; indeed, from 1912-1931, only 40,000 physicians were working (11). The number of medical schools was nine in 1888, and 17 in 1919 (15).

Phase 2 "Rapid production of less-educated physicians": The GOJ increased the number of medical doctors to reduce the wartime shortage. Thus, from 1939-1945, they increased the number of medical schools and three-year extra-affiliated schools of medicine (which offered shorter courses than the medical schools) (15,16). Accordingly, the number of admissions to medical schools increased from 3,078 students (1935) to 10,533 (1945) (11); female students were also accepted (16). The number of medical schools was 26 in 1939, and 69 in 1945 (15). The annual number of graduates from medical schools and extra-affiliated schools increased from around 50,000 (1932-1936) to over 60,000 (1937-1941) (11). This increase was not planned to introduce UHC but rather to account for wartime shortages in personnel; however, these procedures indirectly influenced introduction of UHC.

Phase 3 "Quality improvement phase through national licensing examination": After WWII (1945), physicians who had completed a three-year education returned to Japan, thus increasing the number from 13,833 in 1945 to 65,301 in 1946 and 70,636 in 1947 (11). It was thought that they would spread throughout Japan by returning to their hometowns. Subsequently, the national licensing examination was introduced in 1947; all medical school graduates had to pass this examination. Additionally, in 1948, medical universities became the only authorized medical schools. As such, graduates of three-year education courses had to pass a physician's preparatory examination and undergo one year of clinical training to ensure they were at the same level as medical school graduates (15).

Phase 4 "Predominance of formal physicians": The number of medical university graduates (i.e., the six-year education) increased gradually, with the number of physicians reaching 104,732 in 1961 and 116,568 in 1969 (11) – over eight times the number in 1945.
These trends in the numbers of physicians, nurses, and auxiliary nurses are shown in Figure 1 (11). Based on our data analysis of physicians and nurses, a schematic explanation of their development processes is shown in Figure 2. Notably, many health indicators such as mortality rates from pneumonia and tuberculosis and the infant mortality rate (which was 76.7 in 1947 and 28.6 in 1961) improved gradually over the studied period; however, we observed increasing trends in mortality rates from cancers, cerebrovascular diseases, and cardiac diseases during that same period (4,17).

3. Strategies on health workforce development

Based on the Japanese experience, we extracted the following strategies on health workforce development.

3.1. Focusing on quantity instead of quality

3.1.1. Shorter professional education

Shorter education courses – such as extra-affiliated schools of medicine for physicians and auxiliary nursing education courses for nursing staff – were introduced in Phase 2. For example, with nursing staff, rather than expanding the number of three-year courses, the GOJ increased the number of two-year courses,

Figure 1. Trends of human resources for health in Japan. WWII: World War Second, UHC: Universal Health Coverage.

Figure 2. Schematic framework for human resource development to address its shortage. HR: Human Resources, Arrows in the figure mean "conversion" from less-educated HR to quality improved HR through up-grading course education, licensing examination, or other quality improvement procedures.
that is, auxiliary nursing schools (12). For physicians, a similar strategy was observed, although the expansion of shorter courses was to account for wartime shortages. In other words, the GOJ began rapid production of less-educated physicians with three-year educations instead of six-year ones before 1945 during wartime (Phase 2). Additionally, special medical schools for women were opened to serve people inside of Japan. Then, many physicians, including those less-educated ones, returned to Japan just after the end of WWII (Figure 1), and they covered almost the entire country after 1946.

3.1.2. Fewer admission requirements for professional education

Admission requirements for auxiliary nursing courses were only a basic education (i.e., junior-high school graduates), whereas ordinary nursing courses required at least a high school graduation. There were few high school graduates during the study period; specifically, the admission rate to high school was 42.5% in 1950, whereas ordinary nursing courses required at least a high school graduation. There were few high school graduates), whereas ordinary nursing courses required at least a high school graduation. There were few high school graduates during the study period; specifically, the admission rate to high school was 42.5% in 1950, 51.5% in 1955, 57.7% in 1960, and 70.7% in 1965 (18). This seems to have occurred in other countries as well. In Cambodia, there are few nursing student candidates with high school education, especially in rural areas (19).

However, we did not observe reduced admission requirements to medical schools for physicians' education (15).

3.1.3. Widespread school locations

Widespread schools can contribute to an increasing health workforce. For nurses, one of the reasons for this expansion in schools was that auxiliary nursing schools were usually established in hospitals by local physicians' associations in rural prefectures of Japan. This was because rural local hospitals under the physicians' associations required cheaper labor, and thus wanted to produce such relatively less qualified nurses by themselves. Another reason was that less-educated students seemed to predominantly inhabit rural areas just after WWII. This phenomenon meant that the GOJ began establishing schools throughout the country, although the quality of education in such nursing schools varied. "Those who had stayed longer in rural areas had settled and integrated well within their community" (20); therefore, it can be said that the local recruitment of students is important for staff retention in remote areas. However, it is important to consider how these schools are distributed, because it has been reported that this increase in nursing institutions could only be accomplished by deepening geographical imbalances in human resource distribution (7).

For physicians, 69 schools (including 18 universities and 51 relevant special schools) in 1945 were widely distributed covering almost the entire country (15). 3.2. Shifting from quantity to quality

Ikegami and Buchan pointed out that Japan's focus on quantity was an important factor for UHC introduction (10). This unique Japanese approach of producing auxiliary nurses may be appropriate for increasing the amount of health personnel in rural areas. However, in 1957, once auxiliary nurses had spread throughout the country, Japan introduced education upgrades for two-year courses, thereby allowing auxiliary nurses to become registered nurses (Phase 3). These upgrade courses have continued until the present. Through these processes, registered nurses gradually became the predominant human resource for health, and the four-year nursing university education was introduced (Phase 4). In these last two phases, the GOJ shifted the focus of its policy from increasing the quantity to increasing the quality of the health workforce. For physicians, the GOJ certified less-educated physicians as fully educated physicians via a licensing examination rather than providing an upgraded education (Phase 3).

3.3. Limitation

There are some problems in focusing solely on quantity rather than quality of an individual health workforce to ensure the quality of medical services. However, less-educated health personnel may be better than no health personnel or harmful procedures practiced by some traditional healers.

The year that UHC began in Japan, 1961, was during Phase 3. During this period, some health indicators improved such as the mortality rates for pneumonia or tuberculosis. However, we cannot conclude that the increases in the health workforce were responsible for these improvements, because streptomycin, chest X-rays, improved nutrition, etc. were introduced during that time, which contributed to a reduction in tuberculosis in Japan (21).

4. Conclusion

The Japanese process of introducing UHC is said to have been a complicated and unique case; however, it appears that human resource development was largely responsible and its process can be simplified as we have shown. In other words, before introducing UHC, the GOJ focused on increasing the quantity of health and medical professionals via less stringent admission requirements and shorter professional education courses delivered at institutions covering the entire country. Then, quality improvement procedures such as upgraded courses or quality assurance licensing examinations were introduced to allow existing human resources to be recognized as fully educated professionals. Governments wanting to introduce UHC may be able to use this Japanese model as a means of
human resource development, especially in resource-poor countries.

Acknowledgements

This research was supported by the research fund of the National Center for Global Health and Medicine.

References


(Received September 24, 2015; Revised October 9, 2015; Re-revised October 16, 2015; Accepted October 17, 2015)
Associating liver partition and portal vein ligation (ALPPS): Taking a view of trails

Takeshi Takamoto, Yasuhiko Sugawara*, Takuya Hashimoto, Masatoshi Makuuchi

Divisions of Hepato-Biliary-Pancreatic and Liver Transplantation, Japanese Red Cross Medical Center, Tokyo, Japan.

*Address correspondence to:
Dr. Yasuhiko Sugawara, Divisions of Hepato-Biliary-Pancreatic Surgery and Liver Transplantation, Japanese Red Cross Medical Center. 4-1-22 Hiroo, Shibuya-ku, Tokyo 150-8935, Japan.
E-mail: yasusugatky@gmail.com

Summary

Associating liver partition and portal vein ligation (ALPPS) is introduced as a modified two-staged hepatectomy for advanced liver malignancies, which requires extended hepatectomy with very small future remnant liver volume. It is characterized by rapid and large growth of future remnant liver and potential of widening the indication of curative resection with extended major hepatectomy for liver malignancies. It showed, however, much higher morbidity and mortality than extended hepatectomy after portal vein embolization. Here, we review the literatures and examine the role of ALPPS in Japan, where zero mortality after hepatectomy is highly expected.

Keywords: ALPPS, Japan, hepatectomy, liver malignancies, liver volume, portal vein embolization

1. Introduction

The ultimate goal for liver surgeons in performing hepatectomy for hepatobiliary malignancies is complete resection of tumors with zero mortality. The morbidity and mortality after liver resection are associated with insufficient remnant liver volume and its function. Therefore, several methods to increase the future remnant liver volume before major hepatectomy, including portal vein embolization (1), ligation (2), sequential arterial and portal vein embolizations (3), and two-staged hepatectomy (4), were introduced. These techniques, however, usually required 2-8 weeks interval before completing the entire clearance of tumor burden in the liver and the risk of tumor progression during the period might be critical especially among the patients with borderline resectable tumors or oncologically aggressive tumors (5,6).

In 2011, Baumgart and colleagues reported in situ liver splitting through the umbilical ligament with concomitant right portal vein ligation, achieving future liver remnant (FLR) hypertrophy in 9 days in two-stage right trisectionectomy (7). A multi-institutional study was immediately started and 25 patients with marginally resectable liver malignancies were included (8). In the first operation, surgical exploration, right portal vein ligation and in situ splitting of the liver parenchyma along the falciform ligament were performed. Limited resections for tumors in future remnant liver were performed if necessary. Then after a median interval of days (range: 5-28 days) waiting period, the right trisegmentectomy was completed as second operation. The volume of the left lateral lobe was increased in a median volume ratio of 74% (range: 21%-192%), which is rather larger comparing with the increasing volume ratio of 10-20% in several weeks after portal vein embolization (PVE). The morbidity ratio was, however, up to 68% and 14% of the patients were died within a short follow-up period of 180 days in median (range: 60-776 days) after surgery (8).

This new technique is named as "associating liver partition and portal ligation for staged hepatectomy (ALPPS)" and several authors demonstrated successful cases with the similar procedures (Table 1). Most of all the following studies showed 60% or more increment of remnant liver volume and 100% R0 resection rate. Nevertheless, the postoperative short-term outcome is not satisfactory showing that high incidence of morbidity (mostly over 50%), postoperative liver failure (around 20%), and in-hospital mortality was up to 10-20%. An international registry study, in which 56 institutions from all over the world took part, showed the result of analyzing 202 patients (141 patients with...
colorectal liver metastases) who underwent ALPPS from 2012-2013 (9). Median future remnant liver volume ratio was increased from 21% to 40% for standardized future liver remnant (sFLR) within a median of 7 days. Ninety-day mortality was 9%. Severe complications including mortalities (Clavien-Dindo ≥ IIIb) occurred in 27% of patients.

Although this procedure is discussed vigorously in famous journals of surgery, the practical advantage of ALPPS is still under debate because it showed a high morbidity and mortality rate and the oncological benefits of the aggressive resection are not proven.

### 2. Problems of ALPPS

The ALPPS is potentially effective procedure for patients who requires super extended liver resection to achieve curative resection of extensive liver malignancies. The most notable phenomenon is the rapid liver hypertrophy. Schadde et al. calculated the speed of liver hyperatrophy during the waiting period before final hepatectomy and showed that the extrapolated growth rate was 11 times higher in ALPPS (34.8 cc/day; interquartile range 26-49) compared with PVE/PVL (3 cc/day; IQR2-6; p = 0.001). Attention should be paid, however, to the difference of waiting periods between ALPPS (1-2 weeks) and PVE/PVL (4-8 weeks) in order not to overestimate the impact of ALPPS on liver hypertrophy. The kinetic growth curve of liver regeneration is always convex upward.

The enlarged volume of liver is not always parallel to the increment of liver function, as is often the case with recipients of living-donor liver transplantation who show considerably enlarged transplanted liver graft and are suffering persistent liver insufficiency with hyperbilirubinemia. The effect of inflammation in the ischemic and congestive area in the part of liver with vascular modulation can induce the edema of liver.

An experimental model using mice gave important information about the mechanism of accelerated hypertrophy in ALPPS (10). In the experiment, the mice which underwent either transection or PVL alone received plasma from ALPPS-treated mice or the mice which were subjected to splenic, renal, or pulmonary ablation instead. Injury to other organs or ALPPS-plasma injection combined with PVL induced liver hypertrophy similar to ALPPS. This result supports the hypothesis that liver damage after the first procedure of ALPPS raises inflammatory signals and promotes the liver hypertrophy.

It might be misunderstood that no ischemic area except for a small part of transected segment IV or limited resections are remained in the first operation. Portal flow in veno-occlusive area (congestive area), however, becomes hepatofugal (11) and the congestive area can theoretically change to ischemic when the portal vein was occluded. The process of liver splitting along the Rex-Cantlie's line or right side of falciform ligament is always accompanied with division of hepatic venous tributaries and congestive area appears.

### Table 1. Review of literature on ALPPS

<table>
<thead>
<tr>
<th>Items</th>
<th>Year</th>
<th>n</th>
<th>Diagnosis</th>
<th>Liver Regeneration* (%</th>
<th>Interval (days)</th>
<th>Morbidity (%)</th>
<th>Hepatic Insufficiency (%)</th>
<th>Sepsis (%)</th>
<th>Bile leakage (%)</th>
<th>In-Hospital Mortality (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Schnitzbauer</td>
<td>2012</td>
<td>25</td>
<td>HCC 3 Mets 16</td>
<td>74</td>
<td>9</td>
<td>64</td>
<td>-</td>
<td>20</td>
<td>24</td>
<td>12</td>
</tr>
<tr>
<td>Sala</td>
<td>2012</td>
<td>10</td>
<td>HCC 1 Mets 7</td>
<td>82</td>
<td>7</td>
<td>40</td>
<td>20</td>
<td>-</td>
<td>-</td>
<td>0</td>
</tr>
<tr>
<td>Alvarez</td>
<td>2013</td>
<td>15</td>
<td>HCC 1 Mets 13</td>
<td>78</td>
<td>7</td>
<td>53</td>
<td>20</td>
<td>-</td>
<td>-</td>
<td>20</td>
</tr>
<tr>
<td>Li</td>
<td>2013</td>
<td>9</td>
<td>Mets 3</td>
<td>87</td>
<td>13</td>
<td>16</td>
<td>22</td>
<td>22</td>
<td>22</td>
<td>22</td>
</tr>
<tr>
<td>Schadde</td>
<td>2014</td>
<td>48</td>
<td>HCC 3 CRLM 26</td>
<td>74</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>9.3</td>
<td>15</td>
<td></td>
</tr>
<tr>
<td>Knoefel</td>
<td>2013</td>
<td>7</td>
<td>-</td>
<td>65</td>
<td>6</td>
<td>71</td>
<td>0</td>
<td>-</td>
<td>-</td>
<td>0</td>
</tr>
<tr>
<td>Gauzolino (variations)</td>
<td>2013</td>
<td>4</td>
<td>CRLM 4</td>
<td>27.8</td>
<td>7</td>
<td>75</td>
<td>0</td>
<td>-</td>
<td>25</td>
<td>0</td>
</tr>
<tr>
<td>Robles (ALTPS)</td>
<td>2014</td>
<td>22</td>
<td>HCC 1 Mets 20</td>
<td>63</td>
<td>11</td>
<td>63</td>
<td>23</td>
<td>-</td>
<td>23</td>
<td>9</td>
</tr>
<tr>
<td>Ratti</td>
<td>2014</td>
<td>6</td>
<td>CRLM 3</td>
<td>58.3</td>
<td>7.5</td>
<td>50</td>
<td>0</td>
<td>-</td>
<td>-</td>
<td>17</td>
</tr>
<tr>
<td>Gall (RALPP)</td>
<td>2015</td>
<td>5</td>
<td>CRLM 5</td>
<td>62.3</td>
<td>21.8</td>
<td>20</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

HCC: hepatecellular carcinoma, Mets: metastatic liver tumors, CRLM: colorectal liver metastases, ALTPS: tourniquet in the umbilical fissure and right portal vein occlusion, RALPP: radio-frequency-assisted liver partition with portal vein ligation. * Liver regeneration ratio is showed as the ratio of increased volume to the future remnant liver volume before first operation.
Therefore, larger area than expected can change to be necrotic after the first operation accordingly and such complete devascularized area may become a source of severe sepsis (12). The occurrence of bile leakage in ALPPS is reported up to around 20%, which is much higher than that in ordinary hepatectomy (< 5%) (13). As several authors commented that bile leakage was associated with sepsis, it is possible that bile leakage in ALPPS reflects a large area of liver parenchymal necrosis, because the dark red colored discharge from the necrotic area in liver usually contains high levels of bilirubin.

Although complete resection of liver malignancy by ALPPS procedure is safely achieved, the long-term benefit of aggressive surgical treatment is still unclear, especially for the patients with multiple bilobar colorectal liver metastases or hilar cholangiocarcinoma progressing into the peripheral biliary tree.

3. Modification of ALPPS

According to the original procedure of ALPPS, most of the procedures were performed in the first operation and the right liver and ischemic segment IV put in the plastic bag was removed in second operation. Several modifications of the first operation to lower invasive procedure were proposed aiming at reducing the damage modifications of the first operation to lower invasive plastic bag was removed in second operation. Several and the right liver and ischemic segment IV put in the procedures were performed in the first operation.

According to the original procedure of ALPPS, most of the procedures were performed in the first operation and the right liver and ischemic segment IV put in the plastic bag was removed in second operation. Several modifications of the first operation to lower invasive procedure were proposed aiming at reducing the damage modifications of the first operation to lower invasive plastic bag was removed in second operation. Several

As several authors pointed out that the ALPPS procedure can be said as a clinical study still under phase I (19), the most important issue is to modify this procedure safer and to establish indication criteria to select the cohort of patients who have best risk-benefit balance to adopt this procedure.

References


(Received October 6, 2015; Accepted October 12, 2015)
A systematic review and meta-analysis of feasibility, safety and efficacy of associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) versus two-stage hepatectomy (TSH)

Zhipeng Sun1,2, Wei Tang2,*, Yoshihiro Sakamoto2, Kiyoshi Hasegawa2, Norihiro Kokudo2

1 Oncology Surgery Department, Peking University Ninth School of Clinical Medicine (Cancer Centre, Beijing Shijitan Hospital, Capital Medical University), Beijing, China;
2 Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

Summary

This meta-analysis aimed to review the regeneration rate of future liver remnant (FLR) and perioperative outcomes after associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) and two-stage hepatectomy (TSH). A web search was performed in "MEDLINE", "EMBASE", and "SCIENCE DIRECT" databases using both subject headings (MeSH) and truncated word to identify all the articles published that related to this topic. Pooled risk ratios were calculated for categorical variables and mean differences for continuous variables using the fixed-effects and random-effects models for meta-analysis. Three studies involved 282 patients, of whom 234 were in the TSH group and 48 in the ALPPS group. Morbidity was experienced in 56.3% patients in the ALPPS group and 36.1% in the TSH group. There was a statistical difference (RR = 1.08; Z = 3.24; 95% CI, \( p = 0.001 \)). Second surgeries were performed successfully in 79.1% patients in the portal vein embolization (PVE) group and 100% in the ALPPS group. There was a statistical difference (\( Z = 2.48; 95\% \ CI, p = 0.01 \)). The mean regeneration rate of FLR in the ALPPS group was 56.4% compared with 52.8% in the TSH group. There was no statistical difference (95% CI, \( p = 0.34 \)). So from the outcome of this meta-analysis, TSH had a similar remnant liver regeneration ability compared to ALPPS while the morbidity and mortality rates were relatively low. Cancer progression while waiting for the staged liver resection after portal vein embolization was a drawback for TSH.

Keywords: Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS), portal vein embolization (PVE), two-staged Hepatectomy (TSH), liver regeneration

1. Introduction

During the period of associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) surgery promotion, there were always comparisons with conventional Two-Stage Hepatectomy (portal vein embolization and staged hepatectomy, TSH), which don't need laparotomy and liver parenchyma partition in the first surgery. Some researchers found that TSH had a similar remnant liver regenerative effect compared to ALPPS while the morbidity and mortality rates were relatively low (1-3). There were already 3 randomized control trials comparing the two surgeries up to now that we have summarized as follows.

The major difference between ALPPS and TSH is the extra liver parenchyma partition in ALPPS, which may result in fast remnant liver regeneration. The procedure of cancer-bearing liver partition may also reduce the chance of tumor invasion to the remnant liver (4). The major deficit of conventional two-stage hepatectomy is that the speed of future remnant liver
(FLR) regeneration is not very high. It's rarely over 50% for 4-8 weeks. About 1/10 patients who underwent portal vein embolization as the first surgery of TSH lost the second hepatic resection surgery opportunity while waiting for FLR regeneration because of cancer progress. So conventional TSH now is widely used for hilar cholangiocarcinoma, which grows slowly compared with hepatic cancer. The purpose of this systematic review and meta-analysis was to compare ALPPS with TSH to evaluate feasibility, safety and efficacy.

2. Materials and Methods

2.1. Procedure of data collection

The databases of "MEDLINE", "EMBASE", and "SCIENCE DIRECT" were searched for articles published up to the date of Oct 15th, 2015 using the medical subject headings (MeSH) terms "portal vein ligation", "PVE", "staged hepatectomy", "staged liver resection", "liver resection", "two-stage hepatectomy", "TSH", "associating liver partition and portal vein ligation for staged hepatectomy" and "ALPPS" (Figure 1). There were no language restrictions. Relevant articles were reviewed and duplicates were removed. Articles unrelated to ALPPS, TSH as well as abstracts were excluded. Full-text articles were assessed for eligibility. Editorials and commentary articles as well as case reports were excluded. Studies reporting on up to three patients were classified as case reports. Patients were carefully screened for double reporting, after exclusion of those patients, a quantitative synthesis and meta-analysis was performed.

All patients who underwent liver resection for malignant tumors in both normal and cirrhotic livers were included. Inclusion criteria for searching were studies evaluating the use of TSH and ALPPS for elective liver resection.

2.2. Types of outcome measures

The morbidity rate, second surgery finish rate, FLR regeneration rate of TSH and ALPPS were measured.

Figure 1. Prisma flowchart of databases searched, strategy used, and exclusions performed for "ALPPS" and "TSH". Randomized and case-controlled studies, irrespective of language, country of origin, hospital, blinding, sample size, or publication status that compared ALPPS and TSH were included in this review. The databases of "MEDLINE", "EMBASE", and "SCIENCE DIRECT" were searched for articles published up to the date of Oct 15th, 2015 using the medical subject headings (MeSH) terms "portal vein ligation", "PVE", "staged hepatectomy", "staged liver resection", "liver resection", "ALPPS", "TSH", "associating liver partition and portal vein ligation for staged hepatectomy" and "ALPPS". Relevant articles were reviewed and duplicates were removed. Articles unrelated to ALPPS, TSH as well as abstracts were excluded. Full-text articles were assessed for eligibility. Editorials and commentary articles as well as case reports were excluded. Studies reporting on up to three patients were classified as case reports. Patients were carefully screened for double reporting.
2.3. Statistical analysis

Statistical analysis was performed using Review Manager Version 5.2 software (Cochrane Collaboration). The risk ratio (RR) with 95% confidence interval (CI) was calculated for binary data, and the mean value differences with 95% CI for continuous variables. When median and range were reported instead of mean and variance, the mean and variance were calculated based on the methods described by Hozo et al. (6). Random and fixed effects models were used to calculate the outcomes of both binary and continuous data. In cases of heterogeneity, only the results of the random effects model were reported. Heterogeneity was explored using the Chi-square test, with significance set at \( p < 0.05 \). Low heterogeneity was defined as \( I^2 \leq 33\% \). If the standard deviation was not available, it was calculated according to the guidelines of the Cochrane Collaboration. This process involved assumptions that both groups had the same variance, which may not have been true, and variance was estimated either from the range or from the \( v \) value. Forest plots were used for graphic display of the results. Quality assessment of the included studies was based on the Newcastle-Ottawa scale (7).

3. Results

The strategies of the literature search and the selection of studies are summarized (Figure 1). Three studies comparing ALPPS with TSH procedure met the inclusion criteria (1,2,8). All studies were retrospective. These three studies involved 282 patients, of whom 48 were in the ALPPS group and 234 in the TSH group. Pooled data were analyzed by combining the results of these three studies.

3.1. Comparison of morbidity rate between ALPPS and TSH

There was no heterogeneity among the included studies (\( \chi^2 = 9.97; \text{df} = 2; p = 0.007; I^2 = 80\% \)). Morbidities were experienced in 56.3% of patients in the ALPPS group and 36.1% in the TSH group. In a random effects model, there was statistical difference (RR = 1.08; \( Z = 3.24; 95\% \text{ CI}, p = 0.001 \); Figure 2).

3.2. Comparison of second surgery finish rate between ALPPS and TSH

There was no heterogeneity among the included studies (\( \chi^2 = 1.54; \text{df} = 2; p = 0.46; I^2 = 72\% \)). The staged surgeries were performed successfully in 79.1% of patients in the PVE group and 100% in the ALPPS group. In a random effects model, there was statistical difference (\( Z = 2.48; 95\% \text{ CI}, p = 0.01 \); Figure 3).

3.3. Comparison of FLR regeneration rate after first surgery between ALPPS and TSH

There was no heterogeneity among the included studies.

---

**Table 1.** Comparison of morbidity rate between ALPPS and TSH. There were no heterogeneity amongst the included studies (\( \chi^2 = 9.97; \text{df} = 2; p = 0.007; I^2 = 80\% \)). Morbidity was experienced in 56.3% of patients in the ALPPS group and 36.1% in the TSH group. In a random effects model, there was statistical difference (\( Z = 3.24; 95\% \text{ CI}, p = 0.001 \)).

**Table 2.** Comparison of second surgery finish rate between ALPPS and TSH. There were no heterogeneity amongst the included studies (\( \chi^2 = 1.54; \text{df} = 2; p = 0.46; I^2 = 72\% \)). The secondary surgeries were performed successfully in 79.1% of patients in the PVE group and 100% in the ALPPS group. In a random effects model, there was statistical difference (\( Z = 2.48; 95\% \text{ CI}, p = 0.01 \)).

www.bioscientetrends.com
The mean regeneration rate of FLR in the PVE group was 56.4% compared with 52.8% in the TSH group. In a fixed effects model, there was no difference in the percentage change in FLR increase between ALPPS and TSH (95% CI, $p = 0.34$; Figure 4).

4. Discussion

This meta-analysis shows that about three years after the inaugural publication of the novel ALPPS technique (4), the level of evidence supporting its advantages compared with traditional TSH remains low. Studies confirm the high completion rate of 97% for ALPPS, although with the two common biases of single-center and retrospective design. Perioperative mortality rate was 11% and complications grade IIIa or higher occurred in 44% of all patients (9).

The reasons for the rapid hypertrophy of the FLR observed in ALPPS and the actual functional growth of the FLR are important clinical questions. Although the rapid growth of the FLR after the ALPPS procedure is very impressive, it remains not so clear that it is better compared with a right hemi-liver plus segment 4 PVE. In our meta-analysis there wasn’t any statistical difference between the two types of surgeries in regeneration volume. As reported previously, the hypertrophy of the FLR is negatively correlated with the pre-PVE FLR volume (10). Because hepatic parenchyma transection is usually performed along the umbilical fissure (the segmental border between left lateral lobe and segment 4) in ALPPS procedure (4,11) while PVE is usually performed on right hemi-liver in TSH procedure (12,13). It is incorrect to attribute the reason for the rapid growth of the FLR to hepatic parenchyma partition (8,11). Therefore, more prospective studies about FLR regeneration volume comparison between ALPPS and a right hemi-liver plus segment 4 PVE should be performed.

Second, the mechanism explaining how the in situ splitting facilitates the regeneration of the FLR needs to be clarified. In animal models, there were no differences between TSH and ALPPS for the quantity of effective regenerative liver cells. The comparison for the quantity of effective regenerative liver cells between ALPPS and PVE was performed in rat models. DNA synthesis was assessed by bromodeoxyuridine (BrdU) and proliferating cell nuclear antigen (PCNA) immunohistochemistry staining on paraffin sections. There were no differences in BrdU+ or PCNA+ hepatocytes. The liver weights were assessed seven days after surgery. The weights of the remnant livers were not significantly different following PVL and ALPPS (14). Other research (15) also reported similar results that portal vein ligation and portal vein ligation combined with in situ splitting were performed in two groups of mice. The results showed no obvious differences between the two groups were observed at 24 and 48 hours after surgeries.

This systematic review was limited due to the small number of original publications about comparison of ALPPS, which is a very recently introduced technique, with TSH. The reason for this early systematic review was to support the opinion with data about the ongoing debate on the benefits and deficits of ALPPS compared with TSH. At the same time, the quality of studies published currently has not allowed the establishment of solid evidence for safety and efficacy, as shown by this systematic review. More prospective studies about comparison between ALPPS and TSH should be performed to support further assessment of feasibility, safety and oncologic efficacy.

5. Conclusion

TSH has similar remnant liver regeneration ability compared with ALPPS while the morbidity and mortality rates are relatively low. Cancer progression while waiting for the second stage hepatectomy after portal vein embolization is a major shortcoming for TSH.

Acknowledgements

This research was funded by the Japan-China Sasakawa Medical Fellowship, which is a project of the Sasakawa Memorial Health Foundation. The authors wish to thank the Foundation for its support.

References

1. Ratti F, Schadde E, Masetti M, Massani M, Zanello M,


(Received October 9, 2015; Revised October 21, 2015; Accepted October 24, 2015)
Transarterial Y90 radioembolization versus chemoembolization for patients with hepatocellular carcinoma: A meta-analysis

Yafei Zhang¹, Yiming Li¹, Hong Ji¹, Xin Zhao²,* Hongwei Lu¹,*

¹Department of General Surgery, Second Affiliated Hospital, School of Medicine, Xi’an Jiaotong University, Xi’an, China; ²Department of Hepatobiliary Surgery, The No. 302 Hospital of PLA, Beijing, China.

1. Introduction

Hepatocellular carcinoma (HCC) is a serious cancer with high morbidity and high mortality rate (1). In recent years, HCC has shown a rising incidence worldwide due to increasing hepatitis C virus prevalence and other factors (2). Surgical resection has been considered as definitive treatment for HCC, unfortunately, most HCC patients are diagnosed at an intermediate or advanced stage in which the tumor can't be resected (3). Therefore, locoregional treatment for HCC patients would be actively needed and may help to achieve longer survival.

Transarterial chemoembolization (TACE) is one of the standard locoregional treatments for intermediate stage hepatocellular carcinoma (HCC). Transarterial radioembolization (TARE) using β-emitting yttrium-90 (90Y) integral to the glass matrix of the microspheres has been developed as an alternative to TACE in recent years. Thus, we conducted a meta analysis to evaluate the safety and efficacy of TARE versus TACE for unresectable HCC. We searched PubMed, EMBASE, Web of Science and the Cochrane Library for clinical trials comparing TARE with TACE for unresectable HCC. Response rate, overall survival (OS), time to progression (TTP), hospitalization time days and clinical complications were analyzed and compared. Eight studies published from 2009 to 2014, with a total of 1,499 patients, were included in this meta-analysis. The pooled results showed that TARE (90Y) is significantly better in OS (HR = 0.74; 95% CI: 0.61-0.90), 3-year OS rates (RR = 1.75; 95% CI = 1.01-3.03, p = 0.05), TTP (HR = 0.61; 95% CI: 0.41-0.89), hospitalization time days (mean difference = −2.66; 95% CI: −4.08 -- −1.24) and some complications (abdominal pain [RR = 0.30, 95% CI: 0.11-0.83, p = 0.02]) for patients with HCC, but did not affect tumor response (CR [RR = 1.06; 95% CI = 0.51-2.22], PR [RR = 1.24; 95% CI = 0.79-1.94], SD [RR = 1.13; 95% CI = 0.92-1.39], PD [RR = 0.75; 95% CI = 0.37-1.51], over-all tumor control [RR = 1.16; 95% CI = 0.94-1.44]). The current meta-analysis suggests that TARE (Y90) is significantly better in OS, 3-year OS rates, TTP, hospitalization time days and some complications for patients with HCC.

Keywords: Transarterial Y90 radioembolization, chemoembolization, hepatocellular carcinoma

Address correspondence to:
Dr. Xin Zhao, Department of Hepatobiliary Surgery, The No. 302 Hospital of PLA, Beijing 100039, China.
E-mail: drzhaoxin@126.com

Dr. Hongwei Lu, Department of General Surgery, Second Affiliated Hospital, School of Medicine, Xi’an Jiaotong University, 157 Xiwu Road, Xi’an 710004, China.
E-mail: lhwdoc@163.com

www.bioscienctetrends.com
with unresectable HCC which may help to downstage tumors before surgery (13). However, the effect of TARE with Yttrium-90 in the treatment of unresectable liver tumors still needs to be confirmed (14,15). Therefore, we conducted a meta analysis based on clinical trials to evaluate the efficacy and safety of TARE versus TACE for unresectable HCC.

2. Materials and Methods

2.1. Literature search

We searched PubMed, EMBASE, Web of science, and the Cochrane Library for clinical trials comparing TARE (90Y) with TACE for unresectable HCC. The following searching terms were used: "chemoemboli*" or "emboli*" or "TACE" or "transcatether" or "transarterial" for identification of TACE, "90Y" or "radioemboli*" or "Yttrium-90" or "TARE" for identification of TARE, and "(liver or hepatic or hepatocellular) and (carcinom* OR cancer OR neoplasm* OR malign* OR tumor OR tumor*)" or "HCC" or "hepatoma*" for identification of HCC (16).

The Literature was searched limited to human studies without restricting time or language. The reference lists of all articles were also manually screened for potential studies. Abstracts and citations were screened independently by two authors, and all the agreed articles needed a second screen for full-text reports.

2.2. Review strategy

We used endnote bibliographic software to construct an electronic library of citations identified in the literature search. All the PubMed, EMBASE, Web of science and the Cochrane Library searches were performed using Endnote; duplicates were found automatically by Endnote and deleted manually. All data extraction was checked and calculated twice by two independent investigators (Yafei Zhang and Hong Ji). A standardized data extraction form was used to assist the two investigators. Data extracted from the included studies were as follows: author, year of publication, and country; patients' age and sex; study design; Child-Pugh class; treatment; pretreatment MELD score; BCLC stage; overall survival (OS); time to progression (TTP); hospitalization time days; tumor response; 1, 2, 3-year OS rate; complications and laboratory adverse events. A third reviewer (Hongwei Lu) would participate if some disagreements arose. Mean and standard deviation (SD) were preferred in some data, which will be calculated from the median and range using relevant formulae if it was not reported in the article (17).

2.3. Study inclusion and exclusion criteria

Inclusion criteria: patients were diagnosed as unresectable HCC; compared TARE with TACE monotherapy; compared efficacy and/or safety between TARE (Y90) and TACE. We excluded comments, editorials, systematic reviews or studies only in abstracts from our final analysis. Besides, there was no limitation for publication language.

2.4. Quality assessment

The quality of no cohort studies included in this meta analysis was assessed using a modified Newcastle-Ottawa scale (18), which graded the quality of a study from 0 to 9 points, depending on patient selection, comparability of TARE and TACE, and exposure assessment. Articles exceeding 6 points were considered as high quality.

2.5. Statistical analysis

All statistical analyses were performed using Review Manager (Revman, version 5.2.0, The Cochrane Collaboration, 2012) (19). The hazards ratio (HR) was used to evaluate the OS and TTP. Risk ratio (RR) was applied for tumor response, 1, 2, 3-year OS rates and clinical complications. Mean difference was used to evaluate the hospitalization time days. Afterward, 95% confidence intervals (CIs) were also calculated to indicate the precision of above effect measures. Pooled estimates of HR, RR or mean difference were calculated using the fixed-effects model if no substantial heterogeneity existed, otherwise, the random-effects model was used. Defined as variation between individual studies, heterogeneity was assessed with the Q-test and the I² statistic. Low level of heterogeneity was defined as I² value ≤ 50 % (20). The publication bias was evaluated using a funnel plot (21,22).

3. Results

3.1. Identification of eligible studies

The search strategy identified 2,306 related citations, and 1,543 non-duplicate references were retrieved for titles and abstracts screening. After 1,494 studies were excluded, the remaining 49 studies were examined at length. Finally, seven case control studies (23-29) and one cohort study (30) were eligible for inclusion criteria (Figure 1). A total of 1,499 patients were included among the eight studies, with 451 patients in the TARE group and 1,048 patients in TACE group.

3.2. Characteristics of eligible studies

The baseline characteristics of the eight studies included in our analysis are demonstrated in Table 1. The publication years of the included studies were between 2009 and 2014. Of these included studies, six
were conducted in USA (24-28,30), one in China (23), one in Germany combined with Egypt (29). All the studies were published in English. The baseline liver function of most included patients was in Child-Pugh A (23-29). The etiology of the included patients were reported in seven studies, and most of the patients were a result from HCV and alcohol (23-26,28-30). Three studies reported the BCLC stage, and more than half of the patients were in BCLC-B stage (24-26). The median pretreatment MELD score ranged from 7.5 to 10 (23,25,28,29). All the included patients were definitely diagnosed to conform to the eligibility criteria.

3.3. Quality of the included studies

The quality of the nocohort studies was assessed by the Newcastle-Ottawa Scale (NOS), six of the result scores were 6, and another was 7, indicating that these studies have high quality according to the criteria (Table 2).

3.4. Overall survival (OS)

Among the eight studies included in the meta-analysis, three studies reported the results of data on OS (947 patients) (26,28,30). The meta-analysis showed that the OS was significantly better in the TARE with Y90 group than in the TACE group. The pooled HR for the OS in the included studies performed using the fixed-effects was 0.74 (95% CI: 0.61-0.90; \( p = 0.002 \)). This demonstrated a 26% reduction in the risk of death in patients treated with TARE. There was no evidence of heterogeneity among individual studies (\( p = 0.20; I^2 = 38\% \)) (Figure 2A). Furthermore, the funnel plot revealed no publication bias.

3.5. Time to progression (TTP)

Two of the eight studies included in the meta-analysis reported the results of data on TTP (331 patients) (24,26). The meta-analysis showed that the TTP was significantly better in the TARE with Y90 group than in the TACE group. The pooled HR for the TTP in the included studies performed using the fixed-effects was 0.61 (95% CI: 0.41-0.89; \( p = 0.010 \)). This demonstrated a 39% reduction in the risk of TTP in patients treated with TARE. There was no evidence of heterogeneity among individual studies (\( p = 0.74; I^2 = 0\% \)) (Figure 2B). Furthermore, the funnel plot revealed no publication bias.

3.6. Hospitalization time days

Four of the eight studies included in the meta-analysis reported the results of data on hospitalization time days
Table 1. The baseline characteristics of the eight studies

<table>
<thead>
<tr>
<th>Study</th>
<th>country</th>
<th>Study design</th>
<th>Treatment</th>
<th>n</th>
<th>Age</th>
<th>Male/Female</th>
<th>HBV (%)</th>
<th>HCV (%)</th>
<th>Alcohol</th>
<th>Child-Pugh class (%) (A/B)</th>
<th>Pretreatment MELD score</th>
<th>BCLC stage (A/B/C/D)</th>
</tr>
</thead>
<tbody>
<tr>
<td>She et al. (2014)</td>
<td>China</td>
<td>Case Control study</td>
<td>TARE (90Y)</td>
<td>16</td>
<td>55 (37-73)</td>
<td>15/1</td>
<td>12 (75.0)</td>
<td>0</td>
<td>NA</td>
<td>15/1</td>
<td>7.5 (6-12)</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>TACE</td>
<td>16</td>
<td>62.5 (48-78)</td>
<td>13/3</td>
<td>13 (81.3)</td>
<td>3 (27.3)</td>
<td>NA</td>
<td>14/2</td>
<td>8.5 (6-12)</td>
<td>NA</td>
</tr>
<tr>
<td>El Fouly et al. (2014)</td>
<td>Germany + Egypt</td>
<td>Case Control study</td>
<td>TARE (90Y)</td>
<td>44</td>
<td>66.1 ± 8.9</td>
<td>36/8</td>
<td>6 (14)</td>
<td>8 (18)</td>
<td>10 (23)</td>
<td>37/7</td>
<td>9 ± 3</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>TACE</td>
<td>42</td>
<td>58.3 ± 6.7</td>
<td>38/4</td>
<td>1 (2)</td>
<td>36 (86)</td>
<td>NA</td>
<td>33/9</td>
<td>10 ± 2.5</td>
<td>NA</td>
</tr>
<tr>
<td>Moreno-Luna et al. (2013)</td>
<td>USA</td>
<td>Case Control study</td>
<td>TARE (90Y)</td>
<td>61</td>
<td>64 (29-88)</td>
<td>49/12</td>
<td>NA</td>
<td>8 (13)</td>
<td>12 (20)</td>
<td>53/8</td>
<td>9 (6-18)</td>
<td>23/13/19</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>TACE</td>
<td>55</td>
<td>66 (46-84)</td>
<td>43/12</td>
<td>NA</td>
<td>7 (13)</td>
<td>13 (24)</td>
<td>44/11</td>
<td>9 (6-19)</td>
<td>12/34/14</td>
</tr>
<tr>
<td>Salem et al. (2011)</td>
<td>USA</td>
<td>Case Control study</td>
<td>TARE (90Y)</td>
<td>123</td>
<td>66 (30-88)</td>
<td>87/36</td>
<td>13 (11)</td>
<td>42 (35)</td>
<td>20 (16)</td>
<td>67/54</td>
<td>NA</td>
<td>43/65/13/2</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>TACE</td>
<td>122</td>
<td>61 (33-88)</td>
<td>102/20</td>
<td>12 (10)</td>
<td>56 (46)</td>
<td>21 (17)</td>
<td>67/53</td>
<td>NA</td>
<td>47/61/12/2</td>
</tr>
<tr>
<td>Lance et al. (2011)</td>
<td>USA</td>
<td>Case Control study</td>
<td>TARE (90Y)</td>
<td>38</td>
<td>63 (44-85)</td>
<td>33/5</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>31/7</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>TACE</td>
<td>35</td>
<td>61 (51-84)</td>
<td>28/7</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>24/11</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Kooby et al. (2010)</td>
<td>USA</td>
<td>Case Control study</td>
<td>TARE (90Y)</td>
<td>27</td>
<td>58.7 ± 10.8</td>
<td>23/4</td>
<td>NA</td>
<td>10 (37)</td>
<td>NA</td>
<td>13/22</td>
<td>10.0 ± 3.4</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>TACE</td>
<td>44</td>
<td>61.0 ± 9.9</td>
<td>36/8</td>
<td>NA</td>
<td>25 (57)</td>
<td>NA</td>
<td>14/22</td>
<td>10.4 ± 4.2</td>
<td>NA</td>
</tr>
<tr>
<td>Carr et al. (2010)</td>
<td>USA</td>
<td>Cohort study</td>
<td>TARE (90Y)</td>
<td>99</td>
<td>NA</td>
<td>70/29</td>
<td>9 (9)</td>
<td>30 (30)</td>
<td>37 (37)</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>TACE</td>
<td>691</td>
<td>NA</td>
<td>518/173</td>
<td>97 (14)</td>
<td>132 (19)</td>
<td>217 (31)</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Lewandowski et al. (2009)</td>
<td>USA</td>
<td>Case Control study</td>
<td>TARE (90Y)</td>
<td>43</td>
<td>68 (62.8-75)</td>
<td>38/5</td>
<td>2 (5)</td>
<td>14 (33)</td>
<td>9 (20)</td>
<td>24/19</td>
<td>NA</td>
<td>0/34/9/0</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>TACE</td>
<td>43</td>
<td>65 (58.9-67.8)</td>
<td>36/7</td>
<td>6 (14)</td>
<td>16 (36)</td>
<td>10 (23)</td>
<td>23/18</td>
<td>NA</td>
<td>0/37/4/2</td>
</tr>
</tbody>
</table>

BCLC, Barcelona Clinic Liver Cancer.

Table 2. Newcastle-Ottawa Scale (NOS) for assessing the quality of cohort studies

<table>
<thead>
<tr>
<th>Author</th>
<th>Is the case definition adequate?</th>
<th>Representativeness of the cases</th>
<th>Selection of Controls</th>
<th>Definition of Controls</th>
<th>main factor: Child-Pugh Class</th>
<th>secondary factor: Aetiology</th>
<th>Ascertaining of exposure</th>
<th>Same method of ascertainment for cases and controls</th>
<th>Non-Response rate</th>
<th>Total quality score</th>
</tr>
</thead>
<tbody>
<tr>
<td>She et al. (2014)</td>
<td>*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>7</td>
</tr>
<tr>
<td>El Fouly et al. (2014)</td>
<td>*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>7</td>
</tr>
<tr>
<td>Moreno-Luna et al. (2013)</td>
<td>*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>7</td>
</tr>
<tr>
<td>Salem et al. (2011)</td>
<td>*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>7</td>
</tr>
<tr>
<td>Lance et al. (2011)</td>
<td>*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>7</td>
</tr>
<tr>
<td>Kooby et al. (2010)</td>
<td>*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>6</td>
</tr>
<tr>
<td>Lewandowski et al. (2009)</td>
<td>*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>7</td>
</tr>
</tbody>
</table>
The meta-analysis showed that the hospitalization time days was significantly shorter in the TARE with Y90 group than in the TACE group. The pooled mean difference for the hospitalization time days in the included studies performed using the random-effects was $-2.66$ (95% CI: $-4.08$ to $-1.24$; $p = 0.0002$). The heterogeneity among individual studies was ($p = 0.01$; $I^2 = 73\%$) (Figure 2C). Furthermore, the funnel plot revealed no publication bias.

### 3.7. Tumor response

The tumor response (involves CR [complete response], PR [partial response], SD [stable disease], PD [progressive disease], over-all tumor control [CR + PR + stable disease]) was reported in five case control studies (23,25,26,28,29) and one cohort study (30) (1,181 patients) (Table 3).

For CR, the pooled RR between TARE and TACE group was 1.92 (95% CI = 0.68-5.41; $I^2 = 0\%$) for case control study and 0.57 (95% CI = 0.18-1.80) for cohort study. The pooled RR of all six studies was (RR = 1.06; 95% CI = 0.51-2.22; $I^2 = 11\%$), and suggested that there was no statistical difference between groups (Table 3). Furthermore, the funnel plot revealed no publication bias.

For PR, the meta-analysis of case control studies suggested that the patients in the TARE group had a significantly better response than those in the TACE group (RR = 1.44; 95% CI = 1.02-2.04; $I^2 = 34\%$), but the pooled RR of the cohort study favored the TACE group (RR = 0.70; 95% CI = 0.54-0.90), meta analysis of all available studies suggested that there was no statistical difference between groups (RR = 1.24; 95% CI = 0.79-1.94; $I^2 = 76\%$) (Table 3). Furthermore, the funnel plot revealed no publication bias.

For SD, the meta-analysis in the subgroup of case control studies (RR = 1.05; 95% CI = 0.79-1.40; $I^2 = 0\%$) and subgroup of cohort study (RR = 1.23; 95% CI = 0.92-1.64) suggested the patients that underwent the TARE therapy tended to have a better response to treatment than those underwent TACE treatment, though the estimates failed to achieve statistical significance. Meta analysis of all available studies suggested that there was no statistical difference between groups (RR = 1.13; 95% CI = 0.92-1.39; $I^2 = 0\%$) (Table 3). Furthermore, the funnel plot revealed no publication bias.

For PD, the meta-analysis of case control studies suggested that there was no statistical difference between groups (RR = 0.62; 95% CI = 0.37-1.04; $I^2 = 29\%$), but the pooled RR of the cohort study suggested that the patients in the TARE group had a significantly
better response than those in the TACE group (RR = 2.14; 95% CI = 1.41-3.25), meta analysis of all available studies suggested that there was no statistical difference between groups (RR = 0.75; 95% CI = 0.37-1.51; $I^2 = 77\%$) (Table 3). Furthermore, the funnel plot revealed no publication bias.

For over-all tumor control, the meta analysis of case control studies suggested that the patients in the TARE group had a significantly better response than those in the TACE group (RR = 1.27; 95% CI = 1.14-1.42; $I^2 = 0\%$), but the pooled RR of the cohort study favored the TACE group (RR = 0.86; 95% CI = 0.77-0.96), meta analysis of all available studies suggested that there was no statistical difference between groups (RR = 1.16; 95% CI = 0.94-1.44; $I^2 = 80\%$) (Table 3). Furthermore, the funnel plot revealed no publication bias.
3.8. 1-year, 2-year, and 3-year OS rates

A fixed-effect model was used to analyze the 1-year ($p = 0.25, I^2 = 27\%$), 2-year ($p = 0.84, I^2 = 0\%$) and 3-year ($p = 0.50, I^2 = 0\%$) OS rates since there was no significant heterogeneity among these studies. Three studies reported 1-year OS rates (23,28,29) and two studies reported 2-year OS rates (25,29). The meta analysis showed that there was no statistical difference between groups on both 1-year (RR = 1.00, 95% CI 0.76-1.32, $p = 0.98$) (Figure 3A) and 2-year (RR = 1.19, 95% CI: 0.80-1.79, $p = 0.39$) (Figure 3B) OS rates. However, the pooled RR of three studies (23,25,29) suggested that the patients in the TARE group had a significantly higher 3-year OS rate than those in the TACE group (RR = 1.75; 95% CI = 1.01-3.03, $p = 0.05$) (Figure 3C). Furthermore, the funnel plot revealed no publication bias.
3.9. Clinical complications

We found that the TARE treatment lead to lower abdominal pain (24,25,29) (RR = 0.30, 95% CI: 0.11-0.83, p = 0.02) (Figure 4C) than TACE. However, the meta analysis showed that there was no statistical difference between groups on any complications (25,27,28) (RR = 0.74, 95% CI: 0.50-1.10, p = 0.14) (Figure 4A), fatigue syndrome (24,25,29) (RR = 1.21, 95% CI: 0.58-2.52, p = 0.61) (Figure 4B), nausea/vomiting (24,25,29) (RR = 0.59, 95% CI: 0.21-1.66, p = 0.32) (Figure 4D) or fever (24,25) (RR = 1.16, 95% CI: 0.07-18.61, p = 0.92) (Figure 4E). A random-effect model was used to analyze all the clinical complications for $I^2 > 50\%$ significant heterogeneity existed (Figure 4).

Furthermore, the funnel plot revealed no publication bias.

4. Discussion

As modest benefit locoregional therapeutic modalities for HCC, the use of TACE had been demonstrated by two landmark trials (31,32), which stated that TACE was the standard therapy for intermediate HCCs. TARE with Yttrium-90, however, shows low toxicity and may provide therapeutic benefits for patients with unresectable HCC (33). A randomized controlled trial showed a benefit progression free survival of TARE (Y90) in patient with liver metastasis to colorectal tumors, after which, TARE (Y90) has been approved by the FDA (34). Presently, the safety and effectiveness of TARE (Y90) in advanced HCCs especially associated with portal vein thrombosis have been partly affirmed by many studies (11,35-37). Therefore, it is necessary to compare the efficacy and safety of TARE with Y90 in patients with intermediate or advanced stage HCCs.

To the best of our knowledge, this meta analysis is the first and most comprehensive to compare the efficacy and safety of TARE with Y90 in patients with intermediate or advanced stage HCCs. Seven case control studies and one cohort study were identified and statistically analyzed in the present meta analysis, which included 451 and 1,048 patients with unresectable HCC who were treated with TARE (Y90) and TACE, respectively. With a relatively high level of evidence, the meta analysis showed that HCC patients treated with TARE (Y90) had significantly higher OS, TTP, 3-year OS rates, shorter hospitalization time days, better clinical complications and laboratory AEs than those treated with TACE. The TARE (Y90) therapy in the case control studies subgroup may also improve the PR and over-all tumor control treatment, while the total pooled estimates failed to achieve statistical significance.

Our meta analysis showed that the OS was significantly better in the TARE with Y90 group than in the TACE group (HR = 0.74; 95% CI: 0.61-0.90) (Figure 2A). This demonstrated a 26\% reduction in the risk of death in patients treated with TARE. Furthermore, the meta analysis showed that there was no statistical difference between groups on both 1-year (RR = 1.00, 95% CI: 0.76-1.32, p = 0.98) (Figure 3A) and 2-year (RR = 1.19, 95% CI: 0.80-1.79, p = 0.39) (Figure 3B) OS rates, however, the pooled RR of three studies suggested that the patients in the TARE group had significantly higher 3-year OS rate than those in the TACE group (RR = 1.75; 95% CI: 1.01-3.03, p = 0.05) (Figure 3C), suggesting that the effects of TARE (Y90) were gradually enhanced as time went by. While due to less patients included in our analysis, more studies with patients from different races are needed to further confirm this conclusion.

TTP is one of the most important indexes in treating intermediate stage HCC (26,38). El Fouly (29) reported that the TTP in TARE (Y90) patients (13.3 months) is much longer than in TACE patients (6.8 months), while the difference was not significant. In another study, TTP was significantly longer in a TARE (Y90) group than TACE (24). Our meta-analysis showed that the TTP was significantly better in the TARE with Y90 group than in the TACE group (HR = 0.61; 95% CI: 0.41-0.89), demonstrating a 39\% reduction in the risk of TTP in patients treated with TARE (Figure 2B).

Furthermore, the meta-analysis showed that the hospitalization time days were significantly shorter in the TARE with Y90 group than in the TACE group (mean difference = −2.66; 95% CI: −4.08 - −1.24) (Figure 2C). This may be explained by the fact that most patients were accompanied by re-hospitalization to receive consecutive cycles of TACE (29).

Recently, radiological response rate was assessed according to modified RECIST (5,39-41). In El Fouly's study (29), objective response during a median time of 6 months reached disease control in 75% of TARE (Y90) patients vs. 50% in the TACE cohort, which reflects the higher capability of TARE (Y90) to induce tumor necrosis and ablation in vascular HCCs (4). For the outcome of tumor response, we used subgroup analysis to pool data from case control studies and cohort studies separately according to the study design. For CR, PR, SD and PD and over-all tumor control, meta-analysis of all available studies suggested that there was no statistical difference between groups, though the subgroup of case control studies favored the TARE for PR and over-all tumor control (Table 3). For all the six available studies, five were case control studies, only one was a cohort study, although the cohort studies can reflect the “real-world” and further support the conclusion, cohort data are of course inclined to bias because of patient selection. Thus, physicians should carefully interpret the results when applying them in clinical practice.

Lastly, we found that the TARE treatment lead to lower abdominal pain (RR = 0.30, 95% CI: 0.11-0.83, p = 0.02) than TACE, TARE (Y90) injects radioactive particles into a selected liver artery without causing
arterial occlusion (42). So, there is no overexpression of hypoxia-inducible factor 1a and vascular endothelial growth factor, which is clinically manifested as pain (29). However, the meta-analysis showed that there was no statistical difference between groups on any complications (RR = 0.74, 95% CI: 0.50-1.10, p = 0.14) (Figure 4A), fatigue syndrome (RR = 1.21, 95% CI: 0.58-2.52, p = 0.61), nausea or vomiting (RR = 0.59, 95% CI: 0.21-1.66, p = 0.32) and fever (RR = 1.16, 95% CI: 0.07-18.61, p = 0.92) (Figure 4). The heterogeneity of meta-analysis in clinical complications is significant. This may be due to variety in treatment schedule and complication designing criteria in the original studies. As the number of included studies is insufficient, we are unable to carry out subgroup analysis or meta-regression to explore the source of heterogeneity. The most frequent clinical complication in TARE (Y90) patients is post-embolization fatigue syndrome. While our analysis result showed that there was no statistical difference between the two groups.

There are several potential limitations in this meta-analysis. First, among the eight included studies, only one was a cohort study and the remaining seven were case control studies. While case control data are of course inclined to bias because of investigator selection. Thus, physicians should carefully interpret our results when applying them in clinical practice. Second, the characteristics of population and study designs vary considerably between the included trials, which may lead to heterogeneity and affect the results. Third, the majority of patients involved were from the USA, which limits universality of the conclusion. Hence, the results of updated clinical trials are eagerly awaited. Furthermore, because of the limited number of studies regarding the interest outcomes, caution should be taken when interpreting the results.

In conclusion, the current meta-analysis suggests that TARE (Y90) is significantly better in OS, 3-year OS rates, TTP, hospitalization time days and some complications for patients with HCC. The use of TARE (Y90) for HCC patients is promising. However, further multi-center, well-designed RCTs are needed to improve the treatment benefits for HCC patients.

References


(Received June 26, 2015; Revised September 24, 2015; Accepted October 9, 2015)
Adenovirus-mediated P311 inhibits TGF-β1-induced epithelial-mesenchymal transition in NRK-52E cells via TGF-β1-Smad-ILK pathway

Fanghua Qi¹, Pingping Cai¹, Xiang Liu², Min Peng¹, Guomin Si¹,*

¹Department of Traditional Chinese Medicine, Shandong Provincial Hospital affiliated to Shandong University, Jin’nan, China; ²Department of Nephrology, Shandong Provincial Hospital affiliated to Shandong University, Jin’nan, China.

Summary P311, a highly conserved 8-kDa intracellular protein, has been indicated as an important factor in myofibroblast transformation and in the progression of fibrosis. In the present study, we constructed a recombinant adenovirus vector of p311 (called Ad-P311) and transferred it into rat renal proximal tubular epithelial cells (NRK-52E) to explore the effect of P311 on epithelial-mesenchymal transition (EMT) of NRK-52E cells induced by TGF-β1 and to elucidate its underlying mechanism against EMT. After successfully construction of Ad-P311 and transfer into NRK-52E cells, the proliferation and growth of P311-expressing cells was detected by MTT assay. TGF-β1 was used to induce NRK-52E cells and Western blot analysis was used to examine the EMT markers (E-cadherin and α-smooth muscle actin (α-SMA)), signal transducers (p-Smad2/3 and Smad7). Integran Linked Kinase (ILK) as a key intracellular mediator that controls TGF-β1-induced-EMT was also assayed by Western blot analysis. The results showed that P311 transfection could significantly inhibit the proliferation and growth of TGF-β1 induced NRK-52E cells. The results also showed that TGF-β1 could induce EMT in NRK-52E cells through Smad-ILK signaling pathway with an increase in α-SMA, pSmad2/3 and ILK expression, and a decrease in E-cadherin and Smad7 expression. However, P311 efficiently blocked Smad-ILK pathway activation and attenuated all these EMT changes induced by TGF-β1. These findings suggest that P311 might be involved in the pathogenesis of renal fibrosis by inhibiting the EMT process via TGF-β1-Smad-ILK pathway. P311 might be a novel target for the control of renal fibrosis and the progression of CKD.

Keywords: Renal fibrosis, P311, TGF-β1, epithelial-mesenchymal transition (EMT), NRK-52E cells

1. Introduction

Chronic kidney disease (CKD) has been recognized as a worldwide health issue because of its high prevalence and the accompanying increase in the risk of end-stage renal disease, cardiovascular events, and premature death (1). Renal fibrosis is a pivotal event in the progression of CKD, which is characterized by the deposition of extracellular matrix (ECM) (2). ECM is thought to be produced by myofibroblasts. Epithelial-mesenchymal transition (EMT) of tubular epithelial cells into myofibroblasts is one of the critical pathogenic mechanisms of renal fibrosis (3). During the EMT process, epithelial cells lose their polarity and epithelial surface markers such as E-cadherin, and acquire mesenchymal features such as α-smooth muscle actin (α-SMA) (4). Preventing EMT could ameliorate renal fibrosis and delay the progression of CKD.

Increasing evidence suggests that the EMT of renal tubules is regulated by different growth factors, cytokines, hormones and extracellular signals (5). TGF-β1 is regarded as one of the most important cytokines which regulates the transdifferentiation of tubular epithelial cells into myofibroblasts in renal
fibrosis. It has been shown to initiate and complete the whole EMT process (6). Emerging data indicate that TGF-β1 induced EMT via Smad-dependent and Smad-independent pathways. In the Smad-dependent pathway, TGF-β signals are transduced by transmembrane serine/threonine kinase type II and type I receptors (7). Upon TGF-β1 binding to its receptors, Serine/Threonine kinases are activated and induce phosphorylation of Smad2/Smad3, then phosphorylate Smad2/3 partners with Smad4 translocated into the nucleus where they regulate the transcription of the target genes responsible for EMT (8). Integrin Linked Kinase (ILK) is an intracellular serine/threonine kinase involved in cell-matrix interactions. It is shown to be a key intracellular mediator that controls TGF-β1-induced-EMT in renal tubular epithelial cells (9). Although the involvement of ILK in tubular EMT has been established by several lines of evidence, intriguingly, many components of ILK signaling, including ILK and β1-integrin are induced simultaneously by TGF-β in a Smad-dependent manner (3,10). Therefore, it is widely accepted that TGF-β1 plays an important role in promoting tubular EMT via TGF-β1-Smad-ILK pathway.

P311 is a highly conserved, 8-kDa intracellular protein with a PEST domain abundantly expressed in neurons and muscles (11). It can bind to TGF-β latency associated protein and stimulate the translation of TGF-β via TGF-β1-Smad-ILK pathway. P311 gene adenovirus plasmid was constructed according to previous studies (19). First, according to the sequence of GeneBank, the target gene P311-His_tag was designed and synthesized with His_tag sequence and Spel added at the 3' end and EcoRI added at the 5' end of the P311 gene. Second, both target gene P311-His_tag and shuttle vector pDown-MCS-IRES/eGFP were digested by EcoRI and Spel and recovered by agarose gel electrophoresis. Third, the digested products were purified and ligated with T4 DNA ligase and then co-transformed into E. coli stbl3 cells (Gibco, CA, USA). Thus, the fragment of P311-His_tag gene was cloned into the shuttle plasmid pDown-MCS-IRES/eGFP (Invitrogen, NY, USA), and the recombinant adenoviral plasmid was generated. Following amplification, the plasmid was extracted and cloned.

2. Materials and Methods

2.1. Cells

Rat renal proximal tubular epithelial cells NRK-52E and human embryonic kidney cells HEK293A were purchased from the Institute of Biochemistry and Cell Biology (Shanghai, China) and cultured in DMEM (Gibco, CA, USA) with 10% fetal bovine serum (FBS) (Gibco, CA, USA) in an atmosphere of 5% CO₂ at 37°C.

2.2. Construction and identification of plasmid

Determination of infection efficiency in NRK-52E cells infected by Ad-P311 in vitro and the most optimal MOI

The adenovirus Ad-CMV-eGFP was used as a control and the efficiency of infection was determined by the rate of GFP expression according to standard procedure.

www.biosciencetrends.com
and improved according to previous studies (20). Briefly, reconstructed adenovirus (stored at -80 °C) was serially diluted in DMEM without serum and pre-incubated with Lipofectamine 2000 at a final concentration of 1%. The virus-lipid mixture was incubated at 37 °C for 30 min before adding to the NRK-52E cells. NRK-52E cells within three generations were digested with trypsin and mixed, then transferred into 12-well plates at a density of 1 × 10⁴ cells/well with routine culture until firm adherence. Different volumes (2 μL, 4 μL, 6 μL, 8 μL, 10 μL, and 15 μL) of Ad-P311 and Ad-CMV-eGFP were respectively transferred into NRK-52E cells. Following incubation for 8 h (being rocked every 30 min) at 37°C, CO₂, the cells were routinely cultured for 48 h with complete medium and then observed under the inversion fluorescence microscope. The best multiplicity of infection (MOI) was worked out according to a formula (MOI) = (virus titer) × (virus liquid volume)/(cell number for transfection). The largest MOI not causing a marked cytopathic effect (CPE) was considered as the best MOI. The virus liquid was transferred into NRK-52E cells at its best MOI value in the following experiments.

2.5. P311 mRNA expression in NRK-52E Cells infected by Ad-P311

Firstly, NRK-52E cells were infected with Ad-P311 (as described above) for 48h, and then infected NRK-52E cells were collected. The mRNA expression of P311 was detected by quantitative real-time RT-PCR assay (21). The primers for the P311 and GAPDH were shown as follows: P311: forward 5'-AACAAGGACATGGAGGAAAGG-3' and reverse 5'-TAACTGATTCTTGGGAAAGGC-3'; GAPDH: forward 5'-GGCTCATGACCACAGTCCAT-3' and reverse 5'-TAACTGATTCTTGGGAAAGGC-3'. GAPDH are shown as follows: P311: forward 5'-TCAGCTCTGGGATGACCTTG-3'. First, reverse transcribed into cDNA using the SuperScript II manufacturer's instructions. Then, total RNA was prepared from the cells using TRIzol (Grand Island, NY, USA) reagent according to the manufacturer's instructions. Then, total RNA was reverse transcribed into cDNA using the SuperScript II First Strand Synthesis System (Grand Island, NY, USA) according to the manufacturer's directions. Afterwards, according to the protocol of SYBR Premix Ex Taq™ kit (TaKaRa Bio Inc., Dalian, China), amplification of target gene and GAPDH were conducted using ABI Prism 7500 Detection System (Applied Biosystems, Inc., USA). The analysis of relative gene expression was performed by comparative 2⁻ΔΔCT method.

2.6. Cell treatment

After infection with adenovirus, cells were treated and divided into six groups as follows: NRK-52E group, NRK-52E/GFP group (infected by Ad-CMV-eGFP), NRK-52E/P311 (infected by Ad-P311), and TGF-β1 (5 ng/mL) induced groups: NRK-52E (TGF-β1) group, NRK-52E/GFP (TGF-β1) group, and NRK-52E/P311 (TGF-β1) group. NRK-52E group was control group and the other five groups were treatment groups. At the indicated time points, cells were harvested and processed for the following experiments.

2.7. Cell proliferation assay

A MTT (3-[4, 5-dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide) assay was used to detect cell viability as previously described (22). The cells were cultured at a density of 6 × 10⁴ cells/well in triplicate in 96-well plates with TGF-β1 (5 ng/mL) for 7 days and exposed to fresh media and TGF-β1 every other day. MTT assay was performed every day up to the 7th day. Briefly, 20 μL of 5 mg/mL MTT (Sigma, St. Louis, MO, USA) was added to each well; plates were incubated at 37°C for 4 h. The generated formazan was dissolved in 150 μl dimethyl sulfoxide (DMSO) and measured with a microplate reader (BioRad, Hercules, CA) at an optical density (OD) at 570 nm for determining cell viability. Cell proliferation rate was calculated according to a formula as follows: Cell proliferation rate (%) = OD value of treatment group/OD value of control group × 100%.

2.8. Western blot analysis

After culturing with TGF-β1 (5 ng/mL) for 48h, total cell lysates and cytosolic fractions were prepared as previously described (21). Thirty micrograms of total cellular proteins were resolved using sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS PAGE) and transferred onto polyvinylidene fluoride (PVDF) transfer membranes for Western blotting. The results were quantified using Image J (National Institutes of Health, Bethesda, MD, USA). The following antibodies were used: Smad2/3, Smad7, α-SMA, E-cadherin, ILK, and GAPDH (Santa Cruz Biotechnology, Santa Cruz, CA, USA).

2.9. Statistical analysis

Statistical analysis was performed using SPSS software, version 17.0 (SPSS Inc., USA). The data are expressed as the mean ± standard deviation (SD). The statistical significance differences were calculated using the t-test and one-way analysis of variance (ANOVA), and p < 0.05 was considered statistically significant.

3. Results

3.1. Construction of pAd-P311

The sequence of P311-His_tag was confirmed to be correct by restriction endonuclease reaction (Figure
1A). Then P311-His_tag was cloned into shuttle vector pDown-MCS-ires-eGFP carrying the GFP gene to generate a recombinant plasmid pDown-P311-His_tag-IRES/eGFP and confirmed to be correct by direct sequencing once again and restriction endonuclease reaction. The pDown-P311-His_tag-IRES/eGFP and pAV.Des1d were linearized and simultaneously electroporated into host bacteria E. coli stbl3 cells (lane 1-8, about 1740 bp). (C) HEK293A cells infected by CMV-P311-His-tag-IRES-eGFP. After 8 days infection, the white light and fluorescence were seen (>100).

Figure 1 The construction and identification of Ad P311. (A) P311-His_tag (lane 1 and 2) and shuttle vector pDown-MCS-IRES/eGFP (lane 3 and 4) were digested by EcoRI and SpeI (P311-His tag fragment about 248 bp, and shuttle vector pDown-MCS-IRES/eGFP about 3.8 kb). Lane M: 1-10 kbp DNA Ladder marker. (B) pAV.Exd-P311-His_tag-IRES/eGFP was produced in E. coli stbl3 cells (lane 1-8, about 1740 bp). (C) HEK293A cells infected by CMV-P311-His-tag-IRES-eGFP.

3.2. The efficiency of infection in NRK-52E cells by recombinant Ad-P311

When different volumes (2 μL, 4 μL, 6 μL, 8 μL, 10 μL, and 15 μL) of Ad-P311 and Ad-CMV-eGFP were respectively transferred into NRK-52E cells for 48h, the efficiency of infection was detected using the inverted fluorescence microscope. After infection by Ad-P311 at a volume of 6μL or higher, the transfection rate of NRK-52E cells could reach more than 90% (Figure 2A), and the best MOI was 2205. After infection by Ad-CMV-eGFP at a volume of 4 μL or higher (B), the transfection rate of NRK-52E cells also could reach more than 90% (Figure 2B), and the best MOI was 628. These results indicated that the adenovirus-mediated transfection had a high efficiency in NRK-52E cells.

3.3. P311 mRNA expression in NRK-52E cells infected by recombinant Ad-P311

After determination of optimal MOI as described above, we then infected NRK-52E cells with Ad-P311 (MOI = 2205). The mRNA expression of P311 in NRK-52E cells infected by recombinant Ad-P311 was detected by quantitative real-time RT-PCR assay. As shown in Figure 3, compared to the NRK-52E group and NRK-52E/GFP group, the mRNA expression of P311 in the NRK-52E/P311 group increased significantly. Furthermore, there is no significant difference between NRK-52E group and NRK-52E/GFP group on mRNA expression of P311. These results showed that P311 was expressed stably in
NRK-52E cells after being infected with Ad-p311.

3.4. Growth curve of TGF-β1-induced NRK-52E cells infected by Ad-P311

MTT assays were performed to investigate the effects of P311 on the proliferation of TGF-β1-induced NRK-52E cells, and a growth curve was drawn according to the results. As shown in Figure 4, after incubation with Ad-P311 for 7 days, P311 had a significant growth-inhibiting effect on the TGF-β1-induced NRK-52E cells. The cell proliferation rate was higher in the NRK-52E (TGF-β1) group than in the NRK-52E group, which indicated that TGF-β1 had the effect of inducing NRK-52E cell proliferation. Compared to the NRK-52E (TGF-β1) group, the cell proliferation rate in the NRK-52E/P311 (TGF-β1) was decreased significantly. These results showed that P311 had a significant growth-inhibiting effect on NRK-52E cells.

3.5. EMT related proteins expression in TGF-β1-induced NRK-52E cells infected by Ad-P311

To explore the effect of P311 on TGF-β1-induced EMT in NRK-52E cells, the expression of the epithelial marker E-cadherin, and the mesenchymal marker

www.bioscientetrends.com
α-SMA were examined by Western blot analysis. As shown in Figure 5A and 5B, exposure of cells to TGF-β1 resulted in a significant reduction in E-cadherin and an increase in α-SMA, compared with control. P311 significantly prevented TGF-β1 stimulated changes of E-cadherin and α-SMA expression. These results suggest that P311 prevents the loss of the epithelial marker Ecadherin and the de novo expression of myofibroblast marker α-SMA in renal epithelial cells stimulated by TGF-β1.

To explore the possible mechanism of P311 on TGF-β1-induced EMT in NRK-52E cells, the protein expression of EMT related proteins Smad2/3, Smad7, and ILK were measured by Western blot analysis. As shown in Figure 5C and 5D, exposure to TGF-β1 resulted in a significant increase in Smad2/3 phosphorylation and ILK expression, and a significant reduction in Smad7 expression compared with control. Ad-P311 transfection significantly decreased the phosphorylation of Smad2/3 and the expression of ILK in NRK-52E cells compared with TGF-β1-treated group. These results suggest that P311 inhibits TGF-β1-induced EMT in NRK-52E cells via regulating the expression of Smad2/3, Smad7 and ILK.

4. Discussion

Although previous work has suggested P311 might be an important factor in myofibroblast transformation and in the progression of fibrosis, the related reports about P311 on renal fibrosis are limited and the mechanism of P311 in the progression of CKD remains largely unknown. EMT plays important roles in accelerating renal fibrosis and promoting the progression of CKD. TGF-β1 is a well-known profibrotic cytokine in several renal diseases and plays a critical role in the renal EMT process. Thus, in the current study, we constructed a recombinant adenovirus vector of p311 and transferred it into NRK-52E cells to explore the preventive effect and possible mechanism of P311 on TGF-β1-induced EMT.

We first successfully constructed recombinant adenovirus vector of P311 (called Ad-P311) and transferred it into rat renal tubular epithelial cells NRK-52E (Figure 1). Then we investigated the effects of Ad-P311 transfection on the biological characteristics of NRK-52E cells. Transfection efficiency of Ad-P311 in NRK-52E cells was evaluated by expression of GFP under the fluorescence microscope (Figure 2). After infection by Ad-P311 at a volume of 6μL or higher, the transfection rate of NRK-52E cells could reach more than 90% and the best MOI was 2205, which indicated that the adenovirus-mediated transfection (Ad-P311) had a high efficiency in NRK-52E cells. To investigate the expression of P311 in NRK-52E cells after transfection, the quantitative real-time RT-PCR assay was performed. Results showed that mRNA expression of P311 was specifically expressed in NRK-52E/P311 cells rather than in NRK-52E cells or NRK-52E/GFP cells (Figure 3). All these findings demonstrate that the P311 gene can be highly and stably transfected into NRK-52E cells with adenovirus mediation.

We investigated the proliferation and growth of P311-expressing cells by MTT assay (Figure 4). From the growth curve of NRK-52E cells, we could see that TGF-β1 had a significant effect on inducing NRK-52E cell proliferation. The cell proliferation rate was higher in the NRK-52E (TGF-β1) group than that in the NRK-52E group. We also could see that P311 had a significant growth-inhibiting effect on the TGF-β1-induced NRK-52E cells. Compared to the NRK-52E (TGF-β1) group, the cell proliferation rate in the NRK-52E/P311 (TGF-β1) group was decreased significantly. All these findings demonstrate that P311 transfection can significantly inhibit the proliferation and growth of TGF-β1 induced NRK-52E cells.

To investigate the possible mechanism by which the P311 gene inhibits cell proliferation and TGF-β1 induced EMT in NRK-52E cells, Western blot analysis was performed to detect the expression of EMT-related proteins and signal pathways. EMT is well known as an important process in the pathogenesis of tubulointerstitial fibrosis and involves a loss of epithelial cell characteristics (loss of E-cadherin) and an increase of mesenchymal cell markers (e.g., α-SMA). TGF-β1 is identified as the most potent mediator and convergent pathway in inducing EMT and renal fibrosis (23). Here we found that exposure to TGF-β1 for 48 h in NRK-52E cells, E-cadherin expression was decreased and α-SMA expression was increased significantly (Figure 5A and 5B). However, P311 significantly reverses all of above changes in vitro (Figure 5A and 5B). These results suggest that P311 prevents TGF-β1-mediated renal EMT in vitro.

TGF-β1/Smads signal pathway has been shown to play a critical role in the process of inducing EMT (7). The Smad family has 8 members forming three subfamilies: the R-Smads (receptor regulated Smads), the Co-Smads (common Smad mediators), and the I-Smads (inhibitory Smads), which are the main TGF-β signaling transducers, mediating signaling from cell surface receptors to nuclear target genes (24). Homologous proteins Smad2 and Smad3 belong to the R-Smads, which are highly activated in the fibrotic kidney. It has been demonstrated that activation of TGF-β1 signaling triggers a dramatic induction of Smad2/3 phosphorylation (25). Smad7, as an inhibitory regulator in the TGF-β/Smad signaling pathway, can be induced by TGF-β1 to block the overactivation of TGF-β signals via its negative feedback loop. TGF-β not only induces Smad7 transcription, but also promotes the degradation of Smad7 via the Smad3-dependent Smurfs/arkadia-mediated ubiquitin-proteasome degradation pathway (26). In this study, we investigated the effects of P311 on the TGF-β1/
Smads signal pathway in NRK-52E cells. Here we found that exposure to TGF-β1 for 48 h in NRK-52E cells, p-Smad2/3 expression was increased and Smad7 expression was decreased significantly (Figure 5C and 5D). However, P311 significantly reverses all of the above changes in vitro (Figure 5C and 5D). Our results showed that P311 inhibited p-Smad2/3 activation and promoted Smad7 activation induced by TGF-β1 in NRK-52E cells. We also further studied the effects of P311 on ILK expression, which was the important downstream mediator of TGF-β1/Smads signaling pathway. ILK has shown to be a key intracellular mediator that controls TGF-β1-induced EMT in renal tubular epithelial cells (9). Here we found that exposure to TGF-β1 for 48 h in NRK-52E cells, ILK expression was increased significantly (Figure 5C and 5D), however, P311 significantly reverses the above changes in vitro (Figure 5C and 5D). These results showed that infection of P311 in NRK-52E cells attenuated TGF-β1-induced upregulation of ILK expression.

In conclusion, our data present that P311 could block TGF-β1-induced EMT probably by inhibiting the activation of p-Smad2/3 and ILK and promoting the activation of Smad7 in NRK-52E cells. These findings suggest that P311 might be involved in the pathogenesis of renal fibrosis by inhibiting the EMT process via the TGF-β1-Smad-ILK pathway (Figure 6). P311 might be a novel target for control of renal fibrosis and progression of CKD.

Acknowledgements

The current work was supported by the National Natural Science Foundation of China (No. 81273682) and the Science and Technology Development Program of Shandong Province (No. 2010G0020220).

References


www.biosciencetrends.com


(Received September 29, 2015; Revised October 12, 2015; Accepted October 15, 2015)
DHEA promotes osteoblast differentiation by regulating the expression of osteoblast-related genes and Foxp3\(^+\) regulatory T cells

Xuemlin Qiu\(^{1,2}\), Yuyan Gui\(^{1,2}\), Yingping Xu\(^{1,2}\), Dajin Li\(^{1,*}\), Ling Wang\(^{1,2,*}\)

\(^{1}\) Obstetrics and Gynecology Hospital, Fudan University, Shanghai, China; \(^{2}\) Shanghai Key Laboratory of Female Reproductive and Endocrine-related Disorders, Shanghai, China.

Summary

Several studies have reported that dehydroepiandrosterone (DHEA) promotes osteoblast proliferation and inhibits osteoblast apoptosis and that DHEA inhibits osteoclast maturation. However, whether DHEA regulates osteoblast differentiation remains unclear. The present study first examined the effect of DHEA on bone morphology \textit{in vivo}. DHEA was found to increase bone volume (BV), bone mineral density (BMD), and the number of trabeculae in bone (Th.N) and it was found to decrease trabecular spacing in bone (Th.sp) in ovariectomized (OVX) mice. Next, the effect of DHEA on osteoblast differentiation was examined \textit{in vitro} and osteoblastogenesis-related marker genes, such as \textit{Runx2}, \textit{Osterix}, \textit{Collagen1}, and \textit{Osteocalcin}, were also detected. DHEA increased osteoblast production in mesenchymal stem cells (MSCs) cultured in osteoblastogenic medium, and DHEA increased the expression of \textit{Runx2} and \textit{osterix}, thereby increasing the expression of osteocalcin and \textit{collagen1}. Immune cells and bone interact, so changes in immune cells were detected \textit{in vivo}. DHEA increased the number of Foxp3\(^+\) regulatory T cells (Tregs) in the spleen but it did not affect CTLA-4 or IL-10. When MSCs were treated with DHEA in the presence of Tregs, alkaline phosphatase (ALP) activity increased. Osteoblasts and adipocytes are both generated by MSCs. If osteoblast differentiation increases, adipocyte differentiation will decrease, and the reverse also holds true. DHEA was found to increase the number of adipocytes in osteoblastogenic medium but it had no effect on the number of adipocytes and expression of PPAR\(\gamma\) mRNA in adipogenic medium. This finding suggests that osteoblasts may be involved in adipocyte production. In conclusion, the current results suggest that DHEA can improve postmenopausal osteoporosis (PMO) by up-regulating osteoblast differentiation \textit{via} the up-regulation of the expression of osteoblastogenesis-related genes and \textit{via} an increase in Foxp3\(^+\) Tregs.

Keywords: DHEA, postmenopausal osteoporosis, MSCs, osteoblast, adipocyte, regulatory T cells

1. Introduction

The level of dehydroepiandrosterone (DHEA) in postmenopausal women is lower than that in fertile women, which suggests the potential clinical benefit of DHEA as treatment for postmenopausal osteoporosis (PMO) (1). Treatment of postmenopausal osteoporosis is mainly hormone replacement therapy, but this therapy is often accompanied by adverse reactions, limiting its use (2,3). The pressing task is to identify a new way to treat PMO that can prevent osteoporosis without causing adverse reactions.

Mesenchymal stem cells (MSCs) are able to differentiate into multiple types of cells. Under certain conditions, MSCs can be induced to differentiate into osteoblasts, adipocytes, cartilage cells, and other types of cells (4,5). Inducing MSCs to differentiate into osteoblasts and inhibiting MSCs from differentiating into adipocytes is crucial to preventing PMO.

DHEA begins to increase when the adrenal cortex...
begin to function and it gradually decreases after puberty. Along with other endocrine hormones, DHEA in the blood decreases with the onset of menopause. DHEA can prevent diabetes, cancer, and heart disease and it can enhance immune function, suggesting that DHEA can prolong survival and improve the quality of life.

DHEA has a positive effect on bone metabolism (6-8). DHEA can promote the growth and proliferation of osteoblasts, and mitogen-activated protein kinase signaling pathways are required for expression of osteoblast-specific genes. DHEA can promote a shift in the Th1/Th2 ratio towards Th2, thus improving osteoblast-specific genes. DHEA can promote a shift in the Th1/Th2 ratio towards Th2, thus improving immunity in a model of PMO.

Immune cells and bone interact (9-11). Regulatory T cells (Tregs) are important immunosuppressive cells that regulate the functioning of osteoblasts and osteoclasts (12,13). Whether DHEA affects immune cells and then affects bone metabolism is unclear. Whether DHEA affects the differentiation of MSCs into osteoblasts or adipocytes and the means by which it does so are still unknown. The present study will explore the mechanisms by which DHEA affects the differentiation of MSCs.

2. Materials and Methods

2.1. Mice and reagents

C57BL/6 mice (6-8 weeks of age) were provided by the Laboratory Animal Facility of the Chinese Academy of Sciences (Shanghai, China) and were housed and handled in accordance with the guidelines of the Chinese Council for Animal Care. Sham-operated mice were used as controls, and ovariectomized (OVX) mice were used as a model of PMO. Mice in the sham-operated group underwent surgery but were not OVX. Mice in the treatment groups underwent a bilateral ovariectomy and were divided into 3 groups (OVX, OVX + DHEA, and OVX + E2). One week later, the sham-operated group was treated with saline (containing 0.1% ethanol), and OVX mice group in the treatment groups were given saline, DHEA (5 mg/kg per day orally), or estrogen (100 μg/kg per day orally) (6). The four groups received equal quantities of fluids at the same time during treatment. All mice were sacrificed after 3 months of treatment. Blood was collected from the heart and serum was stored at -80°C for use in cell culture, the spleen was collected for analysis of Tregs, and femurs were stored for micro-CT analysis (14).

2.3. Flow cytometry (FCM)

The spleen was harvested from mice in every group and mechanically disrupted in 10 mL of PBS. The cell suspension was then filtered through nylon mesh with a pore size of 110 μm and treated with NH4Cl/Tris buffer to remove RBC. The cells were then washed three times and transferred into tubes (100 μL per tube) for immunolabeling. The cells were fixed, permeabilized, and stained for Foxp3, IL-10, CTLA-4 using PE-labeled antibodies after cells were labeled with CD4 (FITC) and CD25 (APC). The cells were then washed twice and resuspended in PBS for FCM with a flow cytometer (Becton Dickinson, Palo Alto, CA, USA). PE-conjugated isotypes were used as controls. Statistical analysis was done using isotype-matched controls.

2.4. MSC culture

MSCs were cultured as previously described (15). Mice were anesthetized with 10% chloral hydrate and immersed in 75% ethanol for 10 min. Under aseptic conditions, the femur was removed and rinsed three times with PBS. The epiphysial end of the femur was removed, revealing the marrow cavity. Bone marrow was removed, placed in L-DMEM with penicillin and streptomycin, and repeatedly sieved to obtain a single cell suspension. The suspension was centrifuged at 1,000 r/min for 5 min and the supernatant was discarded. The concentrated cells were placed in culture bottles at a concentration of 1 × 10^6 L^-1 cells. Cells were cultured at 37°C in a 5% CO₂ environment with saturated humidity. Medium was supplemented after 48 h. Medium was completely replaced with fresh medium every 3 d. Cells covering the bottom of the culture bottle formed a 70-80% confluent monolayer. After digestion with 0.25% trypsin, cells were subcultured at a ratio of 1:2.

2.5. MSC-derived osteoblasts

MSCs were seeded as previously reported (16) in order to induce differentiation into osteoblasts. Twenty-four hours after seeding, the growth medium was replaced with osteoblastogenic medium (OM) and 10% FCS was replaced with solvent alone (control), 10^-7 M DHEA, or 10^-7 M E2. Medium was changed every 2-3 days. After 14-21 days of osteogenic differentiation, cells were fixed with 70% ethanol for 1 h, washed three times with demineralized water, and then stained with an ALP.
solution/alizarin red solution for 10 min. Finally, cells were washed three times with PBS.

ALP precipitates were solubilized to quantify ALP activity. Briefly, stained samples were incubated with 800 mL acetic acid (10%) for 30 min, the supernatant was transferred into a 1.5 mL tube and boiled for 10 min at 85°C, and then the supernatant was placed on ice for 5 min. After centrifugation (15,000/g, 15 min), 500 µL of the supernatant was transferred into another 1.5-mL tube and mixed with 200 µL of 10% ammonium hydroxide. Samples were transferred into a 96-well microtiter plate and optical density was measured at 405 nm using a standard ELISA reader. P was calculated with a student's t-test (n = 3) to detect statistically relevant differences.

2.6. MSC-derived adipocytes

Adipogenic culture of MSCs as reported (17) was performed to induce differentiation into adipocytes. Briefly, MSCs in the second or third passage were induced to form adipocytes in an adipogenic medium (α-MEM and 10% FBS) for up to 12 days as determined by peak adipogenesis. At that point, the medium was changed to an adipocyte-sustaining medium consisting of high-glucose DMEM with 10 µg/mL insulin and 10% FBS to promote adipocyte maturity. Cultures were analyzed prior to adipogenesis on day 0 and at specific points in time over a period of 25 days.

2.7. Oil Red O staining

Cells were fixed with 4% paraformaldehyde for 20 min at 4°C. Cells were rinsed and washed and then stained with Oil Red O solution for 15 min to stain lipid droplets/vacuoles. Cells in random fields were manually counted and the number in 5 high power fields was averaged.

2.8. Real-time PCR

RNA treated with DNase was isolated from MSC-derived osteoblasts and adipocytes, enriched adipofibroblasts, and lipid-laden adipocyte cultures at specific time-points using an RNeasy Mini Kit in accordance with the manufacturer’s instructions (Qiagen). Cells were lysed on plates in buffer containing GITC (Buffer RLT). Reverse Transcription was performed immediately after RNA isolation using a Transcriptor First Strand cDNA synthesis kit and oligo-dT primers (Roche, Branchburg, NJ). Real-time PCR was performed using SybrGreen and Taqman technology. Briefly, 10 µL of SybrGreen Master Mix (Applied Biosystems, Darmstadt, Germany) was mixed with 1 µL (10 pg) of forward primer, 1 mL (10 pg) of reverse primer, 6.8 mL of water, and 1.2 mL (60 ng) of template. Levels of expression of the beta-actin gene were used to normalize mRNA expression for real-time PCR. Reactions were performed using the following conditions: 95°C for 10 min and cycles of 95°C for 15 sec, 55-60°C for 30 sec, and 72°C for 30 sec for 40 cycles. The primers used for each gene were as follows: Runx2: Forward GACAGTCCAACCTTCTGTG, Reverse GCAGCAGGTCTCTCACTTC; Osterix: Forward GCTCGTAGATTTCTATCCTC, Reverse CTAGTGACTGCTAAGAGA; Collagen I: Forward TGCCTGGCTGGAGATTCTG, Reverse GCTGCTGTGACATCCATACTT; PPARγ: Forward GAAATAGTACGACTGCTTGGC, Reverse ATCTTCTGGACACCTTGGC; β-actin: Forward CCTCTATGCCAACACAGT, Reverse AGCCACCAATCCACACAG.

2.9. Statistical analysis

All values are expressed as the mean ± SEM. Data were analyzed with the aid of SPSS database, and variance was evaluated with one-way ANOVA. Differences were considered significant at p < 0.05.

3. Results

3.1. The effects of DHEA on bone morphology

Bone volume (BV), bone mineral density (BMD), and the number of trabecules in bone (Tb.N) were lower in the OVX group than in the sham-operated group (p < 0.05). Trabecular spacing (Tb.sp) was wider in the OVX group than in the sham-operated group (p < 0.05), suggesting that a mouse model of PMO was successfully established. Compared to the OVX group that was treated with saline, the OVX + DHEA and OVX + E2 groups had a higher BV, BMD, and Tb.N and a smaller Tb.sp, suggesting that DHEA and E2 improved bone morphology in mice with osteoporosis (Figure 1).

3.2. DHEA increases osteoblastogenesis by up-regulating the expression of osteoblastogenesis-related genes

In osteoblastogenic medium, DHEA promoted MSCs to differentiate into osteoblasts. The ALP activity of osteoblasts was higher in groups treated with DHEA or E2 than that in the control group (p < 0.05) (Figure 2A). The number of bone nodules also increased in the groups treated with DHEA or E2 compared to the control group (p < 0.05) (Figures 2B and 2C). The expression of mRNA by osteogenesis-related genes was examined using real-time PCR in order to explore the mechanisms by which DHEA regulates MSC differentiation. Compared to the control treatment, DHEA and E2 promoted expression of collagen I, osteocalcin, Runx2, and osterix. However, there was no difference in levels of expression in the two groups (Figure 2D).
DHEA increases the proportion of Foxp3+ Tregs in the spleen and enhances osteoblastogenesis

Immune cells can influence bone metabolism, so this study determined whether immune cells were affected after DHEA treatment. Changes in spleen-derived immune cells after DHEA treatment were examined first. Compared to the sham-operated group, the OVX

Figure 1. Effects of DHEA on bone morphology in OVX mice. Sham mice underwent mock surgery and received saline. Ovariectomized (OVX) mice underwent bilateral oophorectomy and were randomly divided into three groups: OVX (treated with saline), OVX + DHEA (treated daily with 5 mL of mixed raw herbs [BSNXD] per kg body weight), and OVX + E2 (treated daily with 5 mL of DHEA per kg body weight). Femur samples were harvested after 12 weeks of treatment. Micro-CT was performed to determine the bone morphology in femurs. Bone volume, bone mineral density, the number of trabecules in bone, and trabecular spacing were measured at the original magnification (200×). Data are presented as the mean ± SEM. (n = 6). * p < 0.05, ** p < 0.01 compared to the OVX group.

Figure 2. DHEA increased ALP activity and expression of mRNA by osteoblastogenesis-related genes. Primary MSCs were exposed to control serum, 10^-7 M DHEA, or 10^-9 M E2 for 48 h under osteoblastogenic conditions. The ALP activity of osteoblasts was determined with a kit to analyze ALP activity after 7 days of culturing (2A), alizarin red staining was performed after 21 days of culturing (2B), and the number of mineralized bone nodules was counted (2C). Runx2, osteix, collagen I, and osteocalcin mRNA were analyzed (2D). Data are presented as the mean ± SEM. (n = 6). * p < 0.05, ** p < 0.01 compared to the control group.
group had fewer Foxp3-positive Tregs. DHEA treatment increased the percentage of Foxp3\(^+\) Tregs (\(p < 0.05\)) while E2 did not. Conversely, E2 treatment increased the percentage of CTLA-4\(^+\) Tregs but DHEA did not significantly influence the number of Tregs (Figure 3). MSCs were cultured in the presence or absence of Tregs in order to determine the effects of Tregs on DHEA-mediated differentiation of MSCs. In the presence of Tregs, ALP activity was higher and bone nodular production increased, suggesting that Tregs can enhance the effect of DHEA on differentiation of MSCs (Figure 3).

3.4. DHEA does not directly affect adipocyte differentiation

MSCs can differentiate into osteoblasts and adipocytes. Increased numbers of adipocytes indicate a significant risk of PMO developing. MSCs cultured in osteoblastogenic medium and treated with DHEA had increased numbers of adipocytes. However, MSCs cultured in adipogenic medium and treated with DHEA or E2 did not produce different numbers of adipocytes. The transcription factor PPAR\(\gamma\) regulates adipogenesis. Expression of this gene was assessed using real-time PCR, and the levels of expression in the group treated with DHEA did not differ from those in the control group and the group treated with E2 (Figure 4).

4. Discussion

Mature OVX mice were previously used to model postmenopausal bone loss (18). Analysis of bone morphology has revealed that OVX mice have significantly reduced bone mass, bone density, and fewer trabecules in bone as well as significantly wider trabecular spacing compared to sham-operated mice (19). These findings were evident in the present study, suggesting that a model of PMO was successfully established.

After treatment with DHEA, the OVX mice had significantly increased bone mass, bone density, and more trabecules in bone as well as significantly smaller trabecular spacing, suggesting that DHEA significantly improves bone morphology. An improvement in bone morphology can increase the mechanical strength and integrity of bone and affect bone growth, suggesting that DHEA has clinical significance in the prevention and treatment of PMO.

Runx2 and osterix are transcription factors associated with osteoblastogenesis while collagen1 and osteocalcin are genes expressed in osteoblasts; all four of these genes are markers of different stages of bone
development (20-22). PPARγ is a transcriptional factor that regulates adipogenesis (23). Although DHEA increases the number of adipocytes in osteoblastogenic medium, it produces no changes in the number of adipocytes in adipogenic medium (24-30). Tregs affect bone metabolism, and this action is directly regulated by Foxp3 and CTLA-4 or it is indirectly regulated by TGF-β and IL-10 (31-36). DHEA can markedly increase the proportion of Foxp3
Tregs and encourage osteoblast differentiation to prevent PMO. DHEA does not affect the ratio of CTLA 4
or IL-10
Tregs, suggesting that DHEA plays a role on osteoblast differentiation via Foxp3.
In a previous study, the current authors found that DHEA significantly promoted proliferation and inhibited apoptosis of osteoblast via mitogen-activated protein kinase signaling pathways independent of either androgen receptors or estrogen receptors, suggesting that it may play a direct role via a DHEA-specific receptor instead of via conversion to androgens or estrogens (6).
Results of in vivo and ex vivo experiments revealed that DHEA can directly promote differentiation of MSCs into osteoblasts. DHEA increased the expression of Runx2, Collagen1, Osterix, and Osteocalcin mRNA, increasing the ALP activity of osteoblasts and the number of mineralized bone nodules. DHEA increases the number of Foxp3
Tregs, increasing osteoblast differentiation. Therefore, DHEA is likely to be an ideal solution to prevent and treat PMO.

**Acknowledgements**

This work was supported by a grant from the National Natural Science Foundation of China (grant no. 81401171 to XM Qiu), a grant from the National Natural Science Foundation of China (grant no. 31571196 to L Wang), a grant from the Shanghai Municipal Science and Technology Commission for a 2015 Science and Technology Project to Guide Medicine (project no. 15401932200; L Wang), a grant from the 2008 JSPS Postdoctoral Fellowship for Foreign Researchers (P08471; L Wang), a grant from the National Natural Science Foundation of China (grant no. 30801502; L Wang), a grant from the Shanghai Pujiang Program (number 11PJ1401900; L Wang), a grant from the Program for Outstanding Leaders in Medicine (D-J Li), and a grant from the Shanghai Project to Develop Key Disciplines in Medicine (Integrated Chinese and Western Medicine).

**References**

3. Caputo EL, Costa MZ. Influence of physical activity


35. Liu JC, Zhou CH, Zhang X, Chen Y, Xu BL, Cui L, Xu DH. Effect of 1,25-dihydroxyvitamin D-3 on regulatory


(Received May 30, 2015; Revised September 9, 2015; Accepted October 7, 2015)
Protective effect of oleanolic acid on oxidized-low density lipoprotein induced endothelial cell apoptosis

Jianhua Cao¹, Guanghui Li¹, Meizhi Wang², Hui Li¹, Zhiwu Han²,*

¹Department of Pharmacy, the Third People’s Hospital of Qingdao, Qingdao, China; ²Department of Pharmacology, the Affiliated Hospital of Medical College, Qingdao University, Qingdao, China.

Summary

Oleanic acid (3β-hydroxyolean-12-en-28-oic acid, OA) is a naturally-occurring triterpenoid with various promising pharmacological properties. The present study was conducted to determine the protective effects of OA against oxidized low-density lipoprotein (ox-LDL) induced endothelial cell apoptosis and the possible underlying mechanisms. Our results showed that ox-LDL significantly decreased cell viability and induced apoptosis in human umbilical vein endothelial cells (HUVECs). OA in the co-treatment showed a protective effect against ox-LDL induced loss in cell viability and an increase in apoptosis, which was associated with the modulating effect of OA on ox-LDL induced hypoxia-inducible factor 1α (HIF-1α) expression. Moreover, our results showed that the modulating effect of OA against ox-LDL induced HIF-1α expression was obtained via inhibition of lipoprotein receptor 1 (LOX-1)/reactive oxygen species (ROS) signaling. Collectively, we suggested that the protective effect of OA against ox-LDL induced HUVEC apoptosis might, at least in part, be obtained via inhibition of the LOX-1/ROS/HIF-1α signaling pathway.

Keywords: Hypoxia-inducible factor 1α (HIF-1α), lipoprotein receptor 1 (LOX-1), reactive oxygen species (ROS)

1. Introduction

Dysfunction of vascular endothelial cells (EC) is now believed to play an important role in the pathogenesis of atherosclerosis (AS) (1). A number of studies have showed that EC apoptosis functions as an initiating step for AS by inducing atherosclerotic lesion formation and plaque shedding (2,3). Oxidized low-density lipoprotein (ox-LDL), an essential atherosclerotic risk factor, has been found to play a crucial role in multiple functional alternations occurring during the pathogenesis of AS, including enhancing EC apoptosis (4,5). Therefore, inhibition of ox-LDL induced EC apoptosis may have therapeutic significance in the prevention and treatment of AS.

The mechanism of ox-LDL induced apoptosis was thought to be related to ox-LDL elicited reactive oxygen species (ROS) release through lipoprotein receptor (LOX), which in turn up-regulates the transcription factor hypoxia-inducible factor 1 (HIF-1) (6,7). In recent years, oleanic acid (3β-hydroxyolean-12-en-28-oic acid), a naturally-occurring triterpenoid with widespread distribution in many fruits and plants like apple, grape, date, pomegranate and olive oil, is attracting much attention for its various pharmacological properties, such as hepatoprotective, vasorelaxant, antiproliferative, anti-inflammatory and apoptosis-inducing effects in various cancerous tissues (8,9). Notably, a synthetic triterpenoid analog of oleanic acid has been shown to have a potent antioxidative effect by inducing NADH-quinone oxidoreductase and heme oxygenase 1 (10). However, the effect of OA against ox-LDL induced apoptosis in EC remains largely unknown.

In this study, we used human umbilical vein endothelial cells (HUVECs) to investigate the effects of OA on ox-LDL induced cytotoxicity in HUVECs and the relevant underlying mechanisms.
2. Materials and Methods

2.1. Cell culture

HUVEC cells were purchased from ATCC (Manassas, VA, USA) and cultured in F-12K medium (ATCC, VA, USA) containing 10% fetal bovine serum (FBS, Gibco BRL Co.Ltd., Grand Island, NY, USA), 1% antibiotic-antimycotic solution (Gibco BRL Co.Ltd., Grand Island, NY, USA), 0.1 mg/mL heparin (Sigma. St. Liou, MO, USA), and 0.03 mg/mL endothelial cell growth supplement (Sigma. St. Liou, MO, USA) under an atmosphere of 5% CO₂ at 37°C. The cells were subcultured and split 1:4 every 4 days.

2.2. Cytotoxicity assay

A viability assay was performed using a trypsin blue exclusion method described previously (11). Briefly, HUVEC (2 x 10⁵ cells) were cultured in 24-well tissue culture plates (Corning-Costar, Cambridge, MA, USA). After drug administration, cells were trypsinized with 0.1% trypsin-EDTA (Gibco-BRL, Grand Island, NY, USA). Following centrifugation and washing, HUVECs were suspended in PBS and stained with trypsin blue dye (Sigma, St Louis, MO, USA). Fractions of dead cells with a blue signal were visualized and counted using a reverse phase microscope (Nikon, Tokyo, Japan).

2.3. Analysis of apoptotic cells

Apoptotic cells were determined according to the method of Tai et al. (12). After drug treatment, HUVECs were harvested and fixed in cold 80% ethanol. Following a process of centrifugation and washing, fixed cells were stained with propidium iodide (Sigma, St Louis, MO, USA). Fractions of dead cells with a blue signal were visualized and counted using a reverse phase microscope (Nikon, Tokyo, Japan).

2.4. Immunoblotting

HUVEC cells in logarithmic growth phase were used and plated in 60 mm dishes at a density of 2 x 10⁵ cells/well and were cultured overnight at 37°C under 5% CO₂. The cells were treated, harvested and lysed as described previously. Briefly, the cells were washed twice with ice-cold PBS and lysed in lysis buffer (25 mmol/L Tris/HCl pH 7.5, 25 mmol/L NaCl, 0.5 mmol/L EGTA, 10 mmol/L NaF, 20 mmol/L h-glycerophosphate, 1 mmol/L Na₃VO₄, 1 mmol/L PMSF, and 10 mg/ml aprotinin) (Sigma. St. Liou, MO, USA) at 4°C. After sonication and centrifugation at 15,000 rpm, the supernatant was used for immunoblotting. The lysate (20 μg protein per lane) was separated on 12% SDS-polyacrylamide gel (Sigma. St. Liou, MO, USA), electroblotted onto nitrocellulose membrane (Millipore, Billerica, MA, USA) and incubated with specific primary antibodies (Cell Signaling Technology, Inc., Boston, MA, USA). The antibodies were probed with a horseradish peroxidase-linked secondary antibody (Cell Signaling Technology, Inc, Boston, MA, USA) using an enhanced chemiluminescence system (Amersham Pharmacia Biotech, Shinjuku-ku, Tokyo). Densitometric analysis was performed using an image scanner and analyzing software. The rabbit polyclonal antibody to β-actin (Cell Signaling Technology, Inc, Boston, MA, USA) was used as a gel loading control.

2.5. Silencing HIF-1α with shRNA and overexpression of HIF-1α

For silencing HIF-1α, the HIF-1α-targeting shRNA (Sense sequence: GATCCCGACAGTTACGTA TTTCCATCAAGTGGAAACTCTGTGCTTTTTT; Antisense sequence: CTAGAAAAAGACAGATTACGTA ACAGATTCCACTCTTGATGGAAATCTGTAAC TGTGCCG) was inserted into pGE31 plasmid (pGE31 PredigestedCloning Kit, Agilent Technologies Inc., Shanghai, China) after cutting with restriction enzymes BamH I and Xba I. Scrambled shRNA was used as a negative control. Transfection of the cells with shRNA was performed following the standard protocol. Briefly, the cells were plated at a density of 5 x 10⁵ cells/well in a 6-well culture plate and incubated to allow 70-80% confluence (about 24 h). The cells were then starved in serum-free culture for 1 h. The transfection mixture containing HIF-1α-targeting shRNA and Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA, USA) was incubated for 20 min at room temperature. The cells were then incubated with the above mixture for 5 h at 37°C in a humidified atmosphere containing 5% CO₂. Subsequently, the cells were washed with PBS and maintained in DMEM containing 10% FBS for 48 h. The expression of HIF-1α was determined by Western blot analysis.

Based on the human HIF-1α sequence, primers (Sense primer: GCGGATCCAACGTCGAAAAGAAA TGCAGTATTGTAGCC; Antisense primer: GCTCTAGAAAGTTTGAGATGGAATACTGTGCTTTTTT) were designed to obtain the HIF-1α sequence. Then the PCR product was cut with restriction enzymes BamH I and Xba I before cloning into pEGFP-N1 vector (Takara Biomedical Technology Co., Ltd., Beijing, China). For HIF-1α overexpression, the HUVECs were grown to sub-confluent densities and transfected with pEGFP-N1 vector (Takara Biomedical Technology Co., Ltd., Beijing, China) constructs using the transfection reagent TransIT-LT-1 and following manufacturer’s instructions (Mirus Bio Corp., Madison, WI, USA). Overexpression of HIF-1α was confirmed by Western blots.
2.9. Statistical analysis

All statistical analysis was performed using PASW Statistical software (version 18.0 for Windows). Values are presented as the mean ± S.D. Statistical comparisons were performed by one-way ANOVA. Tukey’s post hoc test was used for multiple group comparisons and Student’s t-test was used for single comparisons. p < 0.05 was considered to be statistically significant.

3. Results

3.1. Effects of OA on ox-LDL induced cytotoxicity in HUVECs

We first examined the cytotoxicity of OA (Melone Biotech, Ltd., Dalian, China, Purity ≥ 98%) on HUVECs. Our results showed that incremental doses of OA treatment for 24 h did not affect HUVECs cell viability until 25 μM (p < 0.05 vs. control) (Figure 1A). Meanwhile, ox-LDL treatment for 24 h resulted in a dose-dependent decrease in cell viability, 100 μg/mL ox-LDL led to 49% reduction (Figure 1B). Therefore 100 μg/mL ox-LDL was chosen for the following experiments. Then the effect of ox-LDL and OA co-treatment was examined. We found OA at 1, 5, and 10 μM lowered the ox-LDL-caused decrease in viability of HUVECs by 5%, 12%, and 29%, respectively (Figure 1C).

3.2. Effect of OA on ox-LDL induced apoptosis in HUVECs

Apoptosis of HUVECs was analyzed by flow cytometry. As shown in Figure 2A, treatment of HUVECs with 100 μg/mL ox-LDL for 24 h increased the apoptotic cell population up to 31% while OA at 1, 5, and 10 μM significantly lowered the ox-LDL-induced apoptosis of HUVECs by 5%, 12%, and 21%, respectively (Figure 2A). In addition, activation of caspase-3 and PARP was also examined in HUVECs following treatments, which also showed OA treatment at 10 μM significantly attenuated the ox-LDL-induced apoptosis (Figure 2B).

2.6. LOX-1 knockdown and LOX-1 overexpression

LOX-1 knockdown was performed using an RNA interference (RNAi) synthesized based on a previously published sequence (Sense: CCCTTCAGGTAACCTGTGCATATATA) following a siRNA transfection protocol provided by Santa Cruz Biotechnology (Santa Cruz, CA, USA) (13). Briefly, after culturing HUVECs in antibiotic free Dulbecco’s modified Eagle’s medium at 37°C in a humidified atmosphere of 5% CO2 for 24 h, the siRNA duplex solution was added to HUVECs. After transfection for 24 h, the medium was replaced with normal Dulbecco’s modified Eagle’s medium (Sigma, St. Lious, MO, USA), and HUVECs were treated with OA, ox-LDL, or a combination of OA and ox-LDL.

To generate LOX-1 overexpression vectors, CDS region of LOX-1-coding sequences were obtained by RT-PCR and cloned into pEGFP-N1 vector (Takara Biomedical Technology Co., Ltd., Beijing, China). The resulting plasmid was named pEGFP-N1-LOX-1. HUVECs were transfected with pEGFP-N1-LOX-1 vector to induce excessive LOX-1 expression or pEGFP-N1 vector to generate stable clones expressing LOX-1 constitutively as control.

2.7. Quantitative RT-PCR (qRT-PCR)

Total RNA was extract from cells using RNA simple Total RNA Kit (TIANGEN Co., Beijing, China) and 3 μg of RNA was converted into cDNA using the High Capacity cDNA Archive Kit (Applied Biosystems, Foster City, CA, USA). For detection of LOX-1 mRNA the primers used were: upstream 5'-CTGCCAGCCTGAAGTCCATT-3' and downstream 5'-TCTGTCTGTCTGTTGCAAATG-3', with an amplified fragment of 340 bp. The synthesis of the primers used for HIF-1α was based on the published sequence (14). For each PCR reaction, a master mix that including SYBR GREEN mastermix (Solarbio Co., Beijing, China), forward primer, reverse primer, and 10 ng template cDNA was prepared. The PCR conditions were 5 min at 95°C followed by 40 cycles of 95°C for 30 s, 60°C for 30 s, and 72°C for 30 s. Data were analyzed using the comparative ΔCt method (ABPrism software, Applied Biosystems, Foster City, CA) using GAPDH as an internal normalization control.

2.8. Detection of intracellular ROS detection

Intracellular ROS level was measured by oxidation-sensitive fluorescent dye 2,7-dichlorodihydrofluorescein diacetate (DCF-DA) (Invitrogen, Carlsbad, CA, USA) method. Briefly, after washing once with PBS, treated cells were incubated with 20 μM DCF-DA in serum-free DMEM at 37°C for 30 min before analysis.

2.9. Statistical analysis

All statistical analysis was performed using PASW Statistical software (version 18.0 for Windows). Values are presented as the mean ± S.D. Statistical comparisons were performed by one-way ANOVA. Tukey’s post hoc test was used for multiple group comparisons and Student’s t-test was used for single comparisons. p < 0.05 was considered to be statistically significant.

3. Results

3.1. Effects of OA on ox-LDL induced cytotoxicity in HUVECs

We first examined the cytotoxicity of OA (Melone Biotech, Ltd., Dalian, China, Purity ≥ 98%) on HUVECs. Our results showed that incremental doses of OA treatment for 24 h did not affect HUVECs cell viability until 25 μM (p < 0.05 vs. control) (Figure 1A). Meanwhile, ox-LDL treatment for 24 h resulted in a dose-dependent decrease in cell viability, 100 μg/mL ox-LDL led to 49% reduction (Figure 1B). Therefore 100 μg/mL ox-LDL was chosen for the following experiments. Then the effect of ox-LDL and OA co-treatment was examined. We found OA at 1, 5, and 10 μM lowered the ox-LDL-caused decrease in viability of HUVECs by 5%, 12%, and 29%, respectively (Figure 1C).

3.2. Effect of OA on ox-LDL induced apoptosis in HUVECs

Apoptosis of HUVECs was analyzed by flow cytometry. As shown in Figure 2A, treatment of HUVECs with 100 μg/mL ox-LDL for 24 h increased the apoptotic cell population up to 31% while OA at 1, 5, and 10 μM significantly lowered the ox-LDL-induced apoptosis of HUVECs by 5%, 12%, and 21%, respectively (Figure 2A). In addition, activation of caspase-3 and PARP was also examined in HUVECs following treatments, which also showed OA treatment at 10 μM significantly attenuated the ox-LDL-induced apoptosis (Figure 2B).

2.6. LOX-1 knockdown and LOX-1 overexpression

LOX-1 knockdown was performed using an RNA interference (RNAi) synthesized based on a previously published sequence (Sense: CCCTTCAGGTAACCTGTGCATATATA) following a siRNA transfection protocol provided by Santa Cruz Biotechnology (Santa Cruz, CA, USA) (13). Briefly, after culturing HUVECs in antibiotic free Dulbecco’s modified Eagle’s medium at 37°C in a humidified atmosphere of 5% CO2 for 24 h, the siRNA duplex solution was added to HUVECs. After transfection for 24 h, the medium was replaced with normal Dulbecco’s modified Eagle’s medium (Sigma, St. Lious, MO, USA), and HUVECs were treated with OA, ox-LDL, or a combination of OA and ox-LDL.

To generate LOX-1 overexpression vectors, CDS region of LOX-1-coding sequences were obtained by RT-PCR and cloned into pEGFP-N1 vector (Takara Biomedical Technology Co., Ltd., Beijing, China). The resulting plasmid was named pEGFP-N1-LOX-1. HUVECs were transfected with pEGFP-N1-LOX-1 vector to induce excessive LOX-1 expression or pEGFP-N1 vector to generate stable clones expressing LOX-1 constitutively as control.

2.7. Quantitative RT-PCR (qRT-PCR)

Total RNA was extract from cells using RNA simple Total RNA Kit (TIANGEN Co., Beijing, China) and 3 μg of RNA was converted into cDNA using the High Capacity cDNA Archive Kit (Applied Biosystems, Foster City, CA, USA). For detection of LOX-1 mRNA the primers used were: upstream 5'-CTGCCAGCCTGAAGTCCATT-3' and downstream 5'-TCTGTCTGTCTGTTGCAAATG-3', with an amplified fragment of 340 bp. The synthesis of the primers used for HIF-1α was based on the published sequence (14). For each PCR reaction, a master mix that including SYBR GREEN mastermix (Solarbio Co., Beijing, China), forward primer, reverse primer, and 10 ng template cDNA was prepared. The PCR conditions were 5 min at 95°C followed by 40 cycles of 95°C for 30 s, 60°C for 30 s, and 72°C for 30 s. Data were analyzed using the comparative ΔCt method (ABPrism software, Applied Biosystems, Foster City, CA) using GAPDH as an internal normalization control.

2.8. Detection of intracellular ROS detection

Intracellular ROS level was measured by oxidation-sensitive fluorescent dye 2,7-dichlorodihydrofluorescein diacetate (DCF-DA) (Invitrogen, Carlsbad, CA, USA) method. Briefly, after washing once with PBS, treated cells were incubated with 20 μM DCF-DA in serum-free DMEM at 37°C for 30 min before analysis.
with OA caused a dose-dependent decrease of HIF-1α expression, suggesting that OA attenuates ox-LDL-induced enhancement in HIF-1α expression (Figure 3B). To further demonstrate the association between HIF-1α expression and ox-LDL-induced apoptosis, the expression of HIF-1α was manipulated with siRNA and...
overexpressing plasmid. As shown in Figure 3C, siRNA targeting HIF-1α alone did not cause significant change in apoptotic cells while it significantly attenuated ox-LDL-induced HUVEC apoptosis and co-treatment with OA and HIF-1α siRNA synergistically reduced ox-LDL caused cell apoptosis. In comparison, overexpression of HIF-1α alone in HUVECs slightly affected cell apoptosis but almost completely attenuated OA-involved protection against ox-LDL induced apoptotic insults (Figure 3D).

We further examined the expression level of HIF-1α mRNA during co-treatment and found that, contrary to the protein expression pattern, which was suppressed in a dose-dependent manner by OA, the expression of HIF-1α mRNA remained unchanged even with the highest concentration of OA (Figure 3E). We then examined the involvement of the proteasomal degradation of HIF-1α in HUVECs treated by using cycloheximide (CHX, a translational inhibitor). Following incubation with ox-LDL for 24 hours, HUVECs cells were challenged with CHX alone or in combination with OA for 0, 1, 2, and 3 h. As shown in Figure 3F, our results revealed that HIF-1α protein degradation rate was significantly increased in cells treated with both OA and CHX, which indicated that OA interfered with the stabilization of HIF-1α in HUVECs. Collectively, our results showed that OA modulated ox-LDL induced HIF-1α expression by both suppressing translation and promoting degradation.

3.4. Involvement of ROS in the modulating effect of OA on ox-LDL-induced HIF-1α

Recent evidence has showed that HIF-1α can be induced by free radicals, especially ROS, and a number of studies have established that ROS generation was closely associated with ox-LDL induced endothelial cell apoptosis (15-17). Based on these previous studies, we explored the effect of OA on ox-LDL-induced ROS generation and the association between ROS and HIF-1α expression. Our results showed that OA alone did not cause significant change in ROS level in HUVECs while ox-LDL treatment resulted in ROS generation in a dose-dependent manner (Figure 4A). When ox-LDL (100 μg/mL) and OA (10 μM) were used in combination, OA was able to significantly attenuate ox-LDL induced ROS generation (Figure 4B). To further demonstrate the association between ROS generation and HIF-1α, ROS inducer (CoCl2) and inhibitor NAC were employed. We found that NAC, serving as a positive control, was able to significantly downregulate
ox-LDL-induced HIF-1α expression. In contrast, CoCl₂ was able to significantly elevate the level of HIF-1α and the combination of OA and CoCl₂ significantly abolished the attenuating effect of OA on ox-LDL-induced HIF-1α expression. Moreover, the effect of both NAC and CoCl₂ on ox-LDL-induced apoptosis was also examined. Our results showed that NAC, similar to OA, significantly attenuated ox-LDL-induced HUVEC apoptosis while CoCl₂ significantly abrogated the protective effect of OA against ox-LDL-induced HUVEC apoptosis.

3.5. Modulation of OA on LOX-1 mRNA and protein expression

LOX-1 is expressed in endothelial cells and activation of LOX-1 promotes intracellular ROS accumulation (18,19). Given the fact that OA can modulate ox-LDL-induced intracellular ROS generation, we investigated the effect of OA on ox-LDL-induced LOX-1 expression. As shown in Figure 5A, after administration of ox-LDL, the expression of LOX-1 mRNA was enhanced by approximately 3-fold whereas OA decreased ox-LDL-induced LOX-1 mRNA production in a dose-dependent manner. Similar results were obtained when the effect of OA on LOX-1 protein level was analyzed (Figure 5B). The involvement of LOX-1 in the modulation of ROS and protective effect of OA against ox-LDL-induced apoptosis was further investigated by LOX-1 targeting siRNA and LOX-1 overexpressing plasmid. In the HUVECs with LOX-1 knockdown, siRNA targeting LOX-1 by itself did not affect apoptosis or ROS accumulation in HUVECs (Figure 5C and 5D). However, LOX-1 siRNA significantly decreased the
capability of ox-LDL to induce apoptosis as well as ROS accumulation in HUVECs. Cotreatment with OA and LOX-1 siRNA synergistically reduced oxLDL-caused cell apoptosis and ROS generation by 64.7%. Although overexpression of LOX-1 alone in HUVECs did not affect cell apoptosis or ROS generation, enhanced expression of LOX-1 markedly potentiated the capability of ox-LDL to induce ROS accumulation and apoptosis. However, overexpression of LOX-1 significantly attenuated OA involved protection against oxLDL-induced apoptosis and ROS generation in HUVECs (Figures 5E and 5F). Taken together, our results showed that the protective effect of OA against ox-LDL induced HUVEC apoptosis might, at least in part, be obtained via inhibition of LOX-1/ROS/HIF-1α signaling.

4. Discussion

A growing body of evidence suggests that ox-LDL-induced endothelial cell apoptosis plays key roles in the pathogenesis of atherosclerosis by promoting a reduction of vascular integrity, deposition of lipids, invasion of vascular smooth muscle cells, migration of monocytes, and formation of atherosclerotic plaque (20,21). Therefore, suppressing ox-LDL-induced endothelial cell apoptosis may provide a new therapeutic option for prevention and treatment of atherogenesis. In this study, we employed human umbilical vein endothelial cells (HUVECs) which have high relevancy to actual human cardiovascular system cells as an in vitro model to investigate the protective effects of OA protected against ox-LDL-induced apoptosis in endothelial cells. Our results demonstrated that (i) OA protected HUVECs from ox-LDL-induced loss in cell viability and apoptosis in a concentration-dependent manner; (ii) the modulating effect of OA on HIF-1α participated in the anti-apoptotic effects of OA; (iii) the anti-apoptosis effects of OA were obtained.
via suppressing the signaling cascade of LOX-1/ROS/ 
HIF-1α. To our knowledge, this is the first study that elucidates the role of HIF-1α in ox-LDL induced apoptosis in endothelial cells.

The involvement of HIF-1α in the pathogenesis of atherosclerosis has been shown in a variety of cell types (6). A few studies have shown that HIF-1α played an essential role in the function of macrophages when challenged by ox-LDL and promoted the transformation of macrophages to foam cells (22,23). In leucocytes, which function as a key factor in the development and progression of atherosclerotic lesions, HIF-1α has been reported to have a direct effect on the cytokine profile (24). Jeong et al. also reported that activation of HIF-1α in mast cells could stimulate the expression of VEGF, leading to direct and indirect attraction of inflammatory cells into the intima in various stages of atherogenesis (25,26). Moreover, a number of studies have established the crucial role of HIF-1α in vascular smooth muscle cells proliferation exposed to hypoxic stimulus (27). However, the role of HIF-1α in endothelial cells has never been studied. In this study, we found that the ox-LDL was able to induce expression of HIF-1α. Then we manipulated the expression of HIF-1α level in HUVECs with HIF-1α-targeted siRNA and HIF-1α overexpressing plasmid, both did not show any marked effect on HUVECs apoptosis alone. However, HIF-1α-targeted siRNA significantly attenuated ox-LDL-induced apoptosis in HUVECs, suggesting that ox-LDL induced apoptosis, at least partly, was mediated via HIF-1α signaling. Interestingly, we found that OA was able to modulate the expression of HIF-1α, which led to its protective effect against ox-LDL induced apoptosis in HUVECs, as demonstrated by the effect of OA on ox-LDL induced apoptosis in HIF-1α knockdown or HIF-1α overexpressing HUVECs. Based on our results, we suggest that HIF-1α might serve as a novel target in the prevention and treatment of AS.

It is known that intracellular ROS positively correlated with HIF-1α level in a variety cells (28) and OA has been identified as a free radical scavenger (29). Consistent with previous studies, our results also confirmed the role of OA as a free radical scavenger in endothelial cells by demonstrating that OA treatment was able to reduce ox-LDL-induced ROS in a dose-dependent manner. Moreover, a combined use of OA with ROS inducer CoCl2 or ROS inhibitor NAC showed that the modulating effect of OA on HIF-1α level in HUVECs was mediated by regulating the intracellular ROS levels. It was suggested that ROS may be involved in stabilizing HIF-1α, leading to elevated levels of HIF-1α (30). Therefore, interfering with the ROS level will affect the degradation of HIF-1α. Our experiments showed that OA decreased the level of HIF-1α in part by promoting HIF-1α degradation, supporting our argument that OA modulated HIF-1α level via eliminating intracellular ROS. However, it is to be noted that the regulatory effect of OA on HIF-1α level also involved its effect on translational level (our results showed that OA had no effect on HIF-1α mRNA but a dose-dependent effect on HIF-1α protein level in HUVECs), which indicated that OA might modulate HIF-1α level via more than a single pathway. Meanwhile, we also noticed that OA does not always work as a free radical scavenger. A recent study by Lin et al reported that activation of ROS/ASK1/p38 MAPK pathways is responsible for the apoptosis stimulated by OA in cancer cells (31), which suggests that the effect of OA on ROS might be cell specific.

First identified as an endothelial-specific scavenger receptor by Sawamura in 1997 (18), LOX-1 has been found to be expressed in endothelial cells, macrophages, vascular smooth muscle and platelets and can be upregulated by many factors such as ox-LDL, Ang II, shear stress, and advanced glycation (32-34). A number of studies implicated that the apoptosis of endothelial cells induced by ox-LDL was predominantly mediated by LOX-1 whose expression is strongly induced by exposure to ox-LDL (16,34). More importantly, ox-LDL induces apoptosis in endothelial cells, which can be suppressed by agents that are able to downregulate LOX-1 expression (16,35). As shown in the present study, an approximately 3-fold expression of LOX-1 protein/mRNA was observed in ox-LDL treated HUVECs, compared to the control group while OA significantly decreased the induced expression of LOX-1 by ox-LDL in a dose-dependent manner. We also found that OA decreased the intracellular ROS level by downregulating LOX-1, which probably resulted from compromised ox-LDL intake by HUVECs due to less available LOX-1 (18). Moreover, by applying LOX-1-targeted siRNA and LOX-1 overexpressing plasmid in HUVECs, we were able to prove the contribution of downregulating LOX-1 in the anti-apoptotic effect of OA against ox-LDL induced apoptosis in HUVECs. Collectively, our results suggest that the LOX-1/ROS/HIF-1α signaling pathway might, at least partly, be involved in the anti-apoptotic effects of OA.

5. Conclusions

In summary, the present study on HUVECs provides evidence that OA protected ox-LDL induced cell apoptosis by suppressing sequential events cause by ox-LDL treatment including LOX-1 up-regulation, ROS overproduction, and HIF-1α overexpression. Our work provides new insights into therapeutic potential of OA in the treatment of AS.

Acknowledgements

This work was supported by National Natural Science Foundation (No.81274126 and 81473384) and funds from Qingdao University (No.14-2-3-50-nsh).
References


(Received July 9, 2015; Revised September 16, 2015; Accepted October 9, 2015)
Decrease of ZEB1 expression inhibits the B16F10 cancer stem-like properties

Fengshu Zhao1,*, Xiangfeng He2,*, Yaqing Wang1,*, Fangfang Shi1, Di Wu1, Meng Pan1, Miao Li1, Songyan Wu1, Xiaoying Wang1, Jun Dou1,**

1 Department of Pathogenic Biology and Immunology, School of Medicine, Southeast University, Nanjing, China; 2 Department of Medical Oncology, Affiliated Tumor Hospital of Nantong University, Nantong, China.

Summary

Increasing evidence supports that cancer stem cells (CSCs) are responsible for driving tumor initiation and maintenance. Zinc-finger E-box binding homeobox 1 (ZEB1) is a transcription factor for regulating tumor progression, and contributes to maintenance of CSC-like properties. The goal of the present study is to investigate the effect of decreasing ZEB1 expression on the B16F10 CSC-like properties. The recombinant shRNA targeting ZEB1 were transfected into melanoma B16F10 cells, and shZEB1-CD133+CD44+ CSCs were isolated from the stable transfected cells using the magnetic-associated cell sorting method. The shZEB1-CD133+CD44+CSC-like properties were systematically analyzed. The results show the B16F10 shZEB1-CD133+CD44+CSCs significantly decreased the ability of clonogenicity, cellular proliferation, migration, and invasion. Importantly, tumorigenicity and tumor lung metastasis was significantly inhibited in B16F10 shZEB1-CD133+CD44+CSCs compared with B16F10 scramble-CD133+CD44+CSCs. The decrease of ZEB1 expression markedly resulted in down-regulation of vimentin and N-cadherin expression as well as up-regulation of E-cadherin expression in tumor tissues from the mice injected with B16F10 shZEB1-CD44+CD133+CSCs. These findings contribute to understanding the maintenance of B16F10 CD133+CD44+CSC-like properties that was closely associated with ZEB1 expression. ZEB1 may serve as a new therapeutic target for treatment of malignant melanoma.

Keywords: Melanoma, cancer stem cells, stem-like properties, RNA interference, zinc finger E-box-binding protein 1

1. Introduction

Human malignant melanoma is a highly aggressive and drug-resistant skin cancer that contains cancer cell subsets with self-renewing cancer stem-like cells (CSCs). Those cells are considered responsible for tumor resistance to therapies. The frequency of these cells in the tumor, however, is still a topic of debate (1-3). Although increasing study reports were published during the past decade, which have contributed to the advance of knowledge in this field, the complex biological properties of melanoma CSCs and how to regulate the properties are still insufficiently understood (4,5).

Accumulating evidence supports the concept that the epithelial-to-mesenchymal transition (EMT) finishes the typical phenotype changes of cellular epithelial (epithelium) and interstitial (mesenchyma) state conversion in the process of epithelial originated tumor cells, including breast, prostate, ovarian, colorectal, pancreatic cancer cells, etc. (6-8). Though melanoma is not an epithelial originated tumor, it possesses epithelial-like properties through interactions between cancer cells and tumor microenvironment to bear phenotype switching (9-11). Moreover, melanoma cells are characterized by their "stem-like" properties and their more differentiated progeny, which should be eradicated to achieve a durable cure for melanoma patients (12).

Recent discoveries have shown that breast epithelial cells can gain CSC-like properties through an EMT
program, and residual breast cancer cells following chemotherapy are enriched in EMT and CSC-like properties, which allows metastatic CSC colonization in distant organs (13,14). Zinc-finger E-box binding homeobox 1 (ZEB1), a transcription factor, is essential for the physiological processes of differentiation, cell growth, and cell death (15,16), and plays a key function in regulating EMT processes of melanoma cells together with miR-200c feedback loop (5,6,17,18). Thus, ZEB1 function is closely associated with the melanoma CSC-like property maintenance. For this reason, we investigated whether decreasing ZEB1 expression would inhibit the B16F10 CD133/CD44$^+$ CSC-like properties by altering cellular biological behavior including the tumorigenicity and metastatic potential. The data from this study showed that down-regulating ZEB1 expression in B16F10 CD133/CD44$^+$ CSCs resulted in reduced cellular self-renewing, tumorigenicity, and metastatic potential in a mouse model, suggesting that inhibition of the B16F10 CD133/CD44$^+$ CSC-like properties by suppression of EMT processes in vitro and in vivo.

2. Materials and Methods

2.1. Cell line and mice

B16F10 murine melanoma cell line is syngeneic in C57BL/6 mice, ordered from the Cellular Institute of China in Shanghai. Cells were cultured at 37°C in 5% CO$_2$ atmosphere in RPMI 1640 supplemented with 10% fetal bovine serum that contained 100 U/mL penicillin G sodium and 100 mg/L streptomycin sulfate. C57BL/6 mice 5-6 weeks old were obtained from Yangzhou University of China. All mice were housed under pathogen-free conditions and the experiments were performed in compliance with the guidelines of the Animal Research Ethics Board of Southeast University.

2.2. Short hairpin RNA sequence design

Short hairpin RNA sequences of mouse ZEB1 were designed based on the ZEB1 DNA sequence (GenBank NO.NM_011546.3) using siDESIGN software (Dharmacon, http://www.thermoscientificbio.com/design-center/) and BLAST (http://www.ncbi.nlm.nih.gov/BLAST) as well as Block-iTTM RNAi Designer (Invitrogen, Grand island, NY, USA) and were performed as described previously (17,19).

2.3. Construction of recombinant containing shRNA1 targeting the ZEB1 gene

A pSUPER-EGFP1 (enhanced green fluorescent protein 1) vector was used to construct recombinants. The recombinant pSUPER-EGFP1-ZEB1-shRNA (shZEB1) was developed as previously described (19,20). The target sequence for ZEB1 shRNA includes base pairs of 3,458-3,476 bp of the ZEB1 cDNA sequence. shRNA sequences are as follows: ZEB1-siRNA: sense, 5′-GA TCCCCAGGAAGAGGAGGAAGTAACTAAGA GATTATCCAATCTCCTCTCTCTTTTGGAAAA-3′; antisense, 5′-AGCTTTTCCAAAAAAGAAAAGG AGGGAGATAATCCTGGAATTATCCTCCTCTC TT CTTGGG-3′; A pSUPER-EGFP1-scrambled shRNA (scramble) was used as a negative control. Scramble-siRNA: sense, 5′-GA TCCCCCTTCTCTGGAAGCTGTCA CGTTCAGAGAACGTGACAGTTCCGAGATT TTTGAAA-3′; antisense, 5′-AGCTTTTCCAAAAATT TCTCGAGAGTCGTCAGTTCTGGAAACGTGAC ACGTTCGAGAAGGG-3′. The nucleotide sequences underlined contain the restriction endonuclease Bgl II and Hind III sites, respectively. These recombinants were verified by analysis of endonuclease digestion and sequencing.

2.4. Clonal selection, identification and isolation of CD133/CD44$^+$ cells

The constructed recombinant plasmid shZEB1 were transfected into B16F10 cells by using LipofectamineTM 2000 reagent (Invitrogen, USA) according to the manufacturer’s protocol. The stably transfected clones were selected from RPMI containing 800 μg/mL G418 (Clontech, CA, USA), and cloned into the cell line by limiting dilution assay. B16F10 shZEB1-CD133/CD44$^+$ cells or B16F10 scramble-CD133/CD44$^+$ cells were isolated from the B16F10-shZEB1 cells or the B16F10 scramble-cells with the magnetic activated cell sorting (MACS, Miltenyi Biotec, Gladbach, Germany) method that was performed as described previously (2,21). The isolated B16F10 shZEB1-CD133/CD44$^+$ cells were named for B16F10-shZEB1 CD133/CD44$^+$ CSCs while B16F10 scrambled-CD133/CD44$^+$ cells were named for B16F10-Scramble-CD133/CD44$^+$ CSCs.

2.5. Colony forming assay

We investigated the colony formation capability of B16F10-shZEB1 CD44$^+$CD133$^+$ CSCs. A colony with a diameter larger than 75 μm or having more than 50 cells was counted as 1 positive colony according to our previous report (2). The plate clone formation efficiency was calculated as (number of colony/number of cells inoculated) × 100%. As control, B16F10 scramble-CD133/CD44$^+$ cells, and B16F10 CD44$^+$CD133$^+$ CSCs were used in this experiment.

2.6. Proliferative assay

Cell proliferation was measured using a 3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyltetrazolium bromide (MTT) assay (St. Louis, Mo, CA, USA). B16F10-shZEB1 CD133/CD44$^+$ CSCs, B16F10...
scramble-CD133⁺CD44⁺ cells, and B16F10 CD44⁺CD133⁺ CSC suspension were respectively seeded onto a 96-microwell plate (1 × 10⁵/well). The subsequent steps were performed as described in the previous report (22).

2.7. Resistance to chemotherapeutic agents in cells

1 × 10⁶ B16F10-shZEB1 CD133⁺CD44⁺ CSCs or B16F10 Scramble-CD133⁺CD44⁺ cells or B16F10 CD133⁺CD44⁺ CSC suspensions were seeded into a 96-well plate with 10 μg/mL epirubicin in each well for 48h (Baiyunshang Company, Guangdong, China). Cellular resistance to chemotherapeutic agents was calculated according to the previous report (22).

2.8. Cell migration assay

To determine the role of down-regulating ZEB1 expression on cellular migration, B16F10-shZEB1 CD133⁺CD44⁺ CSCs, B16F10 scramble-CD133⁺CD44⁺ cells, and B16F10 CD133⁺CD44⁺ were used in the wound healing assay. Briefly, 5 × 10⁵ cells per well were respectively plated in 6-well plates to form a monolayer one day before the assay; non-adherent cells were removed by PBS washing. On the following day, a uniform scratch was made down the center of the well using a sterile micropipette tip. The distance traveled by the cells was measured between the two boundaries of the cellular area at 0, 12, and 24 h after incubation. Each experiment was performed in triplicate (24,25).

2.9. Cell invasion assay

Briefly, the transwell inserts with 8 μm pores was coated with Matrigel (20 μg/well; Becton Dickinson, Waltham, MA, USA); the different cancer cells were seeded in the upper chamber in RPMI1640 medium supplemented with 10% fetal bovine serum. After incubation at 37ºC, the cells that invaded the lower surface of the Matrigel-coated membranes were fixed with 70% ethanol and stained with trypan blue; cells from five randomly selected fields were then counted under a light microscope (24,25).

2.10. In vivo tumorigenicity experiments

The C57BL/6 mice (female, weight: 16-18 g and age between 5 and 6 weeks) were randomly divided into three groups of equal size (three per group): the B16F10-shZEB1 CD133⁺CD44⁺ CSC group, the B16F10 scramble-CD133⁺CD44⁺ CSC group, and the B16F10 CD133⁺CD44⁺ CSC group. The back of the mice were subcutaneously (s.c.) injected with 5 × 10⁵ of the above cells, respectively. Except for observation of mouse general conditions each day, such as overall behavior, feeding, body weight and appearance of fur, tumor formation and growth in the groups were monitored every two days by 2-dimensional measurements of individual tumors from each mouse. The endpoint for this study was one diameter of tumor ≥ 15 mm, at which point mice were euthanized. The tumorigenicity experiment was repeated twice (22,26).

2.11. Tissue histopathology

To evaluate tumor metastases to the lung, lung tissues were removed from the mice; after the metastatic tumor nodes were counted the lung tissues were fixed in 10% formalin and then embedded in paraffin. Tissue sections of 4 μm thin were cut and mounted on SuperFrost Plus glass slides; the lung tissue sections were fixed in methanol and stained in hematoxylin and eosin (HE). The slides were viewed under a Zeiss Axioplan light microscope at a magnification of ×100 or 400. Arrows represent the metastatic melanoma cells (22,27).

2.12. Immunohistochemistry

Immunohistochemistry was performed as reported previously (27,28). Briefly, 4 μm-thin formalin fixed and paraffin-embedded tumor slides were incubated with the rabbit anti-mouse/human ZEB1, vimentin, and E-cadherin, respectively, overnight at 4°C. The antibody concentration was 1:500. The samples were then labeled with horseradish peroxidase-conjugated streptavidin (Invitrogen, CA, USA), and the chromogenic reaction was developed by using Liquid DAB Substrate Pack according to the manufacturer's instructions. The stained cells from random and non-overlapping fields were counted under a magnification of ×200.

2.13. Western blot

Approximately 1 × 10⁶ tumor tissue cells were collected and lysed in the protein extraction buffer (Novagen, Madison, WI, USA) by following the manufacturer's protocol. Protein (15 μg/lane) was separated by SDS/PAGE (12% gels) and transferred onto a nitrocellulose membrane. The membrane was blocked with saturating buffer for 1 h at 25°C, followed by specific antibodies: the rabbit anti-mouse/human ZEB1, vimentin, and E-cadherin (Invitrogen, CA, USA), respectively, overnight at 4°C. The membrane was rinsed for 5 min with an antibody wash solution 3 times before adding to it the goat anti-rabbit fluorescence secondary antibody. Immunoreactive bands were detected by an Odyssey scanning instrument (LI-COR Odyssey Imaging System, USA). Protein semi-quantitation was calculated using Image Lab software developed by Bio-Rad (6,28).

2.14. Statistical analysis

Values of interest were presented as the mean plus or
minus standard deviation. Statistical comparisons were performed using the Student's t-test method. Bonferroni correction was used where multiple comparisons were made. A p value of < 0.05 was considered statistically significant.

3. Results

3.1. Decrease of ZEB1 expression in CD133⁺CD44⁺ CSCs reduces its ability for colony formation, proliferation, drug resistance, migration, and invasion

To understand the B16F10 CD133⁺CD44⁺ CSC-like properties, we first decreased cellular ZEB1 expression with the RNA interference technique, and then observed the biological behavior that exhibits stem-like properties. The results in Figures 1A and 1B show that B16F10 shZEB1-CD133⁺CD44⁺ CSCs significantly decreased the colony forming rates in common plate medium compared with B16F10 CD133⁺CD44⁺ CSCs (19% vs. 53%, p < 0.0005), and B16F10 scramble-CD133⁺CD44⁺ CSCs (19% vs. 48%, p = 0.0043), respectively; in soft agar medium, the colony forming rates of B16F10 shZEB1-CD133⁺CD44⁺ CSCs was also significantly decreased compared with B16F10 CD133⁺CD44⁺ CSCs (8.5% vs. 4.15%, p < 0.0001), and B16F10 scramble-CD133⁺CD44⁺ CSCs (8.5% vs. 31.9%, p < 0.0003), respectively. Figure 1C shows that the proliferative activity of B16F10 shZEB1-CD133⁺CD44⁺ CSCs dynamically every 24 h as measured by the OD value was markedly reduced when compared with B16F10 CD133⁺CD44⁺ CSCs (p < 0.01) or B16F10 scramble-CD133⁺CD44⁺ CSCs (p < 0.05). Figure 1D shows that drug resistance to epirubicin in B16F10 shZEB1-CD133⁺CD44⁺ CSCs was decreased, which was statistically significant compared with B16F10 CD133⁺CD44⁺ CSCs (41.24% vs. 61.46%, p = 0.0130) or B16F10 scramble-CD133⁺CD44⁺ CSCs (41.24% vs. 59.45%, p = 0.0248).

In addition, the ability of migration and invasion in B16F10 CD133⁺CD44⁺ CSCs with down-regulated ZEB1 expression was significantly inhibited as compared to control cells. We found in Figures 2A and 2B that the results at 24 h showed a statistically significant reduction in wound closures in B16F10 shZEB1-B16F10 CD133⁺CD44⁺ CSCs compared with B16F10 CD133⁺CD44⁺ CSCs or B16F10 scramble-CD133⁺CD44⁺ CSCs (p < 0.0033) or B16F10 CD133⁺CD44⁺ CSCs (p < 0.0074). Consistently, the effect of down-regulated ZEB1 expression on B16F10 CD133⁺CD44⁺ CSC invasive ability was also inhibited, which was done using the transwell invasive assay. The representative photos in Figure 2C show the cell invasive ability was statistically significantly decreased in B16F10 shZEB1-CD133⁺CD44⁺ CSCs compared with B16F10 CD133⁺CD44⁺ CSCs (p < 0.0001) or B16F10 scramble-

Figure 1. Short hairpin ZEB1-B16F10 CD133⁺CD44⁺ CSCs decreases the ability of colony forming, cell proliferation as well as drug resistance in vitro. (A) The colony forming ratios of B16F10 ZEB1-shRNA-CD133⁺CD44⁺ CSCs in plate and soft agar medium was significantly decreased compared with the ratio in B16F10 CD133⁺CD44⁺ CSCs and B16F10 scramble-CD133⁺CD44⁺ CSCs. (B) Between-group differences of colony-forming ratios in the plate medium and the soft agar medium; all the differences were statistically significant. (C) The cell proliferation ability in vitro was detected by MTT assay. At day 8, the proliferation of B16F10 ZEB1-shRNA-CD133⁺CD44⁺ CSCs was significantly inhibited compared with B16F10 CD133⁺CD44⁺ CSCs and B16F10 scramble-CD133⁺CD44⁺ CSCs and B16F10 scramble-CD133⁺CD44⁺ CSCs. (D) Drug resistance to epirubicin (10 μg/mL) in B16F10 ZEB1-shRNA-CD133⁺CD44⁺ CSCs was significantly reduced compared with B16F10 CD133⁺CD44⁺ CSCs and B16F10 scramble-CD133⁺CD44⁺ CSCs; refer to the statistically significant differences as indicated.
CD133+CD44+ CSCs (p < 0.0001) when these cells were cultured for 48 h (Figure 2D).

This findings implied that the maintenance of the B16F10 CD133 CD44+ CSC-like properties, including self-renewal (colony forming and proliferative activity) and drug resistance as well as metastasis (the ability of migration and invasion), may mainly depend on ZEB1 expression or not.
3.2. Decrease of ZEB1 expression in B16F10 CD133⁺CD44⁺ CSCs inhibits tumorigenicity and metastasis in mice

Having found the effects of down-regulated ZEB1 expression on cellular biological behaviors that exhibit the B16F10 CD133⁺CD44⁺ CSC-like properties in vitro, we wanted to know if these effects would inhibit tumorigenicity and metastatic potential of B16F10 shZEB1-CD133⁺CD44⁺ CSCs in the mouse model. Images in Figure 3A indicate that the tumor sizes on day 43 after the mice were injected with B16F10 cells. We found that all 6 mice developed tumors in 35 days after being injected with 5 × 10⁵ B16F10 shZEB1-CD133⁺CD44⁺ CSCs, however, the tumor volume, the time of tumor occurrence, and the tumor-free mice days were significantly different from the other mice, which was statistically significant compared with the B16F10-scramble-CD133⁺CD44⁺ CSC group (p < 0.05), or between the B16F10 shZEB1-CD133⁺CD44⁺ CSC group and the B16F10 CD133⁺CD44⁺ CSC group (p = 0.007), or between the B16F10 shZEB1-CD133⁺CD44⁺ CSC group and the B16F10 scramble-CD133⁺CD44⁺ CSC group (p = 0.0232) (Figure 3B). Notably, a few metastatic tumor cells were seen in lung tissue sections from the mice injected with the B16F10 shZEB1-CD133⁺CD44⁺ CSCs as analyzed by HE staining (Figure 4C). However, a lot of metastatic tumor cells were found in the lung tissue sections from the mice injected with the B16F10 CD133⁺CD44⁺ CSCs or B16F10 scramble-CD133⁺CD44⁺ CSCs as are shown in

Figure 4. The knockdown of ZEB1 in B16F10 CD133⁺CD44⁺ CSCs inhibits tumor lung metastasis in mice. (A) Images show tumor metastatic nodes in mouse lungs stripped from the mice 43 days after mice were injected with 5 × 10⁵ B16F10 ZEB1-shRNA-CD133⁺CD44⁺ CSCs, B16F10 CD133⁺CD44⁺ CSCs and B16F10 scramble-CD133⁺CD44⁺ CSCs, respectively. (B) Quantification analysis of lung tumor metastatic node counts. (C) Tissue sections derived from the mice 43 days after mice were injected with the above different cells, respectively. Arrows point to the metastatic focus (400×). (D) Between-group differences in the tumor metastatic focus in the different lung sections; refer to the statistically significant differences as indicated.
Figures 4C and 4D. From these results, we concluded that the B16F10 CD133^+CD44^+ CSC-like properties were significantly inhibited in the in vivo mouse model.

3.3. Impacts of down-regulation of ZEB1 in B16F10 CD133^+CD44^+ CSCs on EMT-related molecular expression in tumor tissues

To evaluate the functional significance of the decrease of ZEB1 expression, we tested the expression of ZEB1, E-cadherin, N-cadherin, and vimentin in the tumor tissues from B16F10 melanoma bearing mice.
by Western blot analysis. Figure 5A shows E-cadherin expression in the B16F10 shZEB1-CD133'CD44' CSCs was markedly higher than that of both B16F10 CD133''CD44'' CSCs and B16F10 scramble-CD133'CD44' CSCs. There were significant differences between the B16F10 shZEB1-CD133'CD44' CSCs and the B16F10 CD133''CD44'' CSCs (p = 0.0051), and between the B16F10 shZEB1-CD133'CD44' CSCs and the B16F10 scramble-CD133'CD44'' CSCs (p = 0.0042). Whereas the ZEB1, N-cadherin, and vimentin indicated much lower expression in the B16F10 shZEB1-CD133'CD44' CSCs than either B16F10 CD133''CD44'' CSCs or B16F10 scramble-CD133'CD44' CSCs, which was statistically significant as is shown in Figure 5B.

Similarly, the results of the immuno-histochemistry in panels A and C of Figure 6 show the E-cadherin expression in B16F10 shZEB1-CD133'CD44' CSCs was significantly increased while expression of vimentin and ZEB-1 was decreased compared with B16F10 CD133''CD44'' CSCs and B16F10 scramble-CD133'CD44' CSCs, which was statistically significant as is shown in Figure 6B. These results demonstrated that the increased expression of E-cadherin coupled with the decreased expression of vimentin and ZEB-1 may have inhibited the EMT process of B16F10 shZEB1-CD133'CD44' CSCs in the mouse model.

4. Discussion

It is known that there are a subset of cells within a tumor with "stem-like" properties. These cells represent a distinct tumor subpopulation known as CSCs that are responsible for tumor initiation, progression, metastasis, therapeutic resistance and relapse (29). In this study, we focused on the melanoma B16F10 CD133''CD44'' CSC-like properties, and wanted to know whether the inhibition of the B16F10 CSC-like properties would alter cellular tumorigenicity and metastasis potential. We selected the transcription factor ZEB1 as a target to inhibit the B16F10 CSC-like properties because this is the role of ZEB1 and is tightly related with the melanoma CSC-like properties as described by previous reports (5,6,17,18,30).

Since self-renewal is one of the main B16F10 CSC-like properties, we first assessed the clone formation capability and proliferative activity of B16F10 shZEB1-CD133'CD44' CSCs. We found that knockdown of ZEB1 not only markedly decreased clone formation capability in common plate and soft agar media, and proliferative activity of B16F10 CD133''CD44'' CSCs, but also significantly reduced the drug resistance to epirubicin as well as the ability of migration and invasion in vitro compared to B16F10 CD133''CD44'' CSCs and scramble-CD133'CD44' CSCs. The data from this study demonstrated that the knockdown of ZEB1 in B16F10 CD133''CD44'' CSCs reduced the ability for self-renewal, migration and invasion, which may represent the decrease of tumor cell invasiveness and stem-like properties, suggesting inhibitory roles on B16F10 CD133''CD44'' CSC-like properties. More importantly, the knockdown of ZEB1 in B16F10 CD133''CD44'' CSCs inhibited the tumorigenicity and distant lung metastasis potential. According to the CSC hypothesis, the tumorigenicity and metastasis potential represent mainly CSC-like properties in epithelial originated tumor cells (31,32). Consistent with the previously reported findings (2,5,6,17), our current study demonstrated that B16F10 CD133''CD44'' CSCs had a multipotent, self-renewal capacity and strong tumorigenesis, while the decrease of ZEB1 expression in B16F10 CD133''CD44'' CSCs caused reduction of CSC-like properties, which may be good evidence that ZEB1 serves as a crucial factor to maintain CSC-like properties.

Metastasis is associated with poor prognosis for melanoma, which is responsible for about 90% of skin cancer-related mortality. The capacity of cancer cells to undergo EMT is now considered a hallmark of tumor metastasis (11,31). For this purpose, we tested EMT related molecular expression in the tumor tissues. Apparently, B16F10 shZEB1-CD133''CD44'' CSCs exhibited significantly decreased ZEB1 expression compared with the control cells in the tumor tissues analyzed by Western blot and immuno-histochemistry assays. In addition, the expression of E-cadherin and vimentin, which are characteristic molecules of EMT that are closely associated with typical phenotype changes of EMT in tumor cell growth and metastasis (15,33,34), was significantly inhibited in the tumor tissues from the mice injected with B16F10 shZEB1-CD133''CD44'' CSCs. These positive consistent data allow us to suppose that the reduction of tumor cell lung metastasis mainly is due to inhibition of the EMT processes of B16F10 shZEB1-CD133''CD44'' CSCs.

In conclusion, the present study provides a better understanding of ZEB1 roles in melanoma B16F10 CD133''CD44'' CSCs. These data demonstrate that the decrease of ZEB1 expression resulted in inhibitory effects on the B16F10 CD133''CD44'' CSC-like properties, and reduced the tumorigenesis and metastatic potential in the melanoma mouse model. These findings support the use of knockdown of ZEB1 approaches in future melanoma clinical trials.

Acknowledgements

This work was partly supported by the National Natural Science Foundation of China (No. 8120372, 81572887) and supported by the Fundamental Research Funds for the Central Universities, Southeast University (3224005409), and Graduate Research and Innovation Projects in Jiangsu Province of China (KYLX15_0185), and Jiangsu Planned Projects for Postdoctoral Research
Funds (1301099C) as well as China Postdoctoral Science Foundation (2013M530227).

References


(Received August 6, 2015; Revised September 24, 2015; Accepted October 10, 2015)
The risk factors for suboptimal CD4 recovery in HIV infected population: an observational and retrospective study in Shanghai, China

Fengdi Zhang¹, Meiyan Sun¹, Jianjun Sun¹, Liqian Guan¹, Jiangrong Wang¹, Hongzhou Lu¹,²,³,*

¹Department of Infectious Disease, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China; ²Department of Infectious Disease, Huashan Hospital Affiliated to Fudan University, Shanghai, China; ³Department of Internal Medicine, Shanghai Medical College, Fudan University, Shanghai, China.

Summary

Although the initiation of antiretroviral therapy (ART) has promoted the reconstitution of CD4+ T-cell count in the HIV infected population, not all patients can achieve the normalization of their immunologic functions. We analysed the variables associated with immunologic recovery, which is commonly regarded as the increase of CD4 to 350 cell/μL after a year of ART. We collected data from 3,485 patients attending a university-based HIV clinic from June 2005 to July 2014 in Shanghai, China. Logistic regression test was performed to analyse the risk factors for suboptimal CD4+ recovery following yearlong ART. The CD4+ T-cell of 723 participants (41.5% of the 1744 subjects) showed more than 350 cell/μL after one year of ART. Compared with baseline CD4 > 350 cell/μL, patients with baseline CD4 ≤ 200 cell/μL or 200 < CD4 ≤ 350 cell/μL were 42.6, 4.5 times more likely to be incomplete CD4 recovery, respectively. The risk of suboptimal immunologic recovery among patients with regimen including AZT or d4T were 2.1, 2.4 times higher compared with TDF, respectively. In our study, between optimal CD4 recovery group and suboptimal recovery group, there were no significant differences in age, gender, marital status, transmission routes, WHO stage, and CD4 recovery rates. As for the dynamic CD4 change, we found the CD4 recovery rates were 49.9% and 61.8% in the second and third year of ART, respectively. Patients who had a low level of CD4+ T-cell count (< 200 cell/μL) during the initiation of ART exhibited more difficulties recovering to a normal level. Furthermore, the regimen, including AZT or d4T, was not beneficial to CD4 recovery. So, more efforts should be made to guarantee the early diagnosis and timely treatment for HIV/AIDS patients, and simultaneously optimize antiretroviral therapy.

Keywords: HIV, antiretroviral therapy, CD4 recovery, suboptimal immunologic response, risk factors

1. Introduction

For many years, HIV infection has been a serious public health burden worldwide (1-6). The CD4+ T cell plays a critical role in the pathogenesis of the HIV infection. As the main target cells of HIV, after being infected, CD4+ T-cell count reduces significantly and leads to the deconstruction of T-cell immune response, which consequently causes immunodeficiency and increases incidences of opportunistic infections and tumours. Two hundreds cells per microliter of CD4 count is a critical point in clinical practice because patients with CD4 counts above 200 cell/μL have lower risk of clinical events (7,8).

Highly active antiretroviral therapy (HAART) for HIV infection is among the greatest successes of modern medicine, having remarkably prolonged the expected life span of HIV-infected individuals (9-13). With HAART, HIV infection can be prevented from
transforming into clinical AIDS. As a result, what was commonly considered as a fatal disease is now regarded as a chronic condition. However, after the initiation of HAART, the outcome of some patients remained unsatisfactory, with the possible occurrence of virologic failure and suboptimal immunologic response (SIR). Currently, there is no consensus on the definition of suboptimal immunologic response, but certain studies have recommended that immunologic response failure can be identified as not managing to increase CD4 counts to more than 350 cell/μL or 500 cell/μL within a specific time period (e.g., 4 to 7 years) (7).

Given the fact that incomplete CD4 recovery still occurs after the initiation of HAART, risk factors for this outcome should be analysed. According to published data (8,14-18), predictors for suboptimal CD4 recovery are as follows: CD4 < 200 cell/μL at the initiation of ART, older age, co-infected with hepatitis C virus, HIV-2, human T-cell leukaemia virus, regimen of ART, persistent immune activation, loss of the regenerative potential of the immune system and concomitant medical conditions. However, limited studies mainly focused on the risk factors for incomplete immunologic recovery in China, which is a resource-limited place. Therefore, in this context, we conducted an observational and retrospective study to evaluate the influence factors of CD4+ T-cell count recovery rate of the HIV positive population in East China.

2. Materials and Methods

2.1. Study design, subjects and inclusion criteria

We conducted the cohort study of HIV-infected patients who attended the clinic affiliated with Fudan University, from June 2005 to July 2014 in Shanghai, China. Participants were only enrolled if they were HIV positive and on stable ART. Their CD4 count and virus load were not considered. Besides, all participants were not infected with the hepatitis B virus or the hepatitis C virus. Our study conformed to the principles of the Declaration of Helsinki and the current Guideline of Diagnosis and Treatment of AIDS. Every enrolled patient was offered a written informed consent form.

2.2. Data collection

The patients’ data was firstly collected from their charts, and afterwards a professional staff, majoring in Hospital Information Management, manually entered the data into a national electronic database. In addition, the clinicians routinely checked the data to ensure accuracy and consistency.

2.3. ART therapy

ART management at our hospital complied with the Chinese National Antiretroviral Therapy Guidelines. Based on the present situation in China, first-line regimen includes a combination of two nucleoside reverse transcriptase inhibitors (NRTIs): lamivudine (3TC) and zidovudine (AZT) or tenofovir (TDF) or stavudine (d4T) and a nonnucleotide reverse transcriptase inhibitor (NNRTI): efavirenz (EFV) or nevirapine (NVP). In the second-line regimen, a protease inhibitor, preferably lopinavir/ritonavir (LPV/r), is used to substitute for the nonnucleotide reverse transcriptase inhibitor. Approximately every three months, we monitored the ART therapy with CD4+ T-cell count. Apart from the T lymphocyte immunity test, the blood routine examination and blood biomedical assay were also conducted. The patients received the virus load test at the sixth month of ART, and then the test was to be conducted annually. To observe the changing trend of CD4 counts, we gathered follow-up data every three months during the first year, and every six months from the second to the third year.

2.4. CD4+ T-cell count measurement

Blood samples for CD4+ T-Cell count measurement were analysed with CYTOMICS-FC500 at the Shanghai Public Health Clinical Centre affiliated with Fudan University. In our study, we defined the baseline CD4+ T cell count as the most recent test performed within one month before ART was initiated.

2.5. Analysis and statistics

Data analysis was conducted by the IBM SPSS version 19.0 (IBM SPSS, Inc., Armonk, NY, USA). Continuous variables were described using mean and standard deviation (SD), while categorical variables were described by numbers and percentages. The chi square test was used for categorical variables and the t test was used for continuous variables. We used the logistic regression test to analyse the risk factors for suboptimal CD4 recovery after HAART initiation. The confounding factors included: age, gender, marital status, infection route, treatment regimen, WHO stages, initiation of ART timing and baseline CD4 cell counts. All hypothesis testing was two-sided, with a level of α = 0.05.

3. Results

3.1. Characteristics of the participants

1,744 participants, with a mean age of 37.3 years old (min 18, max 88), were enrolled in this study (Figure 1). Most subjects were male and nearly half of the participants were single, while 40% of the participants were married or cohabiting with others. When it comes to the infection routes, the majority of participants...
were infected *via* sexual transmission: 1,017 (58.3%) were homosexual men (MSM) and 395 (22.6%) were heterosexual transmission. Blood transfusion and intravenous drug users (IDU) accounted for 1.7% and 1.5%, respectively. Those who did not know how they became infected with HIV accounted for 15.8%. Of all the participants, a fairly large proportion was at the third WHO stage. As for the timing of ART initiation, 1,187 subjects (68.1%) started ART within six months from the time they were diagnosed as being HIV positive. The mean CD4 count of our participants before they received ART was about 202 cell/μL. After one year of ART, the mean CD4 count was 340 cell/μL, with an increase of some 140 cell/μL. The most commonly used regimen in our study was two NRTIs + 1 NNRTI, in which AZT + 3TC + EFV was received by more than half of the participants (Table 1).

### 3.2. Prevalence and risk factors for suboptimal CD4+ T-cell recovery

One year after the initiation of ART, the CD4+ T-cell count of 723 subjects (41.5% of all 1,744 participants) was above 350 cell/μL, which was defined as the recovered group. While the CD4+ T-cell count of the remaining 1,021 participants failed to achieve the same level; it was defined as the unrecovered group. There was no significance in age between the two above groups (*p* = 0.207). There was also no difference in gender (*p* = 0.461) and marital status (*p* = 0.061) between the two above groups. However, through the chi-square test, we found that the transmission routes of the two groups had discrepancy (*p* < 0.001). Specifically, the rate of those infected with HIV

<table>
<thead>
<tr>
<th>Variable</th>
<th>Number (%) in 1,744 participants</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at start of ART (Mean ± S.D.)</td>
<td>37.3 ± 12.0</td>
</tr>
<tr>
<td>Gender</td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>1588 (91.1)</td>
</tr>
<tr>
<td>Female</td>
<td>156 (8.9)</td>
</tr>
<tr>
<td>Marital status</td>
<td></td>
</tr>
<tr>
<td>Single</td>
<td>901 (51.7)</td>
</tr>
<tr>
<td>Married/cohabiting</td>
<td>692 (39.7)</td>
</tr>
<tr>
<td>Divorced/separated</td>
<td>120 (6.9)</td>
</tr>
<tr>
<td>Widowed</td>
<td>15 (0.9)</td>
</tr>
<tr>
<td>Unknown</td>
<td>16 (0.9)</td>
</tr>
<tr>
<td>Infectious routes</td>
<td></td>
</tr>
<tr>
<td>Blood transfusion</td>
<td>30 (1.7)</td>
</tr>
<tr>
<td>IDU</td>
<td>26 (1.5)</td>
</tr>
<tr>
<td>MSM</td>
<td>1017 (58.3)</td>
</tr>
<tr>
<td>Heterosexual transmission</td>
<td>395 (22.6)</td>
</tr>
<tr>
<td>Unknown</td>
<td>276 (15.8)</td>
</tr>
<tr>
<td>CD4 count (Mean ± S.D.)</td>
<td></td>
</tr>
<tr>
<td>At baseline</td>
<td>202.4 ± 166.1</td>
</tr>
<tr>
<td>At 1 year of ART</td>
<td>339.7 ± 181.5</td>
</tr>
<tr>
<td>Timing of the initiation of ART</td>
<td></td>
</tr>
<tr>
<td>Less than 6 months</td>
<td>1187 (68.1)</td>
</tr>
<tr>
<td>7-12 months</td>
<td>151 (8.7)</td>
</tr>
<tr>
<td>13-24 months</td>
<td>173 (9.9)</td>
</tr>
<tr>
<td>More than 24 months</td>
<td>233 (13.4)</td>
</tr>
<tr>
<td>ART regimen</td>
<td></td>
</tr>
<tr>
<td>AZT+3TC+EFV</td>
<td>1039 (59.6)</td>
</tr>
<tr>
<td>d4T+3TC+NVP</td>
<td>66 (3.8)</td>
</tr>
<tr>
<td>d4T+3TC+EFV</td>
<td>195 (11.2)</td>
</tr>
<tr>
<td>TDF+3TC+EFV</td>
<td>247 (14.2)</td>
</tr>
<tr>
<td>TDF+3TC+LPV/r</td>
<td>22 (1.3)</td>
</tr>
<tr>
<td>AZT+3TC+NVP</td>
<td>118 (6.8)</td>
</tr>
<tr>
<td>AZT+3TC+LPV/r</td>
<td>42 (2.4)</td>
</tr>
<tr>
<td>Others</td>
<td>15 (0.9)</td>
</tr>
<tr>
<td>WHO stage</td>
<td></td>
</tr>
<tr>
<td>Stage 1</td>
<td>12 (0.7)</td>
</tr>
<tr>
<td>Stage 2</td>
<td>26 (1.5)</td>
</tr>
<tr>
<td>Stage 3</td>
<td>1282 (73.5)</td>
</tr>
<tr>
<td>Stage 4</td>
<td>424 (24.3)</td>
</tr>
</tbody>
</table>
These p values were calculated by t-test. The others were analyzed by chi-square test.

through MSM was slightly higher in the recovered group than in the unrecovered group (62.9% vs. 55.0%). On the contrary, the rate of heterosexual transmission and unsexual transmission, 16.0% and 15.5%, respectively, in the recovered group was lower than that of the unrecovered group, 23.4% and 21.5%, respectively.

The rate of different ART regimens was also diverse between the recovered group and the unrecovered group: the regimen included AZT (72.8% vs. 66.0%), d4T (7.3% vs. 21.1%) and TDF (20.0% vs. 12.9%). Surprisingly, no difference was found in the WHO stage between the two groups (p = 0.157). In view of the timing of ART initiation, the proportion of participants who initiated ART earlier (≤ 6 months from being diagnosed with HIV infection) was approximately 64% in the recovered group as compared to about 71% in the unrecovered group. The baseline CD4 count of the two groups showed significant differences (p = 0.033).

When we conducted the univariate logistic analysis, we found that among all the variables, only the ART regimen and the baseline CD4+ T-cell count were associated with suboptimal CD4+ T-cell recovery. Furthermore, the multivariate analysis showed that the lower baseline CD4+ T-cell count and the regimen including AZT and d4T, were higher risk factors for CD4+ T-cell unrecovery (Table 2).

3.3. Follow-up situation of participants

Among all the 1,744 participants, the CD4+ T-cell count of only 101 participants was above 350 cell/μL at baseline. After a year of ART, the CD4 count of 723 subjects was above this level. The data corresponding to the second year of ART decreased by 793 because some patients had not reached the second year of their ART, or we failed to follow up due to certain personal or impersonal factors. In the remaining 951 subjects, 476 people had a CD4+ T-cell count above 350 cell/μL. We had 455 subjects with complete information at the third year of ART, and among them 281 participants had CD4 count above 350 cell/μL (Figure 2A).

At the baseline, only 5.8% of the participants had a CD4+ T-cell count above 350 cell/μL and the CD4 recovery rate increased to 41.5% after a year of ART. After eliminating the participants with missing data, or we failed to follow up due to certain personal or impersonal factors. In the remaining 951 subjects, 476 people had a CD4+ T-cell count above 350 cell/μL. We had 455 subjects with complete information at the third year of ART, and among them 281 participants had CD4 count above 350 cell/μL (Figure 2A).

4. Discussion

In this study, we analysed the risk factors for incomplete CD4 recovery in the HIV-infected population of East China. We found that the ART regimen and the baseline
of CD4+ T-cell count could impact immunological restoration. AZT, d4T and TDF are commonly used among HIV infectors in China. However, compared with TDF, the regimen including AZT and d4T were more likely to suppress the recovery of CD4+ T-cell. Those with higher baseline CD4+ T-cell count are more likely to achieve full immunological recovery. Through statistical analysis, we drew the same conclusion that the lower baseline CD4 count is adverse to immunologic restoration. Compared with those whose baseline CD4 > 350 cell/μL, patients with CD4 between 200 and 350 cell/μL or CD4 < 200 cell/μL at ART initiation were more likely to have suboptimal immunologic responses, with the odds ratio of 42.597 (95% CI: 21.927-82.752) and 4.519 (95% CI: 2.367-8.627), respectively. All of the above results were similar with the results about predictors for incomplete CD4 recovery after HAART initiation mentioned in the US AIDS guidelines (7).

Our study also found that ART regimen could impede CD4 recovery to some extent. As different ART regimens are applied in different countries, we studied ART regimens concerning 3TC, d4T, AZT, and TDF, which are commonly used for patients and free of charge in China. Compared with the ART regimen including TDF, we found that the regimens including AZT and d4T impeded CD4 recovery, and the odds ratio were 2.052 (95% CI: 1.480-2.846) and 2.400 (95% CI: 1.531-3.762), respectively. Our result is similar to the study conducted in 2006 by Gallant JE, et al. and the study conducted in Senegal by G. Batista, et al (8,19). The incomplete CD4 recovery among patients with regimen including AZT or d4T can be explained by the fact that both these drugs have myelotoxicity, and there is a smaller increase of total lymphocyte count when AZT and d4T are included in an ART regimen (20-22). Li TS’ study has demonstrated that the thymus function of adults will gradually decline with the increase of age. It is well known that the maturity of T lymphocytes is in the thymus, thus aging undoubtedly affects CD4+ T-cell count (23). However, our univariate analysis showed that age was not associated with CD4+ T-cell recovery, which was inconsistent with the results in the guideline of the USA. The main reason is that the number of elder subjects (> 60 years) was not large enough comparing with other age groups (chi-square test, p = 0.246).

Nowadays, there is no specific standard for the early therapy of HIV/AIDS, but the current study indicated that early therapy is superior to delayed therapy, resulting in better virus suppression, less confection with other diseases, lower morbidities and better CD4+ T-cell recovery (24). It is difficult to determine when these patients became infected with HIV, so we substituted the diagnosis date for the infection time. We defined early therapy as initiating ART regimen less than six months from the date they received diagnosis reports, and delayed therapy was defined as more than six months from the time of confirmed diagnosis. However, in our study, we found that the timing of ART initiation was not a risk factor for incomplete CD4+ T-cell recovery (univariate analysis, OR = 1.116, 95% CI: 0.879-1.418, p = 0.368). Therefore, a credible way needs to be established to verify the exact time of infection for the accurate analysis of the relationship between the timing of ART initiation and treatment efficacy. Although a high degree of concern is paid to the CD4+ T-cell recovery in the field of HIV/AIDS research, various conclusions have been obtained from different studies. An urban cohort study conducted in sub-Saharan Africa indicated that if the CD4 recovery criterion is stipulated at the cut-off of 200 cell/μL, then the recovery rates would be 57%, 58%, and 81%.
at the sixth, twelfth, and twenty-fourth months of ART, respectively (25). Another study conducted in Senegal declared that if suboptimal immune reconstitution is defined as the increase of CD4 count less than 50 cell/μL in patients with virologic suppression more than six months, then the recovery rate would be 84.5% after a year of ART (8). Our cohort study showed that the CD4 recovery rates were 41.5%, 49.9%, and 61.8% after twelve, twenty-four, and thirty-six months of ART, separately. Apparently, in the same follow-up time, the immune reconstitution rate will be higher if the recovery standard is set at a lower point. Obviously, with the longer period of having ART, the immune reconstitution of patients is more promising.

However, our study still had two limitations. Firstly, not all of the participants had their HIV-RNA levels measured at the baseline due to the high cost of the test. This test was free of charge after a year of ART (8). Our cohort study showed that the CD4 recovery rates were 41.5%, 49.9%, and 61.8% after twelve, twenty-four, and thirty-six months of ART, separately. Apparently, in the same follow-up time, the immune reconstitution rate will be higher if the recovery standard is set at a lower point. Obviously, with the longer period of having ART, the immune reconstitution of patients is more promising.

In conclusion, we carried out an observational, retrospective and cohort research to study the risk factors for suboptimal CD4 recovery in the HIV infected population of Shanghai, China. We discovered that patients who had a low level of CD4+ T-cell count (< 200 cell/μL) at the initiation of ART had more difficulties recovering to the normal level. Furthermore, the regimen including AZT or d4T impedes CD4 recovery. Actually, the CD4 recovery rate is not satisfactory in our settings. To decrease the incidence of opportunistic infection and mortality in the HIV infected population, we should endeavour to facilitate the normalization of their CD4+ T-cell count. At the same time, more efforts should be made to guarantee the early diagnosis and early treatment for HIV/AIDS patients as well as optimizing antiretroviral therapy.

Acknowledgements

This study was supported by key research grants from the Ministry of Science and Technology and the People’s Republic of China (2012ZX09303013 and 2014AA021403).

References


(Received August 11, 2015; Revised October 13; 2015; Accepted October 14, 2015)
Serum concentrations of Flt-3 ligand in rheumatic diseases


Department of Dermatology and Plastic Surgery, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.

1. Introduction

Immune dysfunction and vascular abnormalities are thought to be the common features in rheumatic diseases including rheumatoid arthritis (RA), polymyositis/dermatomyositis (PM/DM), systemic sclerosis (SSc), systemic lupus erythematosus (SLE), mixed connective tissue disease (MCTD) or Sjögren's syndrome (SjS) (1,2). For example, autoantibodies, Raynaud's phenomenon, nailfold bleeding (NFB) and skin ulcers are frequently seen in various rheumatic diseases. These vascular abnormalities are characterized by uncontrolled regeneration of the vasculature and vascular losses due to defective maintenance of the vasculature (3). However, the mechanism is hardly understood, and needs to be clarified.

Fms-like tyrosine kinase 3 (Flt-3), also known as CD135, is a cytokine receptor expressed on the surface of bone-marrow progenitor of hematopoietic cells. Flt-3 ligands are produced by peripheral blood mononuclear cells, and found in various human body fluids. Flt-3 signal is involved in the regulation of vessel formation as well as B cell differentiation, suggesting that Flt-3 signal contributes to the pathogenesis of vascular abnormalities and immune dysregulation in rheumatic diseases. The aim of the present study is to examine serum Flt-3 ligand levels in patients with various rheumatic diseases, and to evaluate the possibility that serum Flt-3 ligand levels can be a useful disease marker. Sera were obtained from 20 dermatomyositis (DM) patients, 36 systemic sclerosis (SSc) patients, 10 systemic lupus erythematosus (SLE) patients, 10 scleroderma spectrum disorder (SSD) patients, 4 mixed connective tissue disease (MCTD) patients, and 12 normal subjects. Flt-3 ligand levels were determined with ELISA. Serum Flt-3 ligand levels were significantly elevated in patients with DM, SSc, SSD and MCTD compared to those in normal subjects. DM patients with elevated Flt-3 ligand levels were accompanied with significantly increased CRP levels and increased frequency of heliotrope rash than those with normal levels. In addition, SSc patients with elevated Flt-3 ligand levels showed significantly reduced frequency of nailfold bleeding. Serum Flt-3 ligand levels can be a marker of cutaneous manifestation in DM and a marker of microangiopathy in SSc. Clarifying the role of Flt-3 ligand in rheumatic diseases may lead to further understanding of these diseases and new therapeutic approaches.

Keywords: Flt-3, dermatomyositis, systemic sclerosis, systemic lupus erythematosus

www.biosciencetrends.com
by peripheral blood mononuclear cells (9), and can be found as soluble homodimeric proteins in various human body fluids including serum. So far, several previous studies have suggested the significance of Flt-3 ligand levels in autoimmune arthritis such as RA and primary Sjögren’s syndrome: there was a significant correlation between serum Flt-3 ligand levels and disease activity in RA patients (10,11). However, the expression of Flt-3 ligand in other rheumatic diseases has yet to be elucidated. Therefore, in this study, we examined serum Flt-3 ligand levels in patients with various rheumatic diseases, and tried to evaluate the possibility that serum levels of Flt-3 ligand can be a useful disease marker.

2. Materials and Methods

2.1. Clinical assessment and patient material

Patients with SSC and SLE fulfilled the criteria proposed by the American College of Rheumatology (ACR) (12,13). All SSC patients were grouped into diffuse cutaneous SSC (dcSSC) and limited cutaneous SSC (lcSSC) according to the classification system proposed by LeRoy et al. (14). The concept of scleroderma spectrum disorder (SSD) was originally proposed by Mariq et al. to unify typical SSC, early forms of SSC and closely related disorders (15,16). After that, Ihn et al. redefined SSD as patients that did not fulfill the ACR criteria of SSC but were thought to develop SSC in the future, and proposed a new diagnostic method (17). Classical DM patients were diagnosed based on the criteria proposed by Bohan and Peter (18,19). Patients with clinically and histopathologically typical cutaneous lesions but without myositis were diagnosed as clinically amyopathic DM (CADM) according to the previous criteria (20). MCTD patients had clinical features of SLE, SSC and PM/DM and anti-U1RNP antibodies, but did not satisfy the criteria for these connective tissue diseases (12,13,18,19), and were diagnosed according to the criteria of Alarcón-Segovia (21,22).

Sera were obtained from randomly chosen 15 classical DM patients (age range: 27-86 years, mean ± SD: 54.1 ± 18.4; disease duration range: 1-24 months, mean ± SD: 7.4 ± 7.5), 5 CADM patients (age range: 33-81 years, mean ± SD: 61.4 ± 19.4; disease duration range: 1-108 months, mean ± SD: 31.2 ± 38.5), 36 patients with SSC (13 dcSSC and 23 lcSSC, age range: 24-85 years, mean ± SD: 62.2 ± 14.6; disease duration range: 1-768 months, mean ± SD: 75.0 ± 151.7), 10 SSD patients (age range: 44-75 years, mean ± SD: 54.9 ± 10.7; disease duration range: 1-120 months, mean ± SD: 27.9 ± 40.1), 10 SLE patients (age range: 23-57 years, mean ± SD: 35.0 ± 11.9; disease duration range: 2-84 months, mean ± SD: 21.3 ± 27.6) and 4 MCTD patients (age range: 44-73 years, mean ± SD: 59.8 ± 12.6; disease duration range: 24-228 months, mean ± SD: 123.0 ± 83.4). Clinical and laboratory data reported in this study were obtained at the time of serum sampling. None of the patients received systemic treatments such as steroid or immunosuppressant at the serum sampling.

Control serum samples were also collected from 12 normal subjects (age range = 32-81 years, mean ± SD: 47.1 ± 16.4). All serum samples were stored at −80°C prior to use. Institutional review board approval and written informed consent were obtained before patients and healthy volunteers were entered into this study according to the Declaration of Helsinki.

2.2. Nailfold bleeding

Nailfold bleeding (NFB) was evaluated macroscopically by the presence of splinter hemorrhages of the nailfold capillaries in more than one finger by 2 investigators in a blinded manner.

2.3. Serum concentrations of Flt-3 ligand

Levels of serum Flt-3 ligand were measured with a specific ELISA kit (R&D Systems, Minneapolis, MN, USA) (23). Briefly, anti-Flt-3 ligand monoclonal antibodies were precoated onto microtiter wells. Aliquots of serum were added to each well, followed by the addition of peroxidase-conjugated antibodies to Flt-3 ligand. Color was developed with hydrogen peroxide and tetramethylbenzidine peroxidase, and the absorbance at 450 nm was measured. Wavelength correction was performed by absorbance at 540 nm. The concentration of Flt-3 ligand in each sample was determined by interpolation from a standard curve.

2.4. Statistical analysis

Statistical analysis was carried out with Mann-Whitney U test for the comparison of medians, and Fisher’s exact probability test for the analysis of frequency. p values less than 0.05 were considered significant. Receiver operating characteristic (ROC) curve analysis was performed to evaluate the diagnostic performance of Flt-3 ligand levels using GraphPad Prism ver. 5.01 (MDF software, Tokyo, Japan).

3. Results

3.1. Serum concentrations of Flt-3 ligand in patients with various rheumatic diseases

The serum Flt-3 ligand levels in patients with various rheumatic diseases are shown in Figure 1. Serum samples were obtained from 20 DM patients (including 5 CADM patients), 36 SSC patients, 10 SSD patients, 10 SLE patients, 4 MCTD patients, and 12 normal
The mean age of normal subjects was 47.1 years, and the ratio of female was 75.0%. Summary of clinical/laboratory features in patients with these rheumatic diseases enrolled in this study are shown in Tables and Supplemental Tables. For example, in DM patients, the mean age at the serum sampling was 56.0 years, and mean CK levels were 2,400.8 IU/L (normal values; 57-284 IU/L for male and 45-176 IU/L for female) (Table 1). Among the rheumatic diseases, DM patients had elevated serum Flt-3 ligand concentration (mean ± SD: 185.1 ± 57.4 pg/mL), and there was a statistically significant difference in the values between DM patients and normal subjects (94.4 ± 21.0 pg/mL, \( p = 0.000011 \), Figure 1). According to the manufacturer's data, mean normal serum Flt-3 ligand level was 93.9 pg/mL, which is consistent with our results. In ROC curve analysis for serum Flt-3 ligand levels to distinguish DM patients from normal subjects, the area under the curve (AUC) was 0.9708 (95% confidence interval; 0.9219-1.020, Figure 2A): AUC more than 0.9 means that the level of Flt-3 ligand is useful for diagnosis of DM patients. When the most optical cut-off point was set at 132.8 pg/mL according to the Youden index (0.90), the sensitivity was 90.0% and the specificity was 100.0%.

Table 1. Correlation of serum Flt-3 ligand levels with clinical/serological features in patients with dermatomyositis

<table>
<thead>
<tr>
<th>Items</th>
<th>All patients (n = 20)</th>
<th>Serum Flt-3 ligand</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Patients with elevated Flt-3 ligand levels (n = 10)</td>
</tr>
<tr>
<td>Age at the time of serum sampling (mean years)</td>
<td>56.0</td>
<td>61.9</td>
</tr>
<tr>
<td>Gender (ratio of female, %)</td>
<td>60.0</td>
<td>50.0</td>
</tr>
<tr>
<td>Duration of disease (mean months)</td>
<td>13.4</td>
<td>6.3</td>
</tr>
<tr>
<td>Type (DM:CADM)</td>
<td>15.5</td>
<td>8.2</td>
</tr>
<tr>
<td>Clinical features</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gottron’s sign (%)</td>
<td>83.3</td>
<td>100.0</td>
</tr>
<tr>
<td>Heliotrope rash (%)</td>
<td>75.0</td>
<td>100.0*</td>
</tr>
<tr>
<td>Laboratory features</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IgG (mg/dL)</td>
<td>1379.2</td>
<td>1365.4</td>
</tr>
<tr>
<td>CK (IU/L)</td>
<td>2400.8</td>
<td>2155.2</td>
</tr>
<tr>
<td>Myoglobin (mg/mL)</td>
<td>694.6</td>
<td>602.6</td>
</tr>
<tr>
<td>Aldolase (U/L)</td>
<td>37.0</td>
<td>21.6</td>
</tr>
<tr>
<td>CRP (mg/dL)</td>
<td>0.83</td>
<td>1.48*</td>
</tr>
<tr>
<td>Organ involvement</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Muscle weakness (%)</td>
<td>76.5</td>
<td>87.5</td>
</tr>
<tr>
<td>Interstitial kung disease (%)</td>
<td>35.3</td>
<td>42.6</td>
</tr>
<tr>
<td>Dysphasia (%)</td>
<td>30.8</td>
<td>40.0</td>
</tr>
<tr>
<td>Joint (%)</td>
<td>28.6</td>
<td>50.0</td>
</tr>
<tr>
<td>ANA specificity</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ANA (+)</td>
<td>50.0</td>
<td>70.0</td>
</tr>
<tr>
<td>(levels, index)</td>
<td>48.6</td>
<td>67.3</td>
</tr>
<tr>
<td>Anti-Jo-1 (%)</td>
<td>10.0</td>
<td>10.0</td>
</tr>
<tr>
<td>(levels, IU/mL)</td>
<td>1.68</td>
<td>1.74</td>
</tr>
</tbody>
</table>

The cut-off vale was set at the mean + 4SD of the value in healthy control subjects. DM, dermatomyositis; CADM, clinically amyopathic dermatomyositis; CK, creatin kinase; ANA, antinuclear antibodies; Anti-Jo-1, Anti-Jo-1 antibodies. * \( p < 0.05 \), versus patients with normal Flt-3 ligand levels using Fisher's exact probability test.
subjects (144.7 ± 60.9 vs. 94.4 ± 21.0 pg/mL, \( p = 0.0026 \)). In ROC curve analysis for serum Flt-3 ligand levels to distinguish SSc patients from normal subjects, AUC was 0.7928 (95% confidence interval; 0.6655-0.9202, Figure 3A): AUC more than 0.7 indicates sufficient diagnostic performance of serum Flt-3 ligand levels. When the most optical cut-off point was set at 114.8 pg/mL by the Youden index (0.56), the sensitivity and specificity were 63.9% and 91.7%, respectively. We could not find any significant differences in Flt-3 ligand levels between dcSSc patients and lcSSc patients (139.8 ± 69.1 vs. 147.6 ± 57.3 pg/mL, \( p = 0.72 \), Figure 3B).

Patients with SSD and MCTD also showed significantly higher serum Flt-3 ligand levels than normal subjects (157.7 ± 65.9 vs. 94.4 ± 21.0 pg/mL, \( p = 0.0083 \) and 194.3 ± 44.1 vs. 94.4 ± 21.0 pg/mL, \( p = 0.0040 \), respectively) (Supplemental Tables 1 and 2, http://www.biosciencetrends.com/docindex.php?year=2015&kanno=5). On the other hand, serum Flt-3 ligand levels were slightly higher in patients with SLE compared with normal subjects, but the difference was not statistically significant (111.0 ± 43.3 vs. 94.4 ± 21.0 pg/mL, \( p = 0.25 \)) (Supplemental Table 3, http://www.biosciencetrends.com/docindex.php?year=2015&kanno=5).

Taken together, significant increases of serum Flt-3 ligand levels were found in patients with DM, SSc, SSD, and MCTD. When the cut-off value was set at the mean + 2SD of Flt-3 ligand levels in normal subjects (136.4 pg/mL), all the values in normal subjects were below the cut-off. On the other hand, increased serum Flt-3 ligand levels were found in 17 of the 20 DM patients (85.0%), 14 of the 36 SSc patients (38.9%), 7 of the 10 SSD patients (70.0%), all of the 4 MCTD patients (100.0%) and 3 of the 10 SLE patients (30.0%). Furthermore, when the cut-off was set at mean + 4SD of values in normal subjects (178.5 pg/mL), increased serum Flt-3 ligand levels were seen in 10 of the 20 DM patients (50.0%), 8 of the 36 SSc patients (22.2%), 2 of the 10 SSD patients (20.0%), and 2 of the 4 MCTD patients (50.0%).
3.2. Correlation of serum Flt-3 ligand levels with clinical manifestations and laboratory data in patients with DM or SSc

Then we examined correlation of serum Flt-3 ligand levels with clinical and serological features of patients with DM or SSc. As shown in Table 1, when Flt-3 ligand levels > mean + 4SD of the values in normal subjects (178.5 pg/mL) were regarded as elevated, DM patients with elevated Flt-3 ligand levels tended to be accompanied with heliotrope rash at a significantly higher prevalence than those with normal levels (100.0% vs. 50.0%, p = 0.029). Furthermore, C-reactive protein (CRP) levels (normal values; < 0.3 mg/dL) in DM patients with elevated Flt-3 ligand levels were significantly higher than in those without (1.48 vs. 0.19 mg/dL, p = 0.019). We could not find any significant differences between patients with and without elevated Flt-3 ligand levels in terms of the frequency of Gottron's sign, the levels of muscle enzymes, or the positive rates and the levels of antinuclear antibody (ANA) and Jo-1 antibody. Duration of disease (between the onset of symptoms and the first hospital visit) was slightly shorter in patients with elevated Flt-3 ligand levels, but not statistically significant.

On the other hand, when SSc patients were divided into two groups according to the cut-off value (136.4 pg/mL, mean + 2SD of normal subjects), patients with elevated Flt-3 ligand levels showed a significantly reduced prevalence of NFB as compared to those with normal levels (26.7 vs. 63.6%, p = 0.027, Table 2). There were no significant differences between patients with elevated Flt-3 ligand levels and those with normal levels in the frequency of major organ involvements.

| Table 2. Correlation of serum Flt-3 ligand levels with clinical/serological features in patients with systemic sclerosis |
|---------------------------------|-----------------|-----------------|
| Items                           | All patients (n = 36) | Patients with elevated Flt-3 ligand levels (n = 14) | Patients with normal Flt-3 ligand levels (n = 22) |
| Age at the time of serum sampling (mean years) | 62.2 | 64.9 | 60.3 |
| Gender (ratio of female, %) | 77.7 | 75.0 | 77.2 |
| Duration of disease (mean months) | 75.0 | 58.2 | 86.6 |
| Type (diffuse:limited) | 13.23 | 6.8 | 7.15 |
| m-TSS | 11.0 | 11.6 | 10.5 |
| Clinical features              |                  |                  |                  |
| Pitting scars (%)              | 43.8 | 50.0 | 40.0 |
| Ulcers (%)                     | 32.0 | 20.0 | 40.0 |
| Nailfold bleeding (%)          | 48.7 | 26.7* | 63.6 |
| Raynaud's phenomenon (%)       | 90.3 | 100.0 | 84.2 |
| Telangiectasia (%)             | 23.1 | 18.2 | 26.7 |
| Contracture of phalanges (%)   | 85.7 | 100.0 | 77.8 |
| Calcinosis (%)                 | 5.9 | 0.0 | 10.0 |
| Diffuse pigmentation (%)       | 28.6 | 42.9 | 21.4 |
| Short SF (%)                   | 75.0 | 85.7 | 70.6 |
| Sicca symptoms (%)             | 53.9 | 45.5 | 60.0 |
| Laboratory features            |                  |                  |                  |
| CRP (mg/dL)                    | 0.75 | 0.95 | 0.57 |
| Pulmonary fibrosis (%)         | 37.1 | 35.7 | 38.1 |
| Mean %VC (%)                   | 102.9 | 100.0 | 104.9 |
| Mean %DLCO (%)                 | 87.0 | 85.1 | 88.4 |
| Pulmonary hypertension (%)     | 28.1 | 27.0 | 29.0 |
| Esophagus (%)                  | 20.6 | 35.7 | 10.0 |
| Heart (%)                      | 29.4 | 28.6 | 30.0 |
| Kidney (%)                     | 0.0 | 0.0 | 0.0 |
| Joint (%)                      | 57.9 | 71.4 | 50.0 |
| Thrombosis (%)                 | 0.0 | 0.0 | 0.0 |
| ANA specificity                |                  |                  |                  |
| Anti-topo I (%)                | 27.8 | 21.4 | 31.8 |
| (levels, IU/mL)                | 36.7 | 33.8 | 39.6 |
| Anti-centromere (%)            | 38.9 | 50.0 | 31.8 |
| (levels, IU/mL)                | 74.5 | 73.0 | 76.1 |
| Anti-U1 RNP (%)                | 16.7 | 21.4 | 13.6 |
| (levels, IU/mL)                | 10.4 | 12.9 | 7.9 |
| Anti-SS-A (%)                  | 30.6 | 57.1 | 13.6 |
| (levels, IU/mL)                | 28.0 | 22.6 | 32.3 |

* p < 0.05 versus patients with normal Flt-3 ligand levels using Fisher’s exact probability test.
or other vascular involvements including Raynaud’s phenomenon, thrombosis, pitting scar or telangiectasia. Furthermore, CRP levels were not significantly different between the two groups. The positive rates and the levels of antibodies against topoisomerase I, centromere, U1 RNP or SS-A were not significantly different between patients with and without elevated Flt-3 ligand levels. Duration of disease was shorter in patients with elevated Flt-3 ligand levels, albeit insignificant.

4. Discussion

We demonstrated several novel findings in this study. First, levels of serum Flt-3 ligand were significantly elevated in patients with DM, SSc, SSD, and MCTD compared to normal subjects. Second, SSc patients with elevated Flt-3 ligand levels showed significantly reduced prevalence of NFB compared to those with normal levels. And lastly, in DM patients, those with elevated Flt-3 ligand levels were accompanied with significantly increased CRP levels and increased frequency of heliotrope rash than those with normal levels.

NFB is one of the earliest vascular events in SSc, and the main factor of the diagnostic criteria for SSD. Although we also performed capillaroscopy on several SSc patients with or without increased serum Flt-3 ligand levels, we could not find any significant differences in the frequency of capillaroscopic findings including bleeding, dilated loops and giant loops between the two groups, probably because the number of patients determined was limited and insufficient to allow statistically based conclusions. Considering the significant elevation of Flt-3 ligand levels in SSD patients and the reduced frequency of NFB in SSc patients with elevated Flt-3 ligand levels, there is a possibility that Flt-3 ligand may start to elevate at the prodromal stage of SSc, and have suppressive effect on NFB. Increased Flt-3 ligand levels may activate Flt-3 signal, and may stimulate vascular formation to repair vascular abnormalities of NFB in these patients.

Although patients in this study were randomly chosen, DM patients showed high CK levels (2,400.8 IU/L) and high CRP levels (0.83 mg/dL) on average. Thus, one of the reasons why DM patients showed the elevated serum Flt-3 ligand values is possibly due to their high disease activities at the sampling point. Higher CRP levels and a higher frequency of heliotrope rash in DM patients with elevated Flt-3 ligand levels indicated that an abnormal increase of Flt-3 ligand may be correlated with the disease activity and the formation of the skin lesions. Crowson et al. previously reported that skin lesions of DM showed more severe endothelial injury, telangiectasia, and deposition of fibrin or C5b-9 on vessels than those of lupus erythematosus, whereas the density of superficial vascular plexus was lower in lesions of DM compared to lupus erythematosus (24). Several investigators also have demonstrated a marked reduction of capillary number in the involved muscles of DM (25,26). These results indicate that vascular abnormalities are present in DM, and play a role in the pathogenesis of skin lesions. Given that Flt-3 signals may be mediated in the vessel formation process, and that uncontrolled activation of angiogenic factors rather than their inactivation is thought to cause vascular abnormalities in rheumatic diseases (27,28). The excessive expression of Flt-3 ligands in DM may also induce dysregulation of the vessel formation, resulting in the formation of heliotrope rash. Consistently, MCTD patients included in this study were accompanied with heliotrope rash, and showed the highest Flt-3 ligand levels among rheumatic diseases, although we could not determine ROC curve analysis or the association with clinical/laboratory findings due to the small number of the patients. On the other hand, although SLE patients are sometimes accompanied with a variety of microangiopathy phenotypes, weaker changes of vessels in SLE than in DM as described above may explain the lower serum Flt-3 ligand levels in SLE.

Taken together, our results suggested that Flt-3 signal may play a different role in each rheumatic disease. Telangiectasia and endothelial injury are commonly observed both in skin lesions of DM including heliotrope rash and in the microangiopathy such as NFB (24,29), which may be associated with increased Flt-3 ligand levels in patients with DM or SSc. However, there are also several differences between these two abnormalities (e.g. distribution or the presence of bleeding). Further researches on the similarities and the dissimilarities are needed in the future.

On the other hand, we had expected that the association of serum Flt-3 ligand levels and immunodysfunction in patients with DM or SSc, but the positive rates and the levels of ANA or other antibodies were not significantly different between patients with and without elevated serum Flt-3 ligand levels.

As the limitation of this study, because the onset ages of SSc, DM, SLE, and MCTD were usually different (30,31), the patients were not age-matched. There was no correlation between serum Flt-3 ligand levels and the age of individuals included in this study (r = 0.399). Furthermore, Kinn et al. have reported that the expression levels of Flt-3 ligand in healthy skin did not show any significant correlation with aging (7), and Metcalf et al. have suggested that Flt-3 ligand levels in peripheral blood mononuclear cells were similar between adult people and old people (32). Thus, the direct correlation between aging and serum Flt-3 ligand levels is not obvious. However, the mean ages of both SSc and DM patients were higher than that of SLE patients, and the levels of Flt-3 ligand in SSc and DM
were higher than those in SLE. Additionally, the mean age of DM or SSc patients with elevated Flt-3 ligand levels tended to be older than the counterpart. Because normal aging is usually associated with minimal/chronic inflammation coined by inflammaging, there is a possibility that the difference of Flt-3 ligand levels can be explained by aging factor. Future studies to measure circulating levels of Flt-3 or Flt-3 ligand in normal aging as well as malignancy or viral infection are needed. On the other hand, albeit insignificant, disease duration of the elevated Flt-3 ligand groups in both SSc and DM patients was shorter than the counterpart. This result suggests that these patients may have more severe symptoms. These points should also be clarified in the future by larger studies.

In conclusion, serum Flt-3 ligand levels may be a marker of cutaneous manifestations in DM patients and a marker of microangiopathy in SSc patients. Clarifying the role of Flt-3 ligand in rheumatic disease by systematic approach is required for further understanding of the diseases and new therapeutic approaches.

Acknowledgements

This study was supported in part by a grant for scientific research from the Japanese Ministry of Education, Science, Sports and Culture, by project research on intractable diseases from the Japanese Ministry of Health, Labour and Welfare, and by Lydia O'leary Memorial Foundation.

References


(Received September 17, 2015; Revised October 21, 2015; Accepted October 24, 2015)
Guide for Authors

1. Scope of Articles

BioScience Trends is an international peer-reviewed journal. BioScience Trends devotes to publishing the latest and most exciting advances in scientific research. Articles cover fields of life science such as biochemistry, molecular biology, clinical research, public health, medical care system, and social science in order to encourage cooperation and exchange among scientists and clinical researchers.

2. Submission Types

Original Articles should be well-documented, novel, and significant to the field as a whole. An Original Article should be arranged into the following sections: Title page, Abstract, Introduction, Materials and Methods, Results, Discussion, Acknowledgments, and References. Original articles should not exceed 5,000 words in length (excluding references) and should be limited to a maximum of 50 references. Articles may contain a maximum of 10 figures and/or tables.

Brief Reports definitely documenting either experimental results or informative clinical observations will be considered for publication in this category. Brief Reports are not intended for publication of incomplete or preliminary findings. Brief Reports should not exceed 3,000 words in length (excluding references) and should be limited to a maximum of 4 figures and/or tables and 30 references. A Brief Report contains the same sections as an Original Article, but the Results and Discussion sections should be combined.

Reviews should present a full and up-to-date account of recent developments within an area of research. Normally, reviews should not exceed 8,000 words in length (excluding references) and should be limited to a maximum of 100 references. Mini reviews are also accepted.

Policy Forum articles discuss research and policy issues in areas related to life science such as public health, the medical care system, and social science and may address governmental issues at district, national, and international levels of discourse. Policy Forum articles should not exceed 2,000 words in length (excluding references).

Case Reports should be detailed reports of the symptoms, signs, diagnosis, treatment, and follow-up of an individual patient. Case reports may contain a demographic profile of the patient but usually describe an unusual or novel occurrence. Unreported or unusual side effects or adverse interactions involving medications will also be considered. Case Reports should not exceed 3,000 words in length (excluding references).

Letters should present considered opinions in response to articles published in BioScience Trends in the last 6 months or issues of general interest. Letters should not exceed 800 words in length and may contain a maximum of 10 references.

3. Editorial Policies

Ethics: BioScience Trends requires that authors of reports of investigations in humans or animals indicate that those studies were formally approved by a relevant ethics committee or review board.

Conflict of Interest: All authors are required to disclose any actual or potential conflict of interest including financial interests or relationships with other people or organizations that might raise questions of bias in the work reported. If no conflict of interest exists for each author, please state "There is no conflict of interest to disclose".

Submission Declaration: When a manuscript is considered for submission to BioScience Trends, the authors should confirm that: 1) no part of this manuscript is currently under consideration for publication elsewhere; 2) this manuscript does not contain the same information in whole or in part as manuscripts that have been published, accepted, or are under review elsewhere, except in the form of an abstract, a letter to the editor, or part of a published lecture or academic thesis; 3) authorization for publication has been obtained from the authors’ employer or institution; and 4) all contributing authors have agreed to submit this manuscript.

Cover Letter: The manuscript must be accompanied by a cover letter signed by the corresponding author on behalf of all authors. The letter should indicate the basic findings of the work and their significance. The letter should also include a statement affirming that all authors concur with the submission and that the material submitted for publication has not been published previously or is not under consideration for publication elsewhere. The cover letter should be submitted in PDF format. For example of Cover Letter, please visit http://www.biosciencetrends.com/downcentre.php (Download Centre).

Copyright: A signed JOURNAL PUBLISHING AGREEMENT (JPA) form must be provided by post, fax, or as a scanned file before acceptance of the article. Only forms with a hand-written signature are accepted. This copyright will ensure the widest possible dissemination of information. A form facilitating transfer of copyright can be downloaded by clicking the appropriate link and can be returned to the e-mail address or fax number noted on the form (Please visit Download Centre). Please note that your manuscript will not proceed to the next step in publication until the JPA Form is received. In addition, if excerpts from other copyrighted works are included, the author(s) must obtain written permission from the copyright owners and credit the source(s) in the article.

Suggested Reviewers: A list of up to 3 reviewers who are qualified to assess the scientific merit of the study is welcomed. Reviewer information including names, affiliations, addresses, and e-mail should be provided at the same time the manuscript is submitted online. Please do not suggest reviewers with known conflicts of interest, including participants or anyone with a stake in the proposed research; anyone from the same institution; former students, advisors, or research collaborators (within the last three years); or close personal contacts. Please note that the Editor-in-Chief may accept one or more of the proposed reviewers or may request a review by other qualified persons.

Language Editing: Manuscripts prepared by authors whose native language is not English should have their work proofread by a native English speaker before submission. If not, this might delay the publication of your manuscript in BioScience Trends.

The Editing Support Organization can provide English proofreading, Japanese-English translation, and Chinese-English translation services to authors who want to publish in BioScience Trends and need assistance before submitting a manuscript. Authors can visit this organization directly at http://www.iacnhr.com/iac-esosupport.php?lang=en. IAC-ESO was established to facilitate manuscript preparation by researchers whose native language is not English and to help edit works intended for international academic journals.

4. Manuscript Preparation

Manuscripts should be written in clear, grammatically correct English and submitted as a Microsoft Word file in a single-column format. Manuscripts must be paginated and typed in 12-point Times New Roman font with 24-point line spacing. Please do not embed figures in the text. Abbreviations should be used as little as possible and should be explained at first mention unless the term is a well-known abbreviation (e.g. DNA). Single words should not be abbreviated.

Title Page: The title page must include 1) the title of the paper (Please note the title should be short, informative, and contain the major key words); 2) full name(s) and affiliation(s) of the author(s); 3) abbreviated names of the author(s), 4) full name including address, telephone/fax numbers, and e-mail address of the corresponding author; and 5) conflicts of interest (if you have an actual or potential conflict of interest to disclose, it must be included as a footnote on the title page of the manuscript; if no conflict of interest exists, this section should be omitted).
interest exists for each author, please state “There is no conflict of interest to disclose”). Please visit Download Centre and refer to the title page of the manuscript sample.

Abstract: The abstract should briefly state the purpose of the study, methods, main findings, and conclusions. For article types including Original Article, Brief Report, Review, Policy Forum, and Case Report, a one-paragraph abstract consisting of no more than 250 words must be included in the manuscript. For News and Letters, a brief summary of main content in 150 words or fewer should be included in the manuscript. Abbreviations must be kept to a minimum and non-standard abbreviations explained in brackets at first mention. References should be avoided in the abstract. Key words or phrases that do not occur in the title should be included in the Abstract page.

Introduction: The introduction should be a concise statement of the basis for the study and its scientific context.

Materials and Methods: The description should be brief but with sufficient details to enable others to reproduce the experiments. Procedures that have been published previously should not be described in detail but appropriate references should simply be cited. Only new and significant modifications of previously published procedures require complete description. Names of products and manufacturers with their locations (city and state/country) should be given and sources of animals and cell lines should always be indicated. All clinical investigations must have been conducted in accordance with Declaration of Helsinki principles. All human and animal studies must have been approved by the appropriate institutional review board(s) and a specific declaration of approval must be made within this section.

Results: The description of the experimental results should be succinct but in sufficient detail to allow the experiments to be understood and interpreted by an independent reader. If necessary, subheadings may be used for an orderly presentation. All figures and tables must be referred to in the text.

Discussion: The data should be interpreted concisely without repeating material already presented in the Results section. Speculation is permissible, but it must be well-founded, and discussion of the wider implications of the findings is encouraged. Conclusions derived from the study should be included in this section.

Acknowledgments: All funding sources should be credited in the Acknowledgments section. In addition, people who contributed to the work but who do not meet the criteria for authors should be listed along with their contributions.

References: References should be numbered in the order in which they appear in the text. Citing of unpublished results, personal communications, conference abstracts, and theses in the reference list is not recommended but these sources may be mentioned in the text. In the reference list, cite the names of all authors when there are fifteen or fewer authors; if there are sixteen or more authors, list the first three followed by et al. Names of journals should be abbreviated in the style used in PubMed. Authors are responsible for the accuracy of the references. Examples are given below:


Tables: All tables should be prepared in Microsoft Word or Excel and should be arranged at the end of the manuscript after the References section. Please note that tables should not be in image format. All tables should have a concise title and should be numbered consecutively with Arabic numerals. If necessary, additional information should be given below the table.

Figure Legend: The figure legend should be typed on a separate page of the manuscript and should include a short title and explanation. The legend should be concise but comprehensive and should be understood without referring to the text. Symbols used in figures must be explained.

Figure Preparation: All figures should be clear and cited in numerical order in the text. Figures must fit a one- or two-column format on the journal page: 8.3 cm (3.3 in.) wide for a single column, 17.3 cm (6.8 in.) wide for a double column; maximum height: 24.0 cm (9.5 in.). Please make sure that the symbols and numbers appeared in the figures should be clear. Please make sure that artwork files are in an acceptable format (TIFF or JPEG) at minimum resolution (600 dpi for illustrations, graphs, and annotated artwork, and 300 dpi for micrographs and photographs). Please provide all figures as separate files. Please note that low-resolution images are one of the leading causes of article resubmission and schedule delays. All color figures will be reproduced in full color in the online edition of the journal at no cost to authors.

Units and Symbols: Units and symbols conforming to the International System of Units (SI) should be used for physicochemical quantities. Solidus notation (e.g. mg/kg, mg/mL, mol/mm/m) should be used. Please refer to the SI Guide www.bipm.org/en/si for standard units.

Supplemental data: Supplemental data might be useful for supporting and enhancing your scientific research and BioScience Trends accepts the submission of these materials which will be only published online alongside the electronic version of your article. Supplemental files (figures, tables, and other text materials) should be prepared according to the above guidelines, numbered in Arabic numerals (e.g., Figure S1, Figure S2, and Table S1, Table S2) and referred to in the text. All figures and tables should have titles and legends. All figure legends, tables and supplemental text materials should be placed at the end of the paper. Please note all of these supplemental data should be provided at the time of initial submission and note that the editors reserve the right to limit the size and length of Supplemental Data.

5. Submission Checklist

The Submission Checklist will be useful during the final checking of a manuscript prior to sending it to BioScience Trends for review. Please visit Download Centre and download the Submission Checklist file.

6. Online Submission

Manuscripts should be submitted to BioScience Trends online at http://www.biosciencetrends.com. The manuscript file should be smaller than 5 MB in size. If for any reason you are unable to submit a file online, please contact the Editorial Office via e-mail at offices@biosciencetrends.com.

7. Accepted Manuscripts

Proofs: Galley proofs in PDF format will be sent to the corresponding author via e-mail. Corrections must be returned to the editor (proof-editing@biosciencetrends.com) within 3 working days.

Offprints: Authors will be provided with electronic offprints of their article. Paper offprints can be ordered at prices quoted on the order form that accompanies the proofs.

Page Charge: Page charges will be levied on all manuscripts accepted for publication in BioScience Trends ($140 per page for black white pages; $340 per page for color pages). Under exceptional circumstances, the author(s) may apply to the editorial office for a waiver of the publication charges at the time of submission.

(Revised February 2013)

Editorial and Head Office:
Pearl City Koishikawa 603
2-4-5 Kasuga, Bunkyo-ku
Tokyo 112-0003 Japan
Tel: +81-3-5840-8764
Fax: +81-3-5840-8765
E-mail: office@biosciencetrends.com
JOURNAL PUBLISHING AGREEMENT (JPA)

Manuscript No.:

Title:

Corresponding Author:

The International Advancement Center for Medicine & Health Research Co., Ltd. (IACMHR Co., Ltd.) is pleased to accept the above article for publication in BioScience Trends. The International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA) reserves all rights to the published article. Your written acceptance of this JOURNAL PUBLISHING AGREEMENT is required before the article can be published. Please read this form carefully and sign it if you agree to its terms. The signed JOURNAL PUBLISHING AGREEMENT should be sent to the BioScience Trends office (Pearl City Koishikawa 603, 2-4-5 Kasuga, Bunkyo-ku, Tokyo 112-0003, Japan; E-mail: office@biosciencetrends.com; Tel: +81-3-5840-8764; Fax: +81-3-5840-8765).

1. Authorship Criteria
As the corresponding author, I certify on behalf of all of the authors that:
1) The article is an original work and does not involve fraud, fabrication, or plagiarism.
2) The article has not been published previously and is not currently under consideration for publication elsewhere. If accepted by BioScience Trends, the article will not be submitted for publication to any other journal.
3) The article contains no libelous or other unlawful statements and does not contain any materials that infringes upon individual privacy or proprietary rights or any statutory copyright.
4) I have obtained written permission from copyright owners for any excerpts from copyrighted works that are included and have credited the sources in my article.
5) All authors have made significant contributions to the study including the conception and design of this work, the analysis of the data, and the writing of the manuscript.
6) All authors have reviewed this manuscript and take responsibility for its content and approve its publication.
7) I have informed all of the authors of the terms of this publishing agreement and I am signing on their behalf as their agent.

2. Copyright Transfer Agreement
I hereby assign and transfer to IACMHR Co., Ltd. all exclusive rights of copyright ownership to the above work in the journal BioScience Trends, including but not limited to the right 1) to publish, republish, derivate, distribute, transmit, sell, and otherwise use the work and other related material worldwide, in whole or in part, in all languages, in electronic, printed, or any other forms of media now known or hereafter developed and the right 2) to authorize or license third parties to do any of the above.
I understand that these exclusive rights will become the property of IACMHR Co., Ltd., from the date the article is accepted for publication in the journal BioScience Trends. I also understand that IACMHR Co., Ltd. as a copyright owner has sole authority to license and permit reproductions of the article.
I understand that except for copyright, other proprietary rights related to the Work (e.g. patent or other rights to any process or procedure) shall be retained by the authors. To reproduce any text, figures, tables, or illustrations from this Work in future works of their own, the authors must obtain written permission from IACMHR Co., Ltd.; such permission cannot be unreasonably withheld by IACMHR Co., Ltd.

3. Conflict of Interest Disclosure
I confirm that all funding sources supporting the work and all institutions or people who contributed to the work but who do not meet the criteria for authors are acknowledged. I also confirm that all commercial affiliations, stock ownership, equity interests, or patent-licensing arrangements that could be considered to pose a financial conflict of interest in connection with the article have been disclosed.

Corresponding Author’s Name (Signature):

Date: